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Introduction to the EACS Guidelines 2018
Welcome to the EACS Guidelines!
These Guidelines were developed by the European AIDS Clinical Society 
(EACS), a not-for-profit organisation, whose mission is to promote excel-
lence in standards of care, research and education in HIV infection and re-
lated co-infections, and to actively engage in the formulation of public health 
policy, with the aim of reducing HIV disease burden across Europe.
The EACS Guidelines were first published in 2005, and are currently availa-
ble in print, online, and as a free App for both iOS and Android devices. The 
Guidelines are translated to several different languages, and are formally 
revised at least annually for the electronic version and biennially for the print-
ed version. The electronic version can, however, be updated at any given 
moment if the panels consider it necessary.
The aim of the EACS Guidelines is to provide easily accessible and com-
prehensive recommendations to clinicians centrally involved in the care of 
HIV-positive persons.
The EACS Guidelines are covering a relatively large and diverse area 
geographically, with different national levels of access to care. As a natural 
consequence, the Guidelines aim to cover a relatively wide range of recom-
mendations as opposed to the often more uniform national guidelines.
The Guidelines consist of five main sections, including a general overview 
table of all major issues in HIV infection, as well as detailed recommen-
dations on antiretroviral treatment, diagnosis, monitoring and treatment of 
co-morbidities, co-infections and opportunistic diseases. 
Each respective section of the Guidelines is managed by a panel of experi-
enced European HIV experts, and additional experts, where needed. All rec-
ommendations are evidence-based whenever possible, and based on expert 
opinions in the rare instances where adequate evidence is unavailable. It 
was decided not to provide formal grades of evidence in the Guidelines. The 
panels make decisions by consensus or by vote when necessary. Yet, it was 
decided not to publish results of the votes or discrepancies if any.
A list of the main references used to produce the Guidelines is provided as a 
separate section. Please reference the EACS Guidelines as follows: EACS 
Guidelines version 9.1, October 2018. Video links to the EACS online course 
on Clinical Management of HIV are provided throughout the Guidelines, see 
Video links. 
The diagnosis and management of HIV infection and related co-infections, 
opportunistic diseases and co-morbidities continue to require a multidiscipli-
nary effort for which we hope the 2018 version of the EACS Guidelines will 
provide you with an easily accessible and updated overview.
All comments to the Guidelines are welcome and can be directed to guide-
lines@eacsociety.org  
We wish to warmly thank all panellists, external experts, linguists, transla-
tors, the EACS Secretariat, the Sanford team and everyone else who helped 
to build up and to publish the EACS Guidelines for their dedicated work.
Enjoy!
Manuel Battegay and Lene Ryom 
October 2018
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ART section
What to start with: 
• New recommendation to use an INSTI as preferred third agent in treat-
ment-naïve persons commencing ART, page 12
• TAF/FTC/BIC, TAF/FTC/DRV/c and the new formulation of RAL 1200 
mg qd added to the recommended regimens, page 12
• Additional footnote on use of TDF and TAF and use of generics, page 
13
• TAF/FTC/EVG/c has been downgraded to alternative regimen, page 13
• Dual regimen with DTG+3TC added to alternative regimens, page 13
Switch strategies: 
• Added recommendation to review drug-drug interactions with ARVs 
and concomitant medication in case of switch, page 15
Virological failure: 
• Changed recommendation to include DTG based regimens, page 16
Treatment of HIV-positive pregnant women: 
• New recommendations against use of DTG, RAL 1200 mg qd, BIC, and 
DRV/c during pregnancy, page 17
Co-morbidities and related sections
• All DDI tables have been updated and revised with data on BIC, pages 
23-33 and 86
• To make room for BIC, data on the older and less used ZDV has been 
moved to the DDI tables footnotes, pages 23-33 and 86
• It was agreed to await additional studies of BIC before adding data on 
BIC to the adverse drug effect and other tables
• Screening recommendations for HCC have been revised in collabora-
tion with the co-infection panel, pages 8, 40, 58, 81
• Data on the fixed dose combination TAF/FTC/DRV/c has been added 
to the tables of swallowing difficulties and dose adjustment for renal 
and hepatic insufficiency, pages 36, 35 and 34
• Practical points on diagnosing hepatic fibrosis have been added in 
collaboration with the co-infection panel, pages 8, 58 and 83
• Minor changes have been added to antihypertensive management and 
treatment section to underline lifestyle changes and use of combination 
drugs, pages 43 and 44
• In the SOT section, it has been specified that HIV-positive persons 
can receive organs from living (renal) and deceased (all types of SOT) 
HIV-negative donors, and the use of HIV-positive donor organs for 
HIV-positive recipients is under evaluation, page 79
Co-infections section
• HCC screening recommendations have been updated. This also in-
cludes changes in the cancer and liver sub-sections of the co-morbidity 
section, pages 8, 40, 58 and 81
• Practical points on diagnosing hepatic fibrosis have been added. This 
also includes changes in the liver sub-section of the co-morbidity sec-
tion, pages 40, 58 and 81
• Wording regarding prevention of HCV MTCT has been added, page 81
• Section on HEV has been added, pages 6 and 81
• Recommendations for persons with failure to DAA treatment have been 
updated, page 84
• DAA table has been updated, page 85
• DDI table has been updated and now includees BIC, page 86
• Figure on management of acute HCV has been amended, page 87
Opportunistic infections section
• A comment has been added at the beginning of the OI section referring 
the reader to ART section for timing of ART initiation in individuals with 
OIs, page 88
• The results of the Reality trial (performed in Africa) added in the 
cryptococcal disease section in v9.0 has been adapted to European 
epidemiological settings, page 91
• The treatment induction phase regimen of two weeks of fluconazole 
1200 mg/day plus flucytosine for cryptococcal meningitis, has been 
added as an acceptable alternative regimen in resource-limited set-
tings, page 91
• A comment has been added pointing out the value of JCV-DNA in plas-
ma for PML diagnosis and as a marker of disease progression, page 94
• Screening recommendations for TB have been revised in the assess-
ment table, page 7
• The regimen of daily rifapentine + isoniasid has been added for the 
treatment of latent TB, page 99
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Abbreviations
3TC lamivudine 
ABC abacavir 
ATV atazanavir 
BIC bictegravir
COBI cobicistat
 (used as booster=/c) 
d4T stavudine 
ddI didanosine  
DRV darunavir 
DTG  dolutegravir
EFV efavirenz 
EVG elvitegravir 
ENF enfuvirtide 
ETV etravirine 
FI fusion inhibitor 
FPV fosamprenavir 
FTC emtricitabine 
IDV indinavir 
INSTI integrase strand  
transfer inhibitor 
LPV lopinavir 
Antiretroviral drug (ARV) abbreviations Other abbreviations 
MVC maraviroc 
NRTI nucleos(t)ide 
reverse transcriptase 
inhibitors 
NNRTI non-nucleoside 
reverse transcriptase 
inhibitors 
NVP nevirapine 
PI protease inhibitors
PI/c protease inhibitors 
pharmacologically 
boosted with 
cobicistat 
PI/r protease inhibitors 
pharmacologically 
boosted with ritonavir 
RAL raltegravir 
RPV rilpivirine 
RTV ritonavir (used as 
booster=/r)
SQV saquinavir
TAF tenofovir alafenamide 
TDF tenofovir disoproxil 
fumarate 
TPV tipranavir 
ZDV zidovudine 
ACE angiotensin converting 
enzyme
ALP alkaline phosphatase
ALT alanine aminotransferase
aMDRD abbreviated modification 
of diet in renal disease 
formula
ART antiretroviral therapy
AST aspartate 
aminotransferase
bid twice daily
BMD bone mineral density
BMI body mass index
BP  blood pressure
cART  combination antiretroviral 
treatment
CKD chronic kidney disease
CKD-EPI CKD epidemiology 
collaboration formula
CMV cytomegalovirus
CNS central nervous system
COPD chronic obstructive 
pulmonary disease
CSF cerebrospinal fluid
CVD cardiovascular disease
CXR chest X-ray
DAA direct acting antiviral drug
DXA dual energy X-ray 
absorptiometry
ECG electrocardiogram
eGFR estimated glomerular 
filtration rate
FBC full blood count
FRAX fracture risk assessment 
tool
GT   genotype
HAV  hepatitis A virus
HBV hepatitis B virus
HCV hepatitis C virus
HDL-c HDL-cholesterol
HEV hepatitis E virus
HIVAN HIV-associated 
nephropathy
HPV human papillomavirus
HSR hypersensitivity reaction
IGRA interferon-gamma release 
assay
ICS          inhaled corticosteroids  
IHD ischaemic heart disease
im  intramuscular
IRIS immune reconstitution 
inflammatory syndrome
iv intravenous
IVDU intravenous drug use
LABA long-acting β2-agonist
LAMA long-acting muscarinic 
antagonist
LDL-c LDL-cholesterol
LGV lymphogranuloma 
venereum
Mg magnesium
MSM men who have sex with 
men
MTCT mother to child 
transmission
NAFLD non-alcoholic fatty liver 
disease
NASH non-alcoholic 
steatohepatitis
PAP  papanicolaou test
PEG-IFN pegylated-interferon
PHI primary HIV infection
po  per oral
PPD purified protein derivative
PPI   proton pump inhibitor
PRT proximal renal tubulopathy
PSA prostate specific antigen
PTH parathyroid hormone
qd once daily
RAS resistance-associated 
substitutions
RBV ribavirin
SABA short-acting β2-agonist
SAMA short-acting muscarinic 
antagonist
sc  subcutaneous
SOT solid organ transplant
STI sexually transmitted 
infection
SVR sustained virological 
response
TC total cholesterol
TDM therapeutic drug 
monitoring
TG triglycerides
tid three times daily
TMP-SMXtrimethoprim-
sulfamethoxazole
UA/C urine albumin/creatinine 
ratio
UP/C urine protein/creatinine 
ratio 
VL viral load (HIV-RNA) 
WB western blot 
Zn zinc 
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Assessment At HIV diagnosis
Prior to  
starting 
ART
Follow-up 
frequency Comment
See 
page
HISTORY
Medical Complete medical history 
including:
+ + First visit On transfer of care repeat assessment
• Family history (e.g. 
premature CVD, diabetes, 
hypertension, CKD)
+ First visit Premature CVD: cardiovascular events in a first 
degree relative (male < 55, female < 65 years)
42-44, 
46-48, 
52
• Concomitant medicines(i) + + Every visit
• Past and current  
co-morbidities
+ + Every visit
• Vaccination history + Annual Measure antibody titres and offer vaccinations 
where indicated, see Vaccination
Psychosocial Current lifestyle (alcohol 
use, smoking, diet, exercise, 
drug use)
+ + 6-12 months Adverse lifestyle habits should be addressed more 
frequently
Provide advice and support if needed
Provide counselling if needed
41
Employment + +
Every visitSocial and welfare + +
Psychological morbidity + +
Partner and children + Test partner and children if at risk
Sexual and  
Reproductive 
Health
Sexual history +
6-12 months
Address issues concerning sexual dysfunction
Risk of sexual transmission should be addressed 
67-69
Safe sex +
Partner status and  
disclosure
+ Recommend starting ART in serodifferent couples
Conception issues + +
Hypogonadism (including 
menopause)
+ + As indicated Persons with complaints of sexual dysfunction 68
HIV DISEASE
Virology Confirmation of HIV Ab pos + More frequent monitoring of HIV-VL at start of ART
Perform genotypic resistance test before starting 
ART if not previously tested or if at risk of super-in-
fection
11-16
Plasma HIV-VL + + 3-6 months
Genotypic resistance test 
and sub-type
+ +/-
At virological 
failure
R5 tropism (if available) +/- Screen if considering R5 antagonist in regimen
Immunology CD4 absolute count and %, 
CD4/CD8 ratio (optional: 
CD8 and %)
+ + 3-6 months Annual CD4 count if stable on ART and 
CD4 count > 350 cells/µL(ii)
CD4/CD8 ratio is a stronger predictor of serious 
outcomes
11-16
HLA-B*5701 (if available) + +/-     Screen before starting ABC containing ART, if not 
previously tested, pages 13, 21
CO-INFECTIONS
STIs Syphilis serology + Annual/ as 
indicated
Consider more frequent screening if at risk 67
STI screen + Annual/ as 
indicated
Screen if at risk and during pregnancy
Viral Hepatitis HAV screen +
Annual/ as 
indicated
Screen at risk (e.g. MSM); vaccinate if non-im-
mune
66, 81, 
82
HBV screen + + Annual screen in susceptible persons; vaccinate if
non-immune. Use ART containing TDF or TAF in 
vaccine non-responders
HCV screen + Annual screen if ongoing risk (e.g. MSM, IVDU)
Measure HCV-RNA if HCV Ab pos or if acute infec-
tion suspected 
HEV screen
As indicated
Screen persons with symptoms consistent with 
acute hepatitis, unexplained flares of aminotrans-
ferases or elevated liver function tests, neuralgic 
amyotrophy, Guillain-Barrè, encephalitis or protein-
uria. Include anti-HEV IgG and IgM and NAT for 
HEV-RNA in blood and if possible in stool
81
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Assessment At HIV diagnosis
Prior to  
starting 
ART
Follow-up 
frequency Comment
See 
page
Tuberculosis CXR +
Re-screen if 
exposure
Consider routine CXR in persons from high TB 
prevalence populations.
Some national guidelines consider the ethnicity, 
CD4 count and ART usage to define indication for 
latent tuberculosis infection screening.
Use of PPD/IGRA depending on availability and 
local standard of care. IGRA should, however, be 
tested before PPD if both are to be used, given the 
potential for a false positive IGRA after PPD.
See Diagnosis and Treatment of TB in HIV-positive 
Persons
97-99, 
18PPD +
IGRA in selected high-risk 
populations (if available)
+
Others Varicella zoster virus 
serology
+ Offer vaccination where indicated 66
91
Measles/Rubella serology + Offer vaccination where indicated 
Toxoplasmosis serology +
CMV serology +
Cryptococcus antigen +/- Consider screening for cryptococcus antigen in 
serum in persons with CD4 count < 100 cells/µL
Leishmania serology +/- Screen according to travel history/origin
Tropical screen (e.g. Schis-
tosoma serology)
+/- Screen according to travel history/origin
Influenza virus + Annual In all HIV-positive persons, see Vaccination 66
Streptococcus pneumoniae + No recommendations available regarding the need 
for a booster dose, see Vaccination
66
Human papilloma virus + As indicated Vaccinate all HIV-positive persons up to age 26 
/ age 40 if MSM. If HPV infection is established, 
efficacy of vaccine is questionable, see Vaccination
66
CO-MORBIDITIES
Haematology FBC + + 3-12 months
Haemoglobinopathies + Screen at risk persons
G6PD + Screen at risk persons
Body  
Composition
Body-mass index + + Annual 41
Cardiovascular 
Disease
Risk assessment  
(Framingham score(iii))
+ + 2 years Should be performed in all men > 40 years and 
women > 50 years without CVD
42
ECG + +/- As indicated Consider baseline ECG prior to starting ARVs 
associated with potential conduction problems
Hypertension Blood pressure + + Annual 43-45
Lipids TC, HDL-c, LDL-c, TG(iv) + + Annual Repeat in fasting state if used for medical interven-
tion (i.e. ≥ 8h without caloric intake)
48
Glucose Serum glucose + + Annual Consider oral glucose tolerance test / HbA1c if 
fasting glucose levels of 5.7-6.9 mmol/L (100-125 
mg/dL)
46-47
Pulmonary  
Disease
Respiratory symptoms and 
risk factors(xii)
+ + Annual If severe shortness of breath is reported with 
preserved spirometry, echocardiography may 
be performed to rule out heart failure and/or pulmo-
nary hypertension
75
Spirometry As indicated Spirometry should be performed in all symptomatic 
persons(xii)
Liver Disease Risk assessment(v) + + Annual 56-61
ALT/AST, ALP, Bilirubin + + 3-12 months More frequent monitoring prior to starting and on 
treatment with hepatotoxic drugs
Staging of liver fibrosis 12 months In HCV and/or HBV co-infected persons (e.g. 
FibroScan, serum fibrosis markers)
57-58,  
81, 84
Hepatic ultrasound 6 months Persons with liver cirrhosis(xiii) 58, 
81, 84
Renal Disease Risk assessment(vi) + + Annual More frequent monitoring if eGFR < 90mL/min, 
CKD risk factors present(vi) and/or prior to starting 
and on treatment with nephrotoxic drugs(ix)
52-55
eGFR (CKD-EPI)(vii) + + 3-12 months
Urine dipstick analysis(viii) + + Annual Every 6 months if eGFR < 60 mL/min or rapid 
decline 
in eGFR (xiv), if proteinuria ≥ 1+ and/or eGFR < 
60 mL/min perform UP/C or UA/C(viii)
Bone Disease Bone profile: calcium, PO4, 
ALP
+ + 6-12 months 49, 51
Risk assessment(x) 
(FRAX®(xi) in persons > 40 
years)
+    + 2 years Consider DXA in specific persons (see page 49 for 
details)
Vitamin D 25(OH) vitamin D + As indicated Screen at risk persons 50
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i  Review all concomitant medicines which may potentially interact with 
ARVs or increase co-morbidities, see
 Drug-drug Interactions between Antidepressants and ARVs                                   
 Drug-drug Interactions between Antihypertensives and ARVs                                
 Drug-drug Interactions between Analgesics and ARVs   
 Drug-drug Interactions between Anticoagulants/Antiplatelet Agents and 
ARVs                                                                     
 Drug-drug Interactions between Antimalarial Drugs and ARVs 
 Drug-drug Interactions between Bronchodilators (for COPD) and ARVs
 Drug-drug Intercations between Immunosuppressants (for SOT) and 
ARVs
 Drug-drug Interactions between Pulmonary Antihypertensives and ARVs  
 Drug-drug Interactions between Corticosteroids and ARVs
 Drug-drug Interactions between Contraceptives and ARVs
 Drug-drug Interactions between DAAs and ARVs
 and http://www.hiv-druginteractions.org
ii  If stable on ART with undetectable HIV-VL and CD4 count > 350 cells/
μL, suggest annual CD4 count.
iii  A risk equation developed from HIV populations is available, see  
https://www.chip.dk/Tools-Standards/Clinical-risk-scores.Of note, if an 
individual receives medicines to control dyslipidaemia and/or hyperten-
sion, the estimation should be interpreted with caution.
iv  A calculator for LDL-cholesterol in cases where TG is not high can be 
found at https://www.mdcalc.com/ldl-calculated.   
v  Risk factors for chronic liver disease include alcohol, viral hepatitis, obe-
sity, diabetes, insulin resistance, hyperlipidaemia and hepatotoxic drugs.
vi  Risk factors for CKD: hypertension, diabetes, CVD, family history, black 
African ethnicity, viral hepatitis, low current CD4 count, smoking, older 
age, concomitant nephrotoxic drugs.
vii  eGFR: use CKD-EPI formula based on serum creatinine, gender, age 
and ethnicity because eGFR quantification is validated > 60 mL/min. 
The abbreviated modification of diet in renal disease (aMDRD) or the 
Cockroft-Gault (CG) equation may be used as an alternative, see https://
www.chip.dk/Tools-Standards/Clinical-risk-scores.
viii  Some experts recommend UA/C (urinary albumin creatinine ratio) or 
UP/C (urinary protein creatinine ratio) as a screening test for proteinuria 
in all persons. UA/C predominantly detects glomerular disease. Use in 
persons with diabetes. UP/C detects total protein secondary to glomeru-
lar and tubular disease.
ix  Different models have been developed for calculating a 5-year CKD risk 
score while using different nephrotoxic ARVs, integrating HIV independ-
ent and HIV-related risk factors [6], [7].
x  Classic risk factors: older age, female gender, hypogonadism, family 
history of hip fracture, low BMI (≤ 19 kg/m2), vitamin D deficiency, smok-
ing, physical inactivity, history of low impact fracture, alcohol excess (> 3 
units/day), steroid exposure (minimum 5 mg for > 3 months).
xi  WHO fracture risk assessment (FRAX®) tool: http://www.shef.ac.uk/
FRAX.
xii  Respiratory symptoms: shortness of breath, chronic cough and sputum. 
Risk factors: tobacco, occupation, in- and outdoor pollution and host 
factors including previous PCP or TB, recurrent pneumonia and Alpha-1 
antitrypsin deficiency. A diagnosis of COPD should be considered in 
persons over the age of 35 years who have a risk factor (current or 
ex-smoker) and who present with exertional breathlessness, chron-
ic cough, regular sputum production, frequent winter ‘bronchitis’ or 
wheeze.
xiii  HCC screening is indicated in all cirrhotic HBV or HCV co-infected 
persons (even if HCV infection has been cured and HBV replication is 
medically suppressed) in a setting where treatment for HCC is available. 
Although the cost-effectiveness of HCC screening in persons with F3 
fibrosis* is uncertain, surveillance may be considered based on an 
individual risk assessment (http://www.easl.eu/research/our-contri-
butions/clinical-practice-guidelines/detail/easl-clinical-practice-guide-
lines-on-hepatocellular-carcinoma). In HBV-positive non-cirrhotics, HCC 
screening should follow current EASL guidelines. Risk factors for HCC in 
this population include family history of HCC, ethnicity (Asians, Africans), 
HDV and age. EASL guidelines propose using the PAGE-B score in 
Caucasians to assess the HCC risk, however this score has not been 
validated in HIV-positive persons. 
* F4 diagnosis made by transient elastography measurement should be 
validated by a biomarker score, signs of cirrhosis in liver in sonography 
or at least repetition of transient elastography after 6 months. F3 diagno-
sis made by transient elastography measurement should be confirmed 
by a second measurement after 6 months. Cut-offs for F4 (cirrhosis): 
13.0 kPa, for F3: 10.0 kPa (http://easl.eu/research/our-contributions/
clinical-practice-guidelines/detail/easl-recommendations-on-treat-
ment-of-hepatitis-c-2018). 
Assessment At HIV diagnosis
Prior to  
starting 
ART
Follow-up 
frequency Comment
See 
page
Neurocognitive 
Impairment
Screening questionnaire + + As indicated Screen all persons without highly confounding con-
ditions. If abnormal or symptomatic, see algorithm 
page 74 for further assessment.
74
Depression Questionnaire + + As indicated Screen at risk persons 70-72
Cancer Mammography 1-3 years Women 50-70 years 40, 
58, 81Cervical PAP 1-3 years HIV-positive women > 21 years or within 1 year 
after sexual debut
Rectal exam and anoscopy 1-3 years MSM and persons with HPV-associated dysplasia. 
Evidence of benefit not known
Ultrasound and alpha-foe-
toprotein
6 months Controversial; persons with cirrhosis and persons 
with HBV co-infection at high risk of HCC(xiii)
Others Controversial 
EACS   European
AIDS Clinical Society
9EACS Guidelines 9.1 PART II
Part II   ART of HIV-positive Persons
Assessing  HIV-positive Persons' Readiness to Start and Maintain ART(x)
Stages of readiness to start ART
Precontemplation: 
“I don’t need it, I feel good.” 
“I don’t want to think about it.”   
Support: Show respect for the person's attitude. / Try to understand the 
person's health and therapy beliefs. / Establish trust. / Provide concise, 
individualised information. / Schedule next appointment.
Contemplation: 
“I am weighing things up and feel  
torn about what to do about it.”  
Support: Allow ambivalence. / Support the person in weighing pros and 
cons. / Assess the person's information needs and support his/her informa-
tion seeking. / Schedule the next appointment.
Preparation: 
“I want to start, I think the drugs  
will allow me to live a normal life.” 
Support: Reinforce the person's decision. / Decide with the person which 
is the most convenient regimen. / Educate the person on adherence, 
resistance and side effects. / Discuss integration into daily life. / Assess  
self-efficacy. 
Ask: How confident are you that you can take your medicines as we dis-
cussed (specify) once you have started? Use VAS 0-10(iii) 
Consider skills training: 
• Medicines-taking training, possibly Medication Event Monitoring System, 
e.g. electronic pill boxes 
• Directly observed therapy with educational support 
• Use aids: mobile phone alarm, pillboxes 
• Involve supportive tools/persons where appropriate
Action: 
“I will start now.” 
‘Final check’: With a treatment plan established, is the person  
capable of taking ART and is ART available?
Maintenance: 
“I will continue.” or ”I have 
difficulties continuing over 
the long run.”
Caveat: A person can relapse 
to an earlier stage, even from 
“maintenance” to “precontemplation”
Assess: Adherence every 3-6 months(iv) 
Evaluate adherence: For persons with good adherence: show respect for 
their success. 
Assess: The person's  own perception of ability to adhere to and continue 
treatment. 
Ask: In the next 3-6 months, how confident are you that you can take your 
medicines? Use VAS 0-10(iii)
For a person without sufficient adherence: use mirroring techniques(v) 
on problems, ask open questions to identify dysfunctional beliefs. 
Assess: Stage of readiness and provide stage-based support 
Assess: Barriers and facilitators(vi)
Schedule next appointment and repeat support
ST
A
R
T 
A
R
T
Goal: to help persons start and/or maintain ART
The equipoise when to start ART has changed in light of the START trial 
[1]. Evidence is accumulating that starting ART on the same day after 
establishing a diagnosis of HIV infection is feasible and acceptable to 
HIV-positive persons. Nevertheless, assessment of the readiness to start 
ART is essential to enable the HIV-positive person to express their pref-
erence and not feel pressured to start ART immediately, unless clinically 
indicated. 
Successful ART requires a person's readiness to start and adhere to the 
regimen over time. The trajectory from problem awareness to maintenance 
on ART can be divided into five stages. Knowing a person's stage, health 
care providers use appropriate techniques to assist them to start and 
maintain ART. 
Identify the person's stage of readiness using WEMS(i) techniques, and 
start discussion with an open question/invitation: 
“I would like to talk about HIV medicines.” <wait> “What do you think about 
them?” 
Based on the person’s response, identify his/her stage of readiness and 
intervene accordingly(ii)
Immediate (same day) start of ART should be considered, especially in the 
following situations:
-   In the setting of primary HIV infection, especially in case of clinical signs 
and symptoms of meningoencephalitis (within hours). In this situation, 
the clinician may start ART immediately after a positive screening HIV 
test and before obtaining confirmatory HIV test results such as a HIV-VL.
-   The wish of an HIV-positive person to start ART immediately.
-   In a setting where loss-to-follow-up is more likely if ART is not started 
the same day.
This section provides an overview of the important aspects of the management of HIV-positive individuals starting or established on ART. Recommendations 
are based on a range of evidence, in particular it is weighted towards randomised controlled clinical trials. Other data have been taken into account, including 
cohort studies, and where evidence is limited the panel has reached a consensus around best clinical practice. The ART section is wide ranging and, with the 
move to starting therapy independently of CD4 count, there is an important section on readiness to start. Treatment recommendations are based on drugs 
licensed in Europe and range from initial therapy through to switching with or without virological failure. We highlight two important areas of ART: pregnancy 
and TB. Details on the use of PrEP, which is being rolled out across Europe, are also included. Finally, with the increasing complexity of co-morbidities and 
concomitant treatments, a large part of the section is devoted to adverse effects, drug interactions and dose adjustments in renal and hepatic disease. 
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Several barriers are known to influence ART decision making and 
adherence to ART
Screen for and talk about problems and facilitators
Consider systematic assessment of: 
• Depression(vii), see page 70-71
• Cognitive problems(viii),  
see page 74
• Harmful alcohol(ix) or recreational 
drug use, see page 39, 41
Consider talking about: 
• Social support and disclosure 
• Health insurance and continuity 
of drug supply 
• Therapy-related factors
Recognise, discuss and reduce problems wherever possible in a  
multidisciplinary team approach.
i WEMS: Waiting (> 3 sec), Echoing, Mirroring, Summarising [2]
ii  The person presenting in the clinic may be at different stages of readi-
ness: precontemplation, contemplation or preparation. The first step is 
to assess the stage, and then to support/intervene accordingly. In the 
case of late presentation (CD4 count < 350 cells/μL), the initiation of 
ART should not be delayed. The person should be closely followed and 
optimally supported. Schedule the next appointment within a short time,  
i.e. 1-2 weeks. 
iii VAS (= Visual Analogue Scale; range from 0 to 10,  
i.e. 0= I will not manage, 10= I am sure I will manage).
I will not manage I will manage
0 10
iv Suggested adherence questions: “In the past 4 weeks how often have 
you missed a dose of your HIV medicines: every day, more than once a 
week, once a week, once every 2 weeks, once a month, never?” / “Have 
you missed more than one dose in a row?” [3]. 
v Mirroring: reflecting back on what a person has said or non-verbally 
demonstrated (e.g. anger or disappointment) WITHOUT introducing new 
material by asking questions or giving information. 
vi Adherence to long-term therapies [4].
vii PHQ-2 or PHQ-9 [5]. Meta-analysis shows a consistent relationship 
between depression and ART non-adherence that is not limited to those 
with clinical depression. Therefore, assessment and intervention aimed 
at reducing depressive symptom severity, even at subclinical level is 
important. Ask: "Over the last two weeks, how often have you been 
bothered by any of the following problems? 1. Little interest or pleasure 
in doing things; 2. Feeling down, depressed or hopeless." Answers: Not 
at all (0) / Several days (1) / More than half the days (2) / Nearly every 
day (3). If the person scores 2 or more, seven additional questions, see 
[6] 
viii Ask: “Do you feel having problems to concentrate in your daily life?” / 
“Do you feel slowed in your thinking?” / “Do you feel having problems 
with your memory?” / “Did relatives or friends express that they feel you 
have problems with your memory or difficulty concentrating?” [7]. 
ix FAST-alcohol use, ask: How often have you had 6 or more units if 
female, or 8 or more units if male, on a single occasion in the last year? 
Never=0, Less than monthly=1, Monthly=2, Weekly=3, Daily or almost 
daily=4. Stop if the answer is 0 (Never). Ask more questions if the an-
swer is 1, 2, 3 or 4. See [8].
x   Algorithm adapted from [9].
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Recommendations for Initiation of ART in HIV-positive Persons with Chronic 
Infection without prior ART Exposure  
Recommendations take into account the level of evidence, the degree of 
progression of HIV disease and the presence of, or high risk for, developing 
various types of (co-morbid) conditions.
ART is recommended in all adults with chronic HIV infection, 
irrespective of CD4 counts(i)
i   ART should always be recommended irrespective of the CD4 count, but 
the lower the CD4 count, the greater the urgency to start ART imme-
diately. Use of ART should also be recommended at any CD4 count in 
order to reduce sexual transmission MTCT of HIV (before third trimester 
of pregnancy).
• In persons with OIs, it is recommended to initiate ART during the 
two weeks following the diagnosis. The exception is cryptococcal 
meningitis, in which delaying ART until four weeks of antimicrobial 
therapy is advised, due to the risk of life-threatening IRIS. For ART 
initiation in persons with TB, see page 18. 
• A possible exception could be persons with high CD4 counts and 
HIV-VL < 1000 copies/mL, although even in such persons ART ini-
tiation has been shown to increase CD4 count, dampen inflamma-
tion and lower the risk of emerging infection with higher HIV-VL.
• Genotypic resistance testing is recommended prior to initiation 
of ART, ideally at the time of HIV diagnosis; otherwise before 
initiation of ART. 
• If ART needs to be initiated before genotypic testing results are 
available, it is recommended to include a drug with a high genetic 
barrier to resistance in the first-line regimen (e.g. a PI/r, PI/c, DTG 
or BIC). Ideally, before starting treatment, the HIV-VL level and 
CD4 count should be repeated to more reliably assess the infec-
tion status and subsequent response to ART.
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Out of the recommended regimens in persons starting ART, we recommend the use of an INSTI as preferred third agent; tailoring antiretroviral regimens for 
each individual is essential as other classes of third agents (e.g boosted PI) might be indicated in the presence of resistance or risk of poor adherence.
A) Recommended regimens (one of the following to be selected)*,**
* Only drugs currently licensed for initiation of therapy by the EMA are taken into consideration (in alphabetical order).
** Generic HIV drugs are becoming more available and can lead to large cost savings. They can be used as long as they replace the same drug and do not 
break recommended fixed dose combinations
Regimen Dosing Caution Food requirement
2 NRTIs + INSTI
ABC/3TC/DTG(i, ii, x) ABC/3TC/DTG 600/300/50 mg, 1 tablet qd Al/Ca/Mg-containing antac-
ids or multivitamins should 
be taken well separated in 
time (minimum 2h after or 
6h before).
DTG 50 mg bid with 
rifampicin.
None
TAF/FTC(iii) or
TDF/FTC(iii)
+ DTG(x)
TAF/FTC 25/200 mg, 1 tablet qd or
TDF/FTC 300/200 mg, 1 tablet qd 
+ DTG 50 mg, 1 tablet qd
None
TAF/FTC/BIC(xi) TAF/FTC/BIC 25/200/50 mg, 1 tablet qd Al/Ca/Mg-containing antac-
ids should be taken 2h after 
BIC (fasting conditions) 
whereas Ca, Mg, Fe or 
multivitamins supplements 
can be administered simul-
taneously with food.
None
TAF/FTC(iii) or
TDF/FTC(iii) 
+ RAL(iv)
TAF/FTC 25/200 mg, 1 tablet qd or
TDF/FTC 300/200 mg, 1 tablet qd 
+ RAL 600 mg, 2 tablets qd or
+ RAL 400 mg, 1 tablet bid
Co-administration of antac-
ids containing Al or Mg not 
recommended. Co-ad-
ministration of RAL 1200 
mg qd with Ca containing 
antacids or with Ca, Mg, Fe 
supplements is not recom-
mended. Use RAL 400 mg 
bid instead.
RAL(iv) 400 or 800 mg bid
with rifampicin.
None
2 NRTIs + NNRTI
TAF/FTC/RPV(iii) or
TDF/FTC/RPV(iii)
TAF/FTC/RPV 25/200/25 mg, 1 tablet qd or
TDF/FTC/RPV 300/200/25 mg, 1 tablet qd
Only if CD4 count > 200 
cells/µL and HIV-VL < 
100,000 copies/mL.
PPI contraindicated; H2 
antagonists to be taken 12h 
before or 4h after RPV.
With food
2 NRTIs + PI/r or PI/c
TAF/FTC(iii) or
TDF/FTC(iii)
+ DRV/c(v) or
+ DRV/r(v)
TAF/FTC 10/200 mg, 1 tablet qd or
TDF/FTC 300/200 mg, 1 tablet qd 
+ DRV/c 800/150 mg, 1 tablet qd or
+ DRV 800 mg, 1 tablet qd + RTV 100 mg, 1 tablet qd or
TAF/FTC/DRV/c 10/200/800/150 mg, 1 tablet qd
Monitor in persons with a 
known sulfonamide allergy.
With food
Initial Combination Regimen for ART-naïve Adult HIV-positive Persons                 
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B) Alternative regimens (to be used when none of the preferred regimens are feasible or available, whatever the reason)
Regimen Dosing Caution Food requirement
2 NRTIs + INSTI
ABC/3TC(i, ii) 
+ RAL(iv)
ABC/3TC 600/300 mg, 1 tablet qd 
+ RAL 600 mg, 2 tablets qd or
+ RAL 400 mg, 1 tablet bid
Co-administration of antac-
ids containing Al or Mg not 
recommended. 
Co-administration of RAL 
1200 mg qd with high dose 
Ca not recommended.
RAL(iv) 400 or 800 mg bid 
with rifampicin.
 None
TAF/FTC/EVG/c(iii, vi) or
TDF/FTC/EVG/c(iii, vi)
TAF/FTC/EVG/c 10/200/150/150 mg, 1 tablet qd or
TDF/FTC/EVG/c 300/200/150/150 mg, 1 tablet qd
Al/Ca/Mg-containing antac-
ids or multivitamins should 
be taken well separated in 
time (minimum 2h after or 
6h before).
With food
2 NRTIs + NNRTI
ABC/3TC(i, ii) 
+ EFV(vii)
ABC/3TC 600/300 mg, 1 tablet qd 
+ EFV 600 mg, 1 tablet qd
Only if HIV-VL < 100,000 
copies/mL. At bed time or 2 hours before 
dinner
TDF/FTC/EFV(iii, vii) TDF/FTC/EFV 300/200/600 mg, 1 tablet qd
2 NRTIs + PI/r or PI/c
ABC/3TC(i, ii) 
+ ATV/c(viii, ix) or
+ ATV/r(viii, ix)
ABC/3TC 600/300 mg, 1 tablet qd
+ ATV/c 300/150 mg 1 tablet qd or
+ ATV 300 mg, 1 tablet qd + RTV 100 mg, 1 tablet qd
Only if HIV-VL < 100,000 
copies/mL.
With food
ABC/3TC(i, ii)
+ DRV/c(v) or
+ DRV/r(v) 
ABC/3TC 600/300 mg, 1 tablet  qd
+ DRV/c 800/150 mg, 1 tablet qd or
+ DRV 800 mg, 1 tablet qd + RTV 1 tablet 100 mg, 1 tablet qd
Monitor in persons with a 
known sulfonamide allergy.
With food
TAF/FTC(iii) or
TDF/FTC(iii) 
+ ATV/c(viii, ix) or 
+ ATV/r(viii, ix)
TAF/FTC 10/200 mg 1 tablet qd or
TDF/FTC 300/200 mg, 1 tablet qd
+ ATV/c 300/150 mg, 1 tablet qd or
+ ATV 300 mg, 1 tablet qd + RTV 100 mg, 1 tablet qd
With food
Other combinations
[DTG(x)
+ 3TC](ii, xii)
DTG 50 mg, 1 tablet qd
+ 3TC 300 mg, 1 tablet qd
Al/Ca/Mg-containing antac-
ids or multivitamins should 
be taken well separated in 
time (minimum 2h after or 
6h before).
Only if HIV-VL <  500,000 
copies/mL
None
[RAL
+ DRV/c(v) or
+ DRV/r(v)](ii)
RAL 400 mg, 1 tablet bid 
+ DRV/c 800/150 mg, 1 tablet qd or
+ DRV 800 mg, 1 tablet qd + RTV 100 mg, 1 tablet qd
Only if CD4 count > 200 
cells/µL and HIV-VL < 
100,000 copies/mL. Co-ad-
ministration of antacids 
containing Al or Mg not 
recommended.
With food
i  ABC contraindicated if HLA-B*5701 positive. Even if HLA-B*5701 negative, coun-
selling on HSR risk still mandatory. ABC should be used with caution in persons 
with a high CVD risk (> 20%). 
ii  Use this combination only if HBsAg-negative.
iii In certain countries TDF is labelled as 245 mg to reflect the concentration of the 
prodrug (tenofovir disoproxil). There are available generic forms of TDF, which 
instead of fumarate use phosphate, maleate, and succinate salts. They can be 
used interchangeably.  When available, combinations containing TDF can be 
replaced by the same combinations containing TAF. TAF is used at 10 mg when 
co-administered with drugs that inhibit P-gp, and at 25 mg when co-administered 
with drugs that do not inhibit P-gp. 
 The decision whether to use TDF or TAF depends on individual characteristics as 
well as availability. So far, there are only limited long-term data on TAF.
 If the ART regimen does not include a booster, TAF and TDF have a similar short-
term risk of renal adverse events leading to discontinuation and bone fractures.
 TAF*** should be considered as a first choice**** over TDF in individuals with: 
- established or high risk of CKD, see page 52;
- co-medication with nephrotoxic drugs or prior TDF toxicity, see page 53;
- osteoporosis / progressive osteopenia or risk factors, see page 49;
- history of fragility fracture, see page 51.
 *** There are limited data on use of TAF with eGFR < 30 mL/min; **** Expert 
opinion pending clinical data.
iv No data on RAL 1200 mg with rifampicin, co-administration not recommended; 
No data on RAL 1200 mg in pregnancy: not recommended.
v A single study has shown increase in CVD risk with cumulative use of DRV [13].
vi TDF/FTC/EVG/c and TAF/FTC/EVG/c are alternative treatments: within INSTI 
class, booster free regimens with equal efficacy are preferred.
 TDF/FTC/EVG/c to be used only if eGFR ≥ 70 mL/min. It is recommended that 
TDF/FTC/EVG/c is not initiated in persons with eGFR < 90 mL/min unless this is 
the preferred treatment.
vii EFV: not to be given if history of suicide attempts or mental illness; not active 
against HIV-2 and HIV-1 group O strains.
viii Co-administration of PPI is contraindicated. If PPI co-administration is judged 
unavoidable, consider an alternative regimen; if given, dose increase of ATV to 
400 mg qd may be considered, close clinical monitoring is recommended and 
doses of PPI comparable to omeprazole 20 mg should not be exceeded and must 
be taken approximately 12 hours prior to the ATV/r. H2 antagonists to be taken 12 
hours before or 4 hours after ATV.
ix Potential renal toxicity with ATV/r and ATV/c.
x DTG should not be prescribed to women seeking to become pregnant; women 
who can become pregnant should use effective contraception while taking DTG.
xi Reduced exposure of TAF/FTC/BIC with rifampicin, co-administration not recom-
mended. No data on TAF/FTC/BIC in pregnancy: not recommended. 
xii   2 large RCTs at 48 weeks have shown non-inferiority of DTG and 3TC dual 
therapy vs triple therapy in treatment-naïve persons with wild-type virus. It is 
considered that longer follow-up beyond 48 weeks is needed before this dual        
regimen is selected as "recommended".  
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Definition of PHI(i-iv)
• High-risk exposure within previous 6 months, and
• Detectable virus in plasma (p24 Ag and/or HIV-RNA) and/or
• Evolving anti-HIV antibody reactivity (negative or indeterminate to positive)
• With (23-92%) or without clinical symptoms.
Classification of PHI(i-iv)
•  Acute infection: HIV detection (p24 Ag and/or HIV-RNA) in the absence of 
HIV antibody. 
•  Recent infection: HIV antibody detection; up to 6 months after infection.
Starting treatment(v-vi)
Treatment of PHI is recommended for all HIV-positive persons. Several 
circumstances indicate immediate treatment initiation. 
Circumstances where immediate treatment initiation should be advised
Acute infection
Severe or prolonged symptoms
Neurological disease
Age ≥ 50 years
CD4 count < 350 cells/µL
Pregnancy
The recommendation is based on: 
• Demonstrated virological and immunological benefits and anticipated 
clinical benefits of early therapy(v)
• Reduced risk of transmission
• Usually short interval between identification of PHI and a CD4 count < 500 
cells/µL
• Reduced anxiety and facilitated disclosure to contacts
The HIV-positive person must be willing to take therapy and counselling 
should promote engagement by emphasising the benefits of starting 
treatment early. The HIV-positive person should also be made aware of the 
potential disadvantages of early treatment(vi).
Asymptomatic persons with PHI with a recent infection and a preserved CD4 
count who decide to defer therapy should enter follow-up according to the 
guidance outlined for established (chronic) infection.
Once treatment is started, it should be continued. A subsequent interruption 
is not recommended.
Treatment selection
•  The HIV-positive person should preferably be recruited into a clinical trial or  
studies investigating HIV curative strategies. 
•  Any use of pre-exposure or post-exposure prophylaxis should be identified  
and taken into account when choosing the initial regimen.
•  A drug resistance test is recommended in all cases as soon as possible  
after diagnosis. A genotypic (rather than phenotypic) test is recommended  
due to increased sensitivity and wide availability.
•  Where there are indications for immediate treatment (see table), therapy 
may have to start before the results of resistance testing become available. 
Whilst evidence is evolving, current guidance remains that in such cases 
preference should be given to starting a PI/r or PI/c in order to increase 
the barrier to resistance of the overall regimen. An INSTI should also be 
included in order to induce rapid viral load suppression. A combination of 
TDF or TAF, FTC, and either boosted DRV, or an INSTI should therefore be 
considered, and the regimen adjusted, if needed, once the resistance test 
becomes available and viral load suppression is achieved. Where such a 
regimen is not available, national epidemiological data on prevalence and 
patterns of transmitted drug resistance (where available and sufficiently 
representative) may assist with the treatment selection process. 
Primary HIV Infection (PHI)     
Other considerations
• All HIV-positive persons should undergo investigations to diagnose sex-
ually transmitted infections (e.g. syphilis, gonorrhoea, chlamydia), HBV 
and HCV. Antibody seroconversion can be delayed and tests to identify 
the viral RNA are required in order to identify a recent HCV infection.
• All HIV-positive women of reproductive age should have a pregnancy 
test.
• All HIV-positive persons  should be counselled about the high risk of 
transmission, preventive measures, and importance of notifying partners.
i HIV-1 RNA becomes detectable in plasma around day 11 after expo-
sure, approximately 7 days before p24 Ag and 12 days before anti-HIV 
antibodies.
ii Where available, Western Blot (WB) or Immunoblot patterns of reactivity 
can be used to stage the infection as follows [12]; 
• Stage I: HIV-RNA positive only (average duration 5 days). HIV-VL levels 
are median 2,000 copies/mL (IQR 300-20,000 copies/ml), and are < 100 
copies/mL in approximately 10% of HIV-positive persons. Low HIV-VL 
levels should be interpreted with caution due to the risk of false positivity 
(e.g., due to contamination) 
• Stage II: HIV-RNA and p24 Ag positive only (average duration 5.3 days). 
NB: HIV-VL levels are usually > 10,000 copies/mL
• Stage III: HIV-RNA, p24 Ag and anti-HIV antibody positive by immuneas-
say, no specific WB bands (average duration 3.2 days)
• Stage IV: as Stage III but indeterminate WB pattern (5.6 days) 
•  Stage V: as Stage III, but reactive WB pattern lacking p31 reactivity 
(average duration 69.5 days)
• Stage VI: as stage III but full WB reactivity including a p31 band (indefi-
nite)
iii Everyone with detectable HIV-VL and negative or indeterminate serology 
must receive confirmation of anti-HIV antibody seroconversion in fol-
low-up testing. The interval of testing (up to stage V) is one week.
iv Some centres may have access to sero-incidence markers (e.g., anti-
body avidity testing) that identify an infection acquired within the previous 
3-6 months. Assay reliability varies and results should be interpreted with 
caution when they are the sole indicators of a recent infection.
v Potential benefits of treatment: reduce severity of acute symptoms; lower 
the HIV-VL set-point and size of the viral reservoir; reduce viral genetic 
evolution; reduce immune activation and inflammation; preserve immune 
function and integrity of lymphoid tissue; possibly exert neurological and 
gut protection; possibly enhance post-treatment control and response to 
future eradication strategies. These effects are more likely if treatment is 
started in the acute phase of PHI. 
vi Potential disadvantage of treatment: firm, controlled evidence that treat-
ment of PHI results in clinical benefit in the long-term (relative to starting 
therapy past the PHI stage) is currently lacking. Data supporting imme-
diate treatment are mostly derived from persons with symptomatic PHI. 
Low likelihood of post-treatment control; treatment interruption usually 
leads to rebound of HIV-VL and inflammation markers; possible adverse 
consequences of long-term ART (toxicity, drug resistance). A small 
subset of HIV-positive persons can spontaneously control the infection 
without treatment (elite controllers).
 
 See online video lectures When to start ART-Part 1, When to start ART-
Part 2, What ART to start-Part 1 and What ART to start-Part 2 from the 
EACS online course on Clinical Management of HIV.
EACS   European
AIDS Clinical Society
15EACS Guidelines 9.1 PART II
Definition of virologically suppressed
Clinical trials exploring switching strategies have defined suppression as an 
HIV-VL < 50 copies/mL for at least 6 months. 
Indications
1. Documented toxicity caused by one or more of the antiretrovirals includ-
ed in the regimen. Examples of these reactive switches: lipoatrophy (d4T, 
AZT), central nervous system adverse events (EFV), diarrhoea (PI/r) and 
jaundice (ATV), proximal renal tubulopathy and low bone mineral density 
(TDF), see Adverse Effects of ARVs and Drug Classes.
2. Prevention of long-term toxicity. Example of this proactive switch: 
prevention of lipoatrophy in persons receiving d4T or AZT and prevention 
of proximal renal tubulopathy with TDF, see Adverse Effects of ARVs and 
Drug Classes.
3. Avoid serious drug-drug interactions
4. Planned pregnancy
5. Ageing and/or co-morbidity with a possible negative impact of drug(s) in 
current regimen, e.g. on CVD risk, metabolic parameters.
6. Simplification: to reduce pill burden, adjust food restrictions and improve 
adherence.
7. Starting of HCV treatment in case of drug-drug interaction, see Drug-
drug Interactions between DAAs and ARVs.
Principles
Clinicians should always review possible adverse events or tolerability 
issues with current antiretroviral regimens. Just because the HIV-VL is 
suppressed it should not be assumed that the HIV-positive person is 
well adapted and tolerating the current regimen.
 
1.  The objectives of treatment modification should be to eliminate or 
improve adverse events, facilitate adequate treatment of co-morbid con-
ditions, and improve quality of life.
2.  The primary concern when switching should be to sustain and not to jeop-
ardize virological suppression. In persons without prior virological failures 
and no archived resistance, switching regimens entail a low risk of subse-
quent failure if clinicians select one of the recommended combinations 
for first-line therapy. The majority of clinical trials showing non-inferiority 
of the new regimen after the switch have actively excluded persons with 
prior virological failures. 
3.  A complete ARV history with HIV-VL, tolerability issues and cumula-
tive genotypic resistance history should be analysed prior to any drug 
switch. 
4.  A PI/r or PI/c may be switched to unboosted ATV, an NNRTI, or an 
INSTI only if full activity of the 2 NRTIs remaining in the regimen can 
be guaranteed. Switches have to be planned especially carefully when 
they result in a decrease in the genetic barrier of the regimen in case of 
prior virologic failures. Clinicians should review the complete ARV history 
and available resistance test and HIV-VL results before switching, and 
ensure no drug-drug interactions may lead to suboptimal drug levels (e.g. 
unboosted ATV and TDF). 
Switch Strategies for Virologically Suppressed Persons   
5.  Before switching, remaining treatment options in case of potential 
virological failure of the new regimen should be taken into consideration. 
For example, the development of the M184V RT mutation in HIV-positive 
persons who fail a 3TC-containing regimen might preclude the future use 
of all currently available single-tablet regimens.
6.  Switches of single drugs with the same genetic barrier (for example EFV 
to RAL) is usually virologically safe in the absence of resistance to the 
new compound.
7.  When selecting a new regimen, clinicians should carefully review the 
possibility of new drug-drug interactions with antiretroviral and concom-
itant medication, as well as the lag time for hepatic enzyme induction or 
blockade following discontinuation of the offending drug.
8.   If the switch implies discontinuing TDF and not starting TAF, clinicians 
should check the HBV status (avoid discontinuation of TDF in persons 
with chronic HBV and assess HBV vaccination status).
9.  HIV-positive persons should be seen soon (e.g. 4 weeks) after treatment 
switches to check for maintenance of suppression and possible toxicity of 
the new regimen. 
10. If a HIV-positive person receives and tolerates a regimen that is no 
longer a preferred option, there is no need to change. Example: persons 
tolerating EFV-containing regimens.
11. See online video lecture How to Change ART from the EACS online 
course Clinical Management of HIV. 
Class-sparing strategies
Dual therapy: 
    DTG + RPV 
    3TC + (DRV/r or DRV/c) or
    3TC + (ATV/r or ATV/c)
In clinical trials these strategies have not been associated with more virologi-
cal rebounds than triple therapy.
Monotherapy with DRV/r:
In clinical trials this strategy has been associated with more virological 
rebounds than triple therapy. DRV/r monotherapy is an option only for excep-
tional persons who are not candidates for dual therapies.
In persons with suppression of HIV-VL < 50 copies/mL for the past 6 months
dual therapy with 3TC + PI/r or PI/c should only be given if there is 
a) no resistance and b) absence of chronic HBV co-infection. 
The same applies to DRV/r monotherapy.
Strategies not recommended
a.  Monotherapy with ATV/r 
b.  Monotherapy with DTG 
c.  Triple NRTIs combinations
d.  Specific two-drug combination, i.e. 1 NRTI + 1 NNRTI or 1 NRTI + 1 
unboosted PI, 1 NRTI + RAL, 2 NRTIs, MVC + RAL, PI/r or PI/c + MVC,
ATV/r or ATV/c + RAL
e.  Intermittent therapy, sequential or prolonged treatment interruptions
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Definition INCOMPLETE SUPPRESSION: HIV-VL > 200 copies/
mL at 6 months(i) after starting therapy in persons not 
previously on ART. 
REBOUND: confirmed HIV-VL > 50 copies/mL in persons 
with previously undetectable HIV-VL.
General 
measures
Review expected potency of the regimen
Evaluate adherence, compliance, tolerability, drug-drug 
interactions, drug-food interactions, psychosocial issues
Perform resistance testing on failing therapy (usually 
routinely available for HIV-VL levels > 350-500 copies/
mL and in specialised laboratories for lower levels of 
viraemia) and obtain historical resistance testing for 
archived mutations
Tropism testing
Consider TDM
Review ART history
Identify treatment options, active and potentially active 
drugs/combinations
Management 
of virological 
failure (VF)
If HIV-VL > 50 and < 500 copies/mL:
Check for adherence
Check HIV-VL 1 to 2 months later
If genotype not possible, consider changing regimen 
based on past treatment and resistance history
If HIV-VL confirmed > 500 copies/mL: 
Change regimen as soon as possible. What to change will 
depend on the resistance testing results:
If no resistance mutations found: re-check for adherence, 
perform TDM
If resistance mutations found: switch to a suppressive 
regimen based on drug history; multidisciplinary expert 
discussion advised
Goal of new regimen: HIV-VL < 50 copies/mL within 6 
months
 Virological Failure                                                                 
In case of 
demonstrated 
resistance 
mutations
General recommendations:
Use at least 2 and preferably 3 active drugs in the new 
regimen (including active drugs from previously used 
classes) based on resistance mutations present in current 
and earlier genotypic analyses
Any regimen should use at least 1 fully active boosted PI 
(e.g. DRV/r) plus 1 drug from a class not used previously 
e.g. INSTI, FI, or CCR5 antagonist (if tropism test shows 
R5 virus only), or 1 NNRTI (e.g. ETV), assessed by 
genotypic testing.
Alternatively, a regimen can be constructed with DTG 
(when fully active) plus 2 NRTIs, of which at least 1 NRTI 
is fully active.  
Defer change if < 2 active drugs available, based on 
resistance data, except in persons with low CD4 count 
(< 100 cells/μL) or with high risk of clinical deterioration 
for whom the goal is the preservation of immune function 
through partial reduction of HIV-VL (> 1*log10 reduction) 
by recycling 
If limited options, consider experimental and new drugs, 
favouring clinical trials (but avoid functional monotherapy)
Treatment interruption is not recommended
Consider continuation of 3TC or FTC in particular 
situations even if documented resistance mutation 
(M184V/I)
If many options are available, criteria of preferred choice 
include: simplicity of the regimen, toxicity risks evaluation, 
drug-drug interactions, and future salvage therapy
i  In persons with very high baseline HIV-VL (> 100,000-500,000 copies/mL) 
achieving viral suppression may take longer than 6 months.
 See online video lecture Adherence and Prevention of HIV Drug Resist-
ance from the EACS online course Clinical Management of HIV.
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Criteria for starting ART in pregnant women (see different scenarios) Same as for non-pregnant
Objective of treatment in pregnant women Full plasma HIV-VL suppression at least by third trimester and specifically 
at time of delivery. In such instance, risk of transmission is 0 to < 0.5%
Resistance testing Same as for non-pregnant women, i.e. before starting ART and in case of 
virological failure
SCENARIO
1. Women planning to be pregnant while already on ART 1.  Maintain ART, unless taking some contraindicated regimen during 
    pregnancy (DTG in the first trimester, ddI + d4T, triple NRTI         
combinations)
2.  Women becoming pregnant while already on ART 2. Maintain ART, unless taking some contraindicated regimen during 
    pregnancy (DTG in the first trimester, ddI + d4T, triple NRTI 
combinations)
3.  Women becoming pregnant while treatment-naïve 3. Starting ART as soon as possible is highly recommended
4.  Women whose follow-up starts late in the second or in the third trimester 4.  Start ART immediately and consider RAL as the preferred choice to 
obtain rapid HIV-VL decline and to ensure the HIV-VL is undetectable by 
the time of delivery
5.  Women whose HIV-VL is not undetectable at third trimester 5.  Perform resistance testing and consider changing to or adding INSTI 
(RAL or DTG) if not on this class to obtain rapid HIV-VL decline
Antiretroviral regimen in pregnancy
Same as non-pregnant
If on RAL (400 mg bid), RPV or DRV/r: could be continued 
No data on RAL 1200 mg qd: not recommended
Women on EVG/c need to be informed that more monitoring of HIV-VL and 
drug levels may be necessary during pregnancy 
Women on DTG need to be switched to a different third agent, at least 
for the first trimester (evidence of increased risk of neural tube defect in 
newborns exposed to DTG from one observational cohort)
Among PI/r, prefer ATV/r 
RTV is the recommended booster for women on treatment with boosted PI 
during pregnancy
DRV/c is not recommended during pregnancy due to significant lower 
exposures of DRV and COBI in the second and third trimester of 
pregnancy
EFV is a suitable alternative for pregnant persons needing to start 
treatment. It can be continued if already started before pregnancy 
NVP not to be initiated, but continuation is possible if started before 
pregnancy 
Limited experience with TAF in pregnancy: not recommended in initial 
regimen
No experience with BIC in pregnancy: not recommended
Drugs contraindicated during pregnancy DTG (first trimester), ddI + d4T, triple NRTI combinations
iv ZDV during labour Only if HIV-VL > 50 copies/mL at week 34-36
Single dose NVP during labour Not recommended
Caesarean section Only if HIV-VL > 50 copies/mL at week 34-36 
Breastfeeding We advise against breastfeeding. In case a woman insists on 
breastfeeding, we recommend follow-up with increased clinical and 
virological monitoring of both the mother and the infant
Treatment of HIV-positive Pregnant Women                                                                                         
Pregnant women should be monitored every month and as close as  
possible to the predicted delivery date
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Important drug-drug interactions between ART and  
rifampicin / rifabutin
ARV drug 
class
Specific ARVs Drug-drug interactions and recom-
mended adjustment of dose of either 
or both drugs
NRTIs(i) rifampicin: standard dose of all drugs 
rifabutin: standard dose of all drugs
PI/r and 
PI/c
rifampicin: not recommended
PI/r Monitor liver 
enzymes and, 
whenever possible, 
perform TDM for PI
rifabutin: dose as 150 mg qd(ii). PI/r at 
standard dose
PI/c rifabutin: not recommended. If needed 
recommended dose of rifabutin: 150 mg 
qd(iii)
NNRTIs EFV rifampicin: No dose change required. 
EFV: standard dose ARV TDM recom-
mended after 2 weeks
rifabutin: 450 mg qd. EFV: standard dose 
NVP neither rifampicin nor rifabutin recom-
mended 
RPV rifampicin: not recommended
rifabutin: standard dose. RPV dose 
should be increased (use with caution)
ETV rifampicin: not recommended
rifabutin: standard dose of both drugs 
(few data – use with caution)
INSTI EVG/c rifampicin: not recommended
rifabutin: 150 mg qd. EVG: standard 
dose. Use with caution.
RAL rifampicin: standard dose. RAL 400 or 
800 mg bid and perform TDM for RAL.
No data with RAL 1200 mg: do not use
rifabutin: standard dose of both drugs
DTG rifampicin: standard dose. DTG 50 mg bid 
(use only in absence of INSTI resistance)
rifabutin: standard dose of both drugs
BIC rifampicin: not recommended
rifabutin: no data available, not recom-
mended
Other 
ART
MVC rifampicin: MVC 600 mg bid
rifabutin: standard dose of MVC (300 
mg bid in absence of a PI, 150 mg bid in 
presence of a PI)
i The drug-drug interaction between TAF and rifampicin has not been 
evaluated in a clinical trial, therefore no clinical outcomes are available 
yet (only PK data available). 
ii Initial pharmacokinetic studies in healthy volunteers showed that 
concentrations of rifabutin and its active metabolite were significantly in-
creased when combined with PI/r. Thus, a reduction of rifabutin dosage 
to 150 mg x3/week was recommended to reduce the risk of rifabutin- 
related toxicity. However, more recent pharmacokinetic data derived 
from HIV/TB co-infected persons have shown that the co-administration 
of LPV/r or ATV/r with rifabutin (150 mg x3/week) resulted in rifabutin 
concentrations that were lower than those observed with rifabutin 300 
mg x1/day without PI/r suggesting that rifabutin dosage may be inade-
quate. Cases of relapses with acquired rifamycin-resistant TB have been 
described in co-infected persons treated with rifabutin 150 mg x3/week 
and LPV/r or ATV/r. The US guidelines for HIV treatment recommend the 
administration of rifabutin at 150 mg qd with PI/r. Due to the limited safe-
ty data with this dose and combination, persons receiving rifabutin 150 
mg qd with PI/r should be closely monitored for rifabutin related toxicities 
(i.e. uveitis or neutropenia). 
iii    Few data are available. Use with caution and always seek the advice 
of an HIV specialist. Some experts advise that, in presence of COBI a 
rifabutin dose of 150 mg x3/week may be used in order to reduce the 
risk of toxicity. If used at 150 mg qd, enhanced monitoring of rifabutin 
toxicity is needed.       
ART in TB/HIV Co-infection           
Principles
Persons with TB should be started on standard TB therapy with 2 months 
rifampicin/isoniazid/pyrazinamide/ethambutol followed by 4 months  
rifampicin/isoniazid (choice of drugs and length of treatment depends on 
drug susceptibility and site of disease), see Diagnosis and Treatment of TB 
in HIV-positive Persons
All persons with TB/HIV co-infection should start ART irrespective of CD4 
count. Treatment supervision and adherence evaluation are very important. 
Suggested timing of ART initiation in TB/HIV co-infection  
according to CD4 count 
< 50 cells/µL*,** : As soon as TB treatment is tolerated and wherever possible 
within 2 weeks 
≥ 50 cells/µL: Can be deferred until between 8 and 12 weeks of TB treat-
ment, especially when there are difficulties with drug-drug interactions, 
adherence and toxicities
Although a RCT showed that early ART (within 2 weeks) did not reduce mor-
tality in TB meningitis, recommendations on ART initiations should be based 
on the CD4 count in HIV-positive persons with TB co-infection.
*  Be aware of IRIS reaction in persons starting ART at low CD4 count lev-
els and with early initiation of ART. Corticosteroids should be considered 
for treatment of symptomatic IRIS, with dosages and duration tailored 
according to response.
 See online video lectures HIV and IRIS-Part 1 and HIV and IRIS-Part 2 
from the EACS online course Clinical Management of HIV. 
**  Although the data suggest a cut-off of 50 cells/µL, because of the daily 
variability in CD4 count, a cut-off of 100 cells/µL may be more appropri-
ate.
Recommended 1st line ARV combination with anti-TB medicines
TDF/FTC + RAL or TDF/FTC/EFV (see table for dose adjustment with 
rifamycins).
Alternatives
Where combinations are not recommended or to be used with caution or 
because of resistance/intolerance, specialist HIV treatment advice should be 
sought.
• TDF/FTC + PI/r, using rifabutin instead of rifampicin (see table for dose 
adjustment of rifabutin). Use with caution. 
• TDF/FTC + DTG bid with rifampicin. 
In countries where neither DTG nor rifabutin are available, following combi-
nations could also represent a short-term alternative until anti-TB treatment 
has been completed.
• Rifampicin plus fixed-dose combination of ABC/3TC/ZDV bid + TDF qd (if 
HIV-VL < 100,000 copies/mL).
• Rifampicin plus double dose LPV/r or with RTV super boosted (400 mg 
bid) + LPV.
• For other regimens based on 2 NRTIs plus NVP, RPV, ETV or MVC, con-
sultation with an HIV specialist is recommended. 
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Post-exposure Prophylaxis (PEP)                                       
PEP recommended in case of:
Risk Nature of exposure                            Status of source person
Blood Subcutaneous or 
intramuscular penetration 
with iv or im needle, or 
intravascular device
HIV-positive or recent 
serostatus unknown, 
but presence of HIV risk 
factors
Percutaneous injury with 
sharp instrument (lancet), 
im or sc needle, suture 
needle
Contact > 15 min of 
mucous membrane or non- 
intact skin
HIV-positive
Genital 
secretions
Anal or vaginal sex Viraemic HIV-positive 
or serostatus unknown 
but presence of HIV risk 
factors. If source person 
is on ART, PEP should 
be started, HIV-VL should 
be repeated, and, if 
undetectable, PEP can be 
stopped
Receptive oral sex with 
ejaculation
Viraemic HIV-positive
Intravenous 
drug use 
Exchange of syringe, 
needle, preparation 
material or any other 
material
HIV-positive
• Rapid testing of the source person for HCV and HIV (if HIV-status 
   unknown) recommended.
• If source person HIV-positive on ART, order resistance testing  
if HIV-VL detectable.
• Individualise PEP according to the source’s treatment history and  
previous resistance tests.
• For sexual exposure, if HIV-positive source has documented undetectable 
HIV-VL, PEP is no longer recommended.
• PEP to be started ideally < 4 hours after the exposure, and no later than 
48/72 hours.
• Duration of PEP: 4 weeks (unless discontinued due to lack of indication)
• PEP regimens: TDF/FTC (alternative: ZDV/3TC) + RAL bid, or + DRV/r 
qd or + LPV/r bid. TDF/FTC + DTG qd may be also considered as an 
alternative.
• Clinical experience with TAF in the PEP setting is lacking, hence its use 
should be avoided.
• Full sexual health screen in case of sexual exposure.
• Emergency contraception counselling for sexual exposure.
• Follow-up:
– HIV serology + HBV and HCV, pregnancy test (women)  
within 48 hours of exposure
– Re-evaluation of PEP indication by HIV expert within 48-72 hours
– Assess tolerability of PEP regimen
– Transaminases, HCV-PCR and HCV serology at month 1 if source 
person HCV-positive (observed or suspected)
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Pre-exposure Prophylaxis (PrEP)                                       
1. PrEP should be used in adults at high-risk of acquiring HIV infection 
when condoms are not used consistently. Before PrEP is initiated, HBV 
serology status should be documented.  
• Before PrEP is initiated, HBV serology status should be documented. 
If HBsAg positive, see Clinical Management and Treatment of HBV 
and HCV Co-infection in HIV-positive Persons.
• Counsel that PrEP does not prevent other types of STIs; screen for 
STI (including HCV) when starting PrEP and regularly during use of 
PrEP.
• Counsel that PrEP may impact renal and bone health, see pages 
49 and 52-53. Check renal function before starting PrEP and check 
renal function and bone mineral density during PrEP according to 
guidelines on TDF use. 
• Counsel that PrEP, like other prevention methods, only works when it 
is taken. Adherence counselling is recommended.
• Counsel that PrEP can be prescribed long-term but that each 
consecutive PrEP prescription should be for a period of maximum 3 
months (90 tablets) to ensure appropriate monitoring.
 See online video lectures PrEP-Part 1 and PrEP-Part 2 from the 
EACS online course Clinical Management of HIV.
 
3.     PrEP regimen
• TDF/FTC 300*/200 mg 1 tablet qd. For MSM with high-risk sexual 
behaviour PrEP may be dosed ‘on demand’ (double dose of TDF/
FTC 2-24 hours before each sexual intercourse, followed by two 
single doses of TDF/FTC, 24 and 48 hours after the first drug intake). 
If dosed ‘on demand’, the total dose per week should not exceed 7 
tablets. 
• Use of generic formulations of TDF/FTC, if and where available, may 
help to improve the cost-effectiveness of PrEP, which is essential for 
its use as public health approach.
• There are not currently clinical data on the use of 3TC or TAF for 
PrEP. 
* In certain countries TDF is labelled as 245 mg rather than 300 mg to 
reflect the amount of the prodrug (tenofovir disoproxil) rather than the 
fumarate salt (tenofovir disoproxil fumarate).
• Recommended in HIV-negative men who have sex with men (MSM) 
and transgender individuals when condoms are not used 
 consistently with casual partners or with HIV-positive partners who are 
not on treatment. A recent STI, use of post-exposure prophylaxis or 
chemsex may be markers of increased risk for HIV acquisition.
• May be considered in HIV-negative heterosexual women and men who 
are inconsistent in their use of condoms and have multiple 
 sexual partners where some of whom are likely to have HIV 
 infection and not being on treatment.
2. PrEP is a medical intervention that provides a high level of protection 
against HIV acquisition but does not protect against other STIs and 
should be used in combination with other preventive interventions.
 PrEP should be supervised by a doctor, experienced with sexual health 
and use of HIV medicines, possibly as part of a shared care arrange-
ment. 
The following procedures are recommended: 
• Documented negative fourth generation HIV test prior to starting PrEP. 
During PrEP, this test should be repeated every 3 months, and PrEP 
should be stopped immediately in case of early clinical signs of HIV 
 seroconversion or a positive HIV diagnostic test and the person 
 referred for evaluation to an HIV unit.
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Adverse Effects of ARVs and Drug Classes Bold: Frequent effectsRed: Severe effects 
Black: Neither Frequent nor Severe(i)
Skin Digestive Liver CV Musculo-skeletal
Genito-
urinary Nervous Body fat Metabolic Other
NRTIs
ABC Rash* Nausea*
Diarrhoea*
IHD *Systemic 
hypersensitivity 
syndrome
(HLA B*5701 
dependent)
ZDV(ii) Nail pigmen-
tation
Nausea Steatosis Myopathy,
Rhabdomy-
olysis
Lipoatrophy
Dyslipi-
daemia,
Hyperlacta- 
taemia
Anaemia
d4T(ii)
Pancreatitis
Steatosis
Peripheral 
neuropathy
Dyslipi-
daemia,
Hyperlacta- 
taemia
ddI(ii) Steatosis, 
Liver fibrosis
IHD Hyperlacta- 
taemia
3TC
FTC
TDF(iii) Hepatitis ↓ BMD,  
Osteomalacia
↑ Fractures 
risk
↓ eGFR,
Fanconi  
syndrome
TAF(iii)
NNRTIs
EFV Rash Hepatitis Depression, 
Sleep  
disturbances,  
Headache,
Suicidal 
ideation
Dyslipi-
daemia,
Gynaeco-
mastia
↓ plasma 
25(OH) 
vitamin D  
ETV Rash
NVP Rash* Hepatitis* *Systemic 
hypersensitivity 
(CD4 count and 
gender
dependent)
RPV Rash Hepatitis ↓ eGFR(iv) Depression,  
Sleep  
disturbances, 
Headache
PIs
ATV(v)
Nausea
and
Diarrhoea(vii)
Hyperbiliru-
binaemia,
Jaundice,
Cholelithiasis
↓ eGFR, 
Nephrolithiasis
Dyslipi-
daemia
DRV(v) Rash IHD Nephrolithiasis Dyslipi-
daemia
FPV(vi) Rash IHD Dyslipi-
daemia
IDV(vi) Dry skin, 
Nail 
dystrophy
Jaundice IHD Nephrolithiasis  ↑ Abdominal 
fat
Dyslipi-
daemia,
Diabetes 
mellitus
LPV IHD ↓ eGFR Dyslipi-
daemia
SQV(vi) Dyslipi-
daemia
TPV(vi) Hepatitis Intracranial 
haemorrhage
Dyslipi-
daemia
Boosting
RTV ↓ eGFR(iv)
COBI ↓ eGFR(iv)
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FI
ENF Injection 
nodules
Hypersensitivity
INSTI
RAL Nausea Myopathy,
Rhabdomy-
olysis
Sleep 
disturbances,
Headache
Systemic 
hypersensitivity 
syndrome(viii)
DTG Rash Nausea ↓ eGFR(iv) Sleep 
disturbances,
Headache
Systemic
hypersensitivity 
syndrome
(< 1%)
EVG/c Nausea, 
Diarrhoea
↓ eGFR(iv) Sleep 
disturbances, 
Headache
CCR5 inhibitor
MVC Hepatitis  
i  "Frequent effects" (events expected in at least 10% of treated 
HIV-positive persons), in bold. 
 "Severe effects" (events that can put a person's life at risk and represent 
a medical emergency), in red. 
 "Neither frequent nor severe effects", in black. 
ii   Still available, but generally not recommended due to toxicity. 
iii   TDF has been the classical prodrug of tenofovir. TAF has lower tenofo-
vir-related kidney and bone adverse effects, but long-term 
  experience is lacking, see pages 52-53 and page 49. 
iv   Due to inhibition of renal tubular creatinine secretion without affecting 
glomerular filtration itself. 
v   ATV can be used unboosted, or boosted with low-dose RTV or COBI. 
ATV-related adverse effects are more common with boosting. DRV can 
be used boosted with low-dose RTV or COBI. Both low-dose RTV and 
COBI as boosters may cause similar minor digestive problems. 
vi   Still available but seldom used. Requires RTV-boosting.
vii  Frequency and severity differs between individual ARVs.
viii DRESS syndrome reported, but currently in only 6 cases.
*   Refers to effects seen in relation to hypersensitivity reactions.
Note: the adverse effects included in the table above are not exhaustive, but 
represent the most important effects with a likely causal relation. Nausea, 
diarrhoea and rash are frequently observed in persons on ART, and these 
symptoms are indicated in the table for drugs where clinical experience 
suggests a possible causal link. 
See online video lecture Adverse Effects and Monitoring of ART from the 
EACS online course Clinical Management of HIV.
Skin Digestive Liver CV Musculo-skeletal
Genito-
urinary Nervous Body fat Metabolic Other
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Drug-drug Interactions between ARVs and Non-ARVs(i)
Non-ARV drugs ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
C
ar
di
ov
as
cu
la
r d
ru
gs
atorvastatin ↑822% ↑ ↑290% ↑ ↑490% ↓43% ↓37% ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
fluvastatin ↑ ↑ ↑ ↔ ↔ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
pravastatin ↑ ↑ ↑ ↑81% ↔ ↓44% ↓ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
rosuvastatin ↑242% ↑213% ↑93% ↑48% ↑107% ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑38% ↔ ↔ ↔ ↔ ↔ ↔
simvastatin ↑ ↑ ↑ ↑ ↑ ↓68% ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
amlodipine ↑iii ↑iii ↑ ↑ ↑iii ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
diltiazem ↑iii ↑iii ↑ ↑ ↑iii ↓69% ↓E ↓ E E E ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
metoprolol ↑iii ↑iii ↑ ↑ ↑iii ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
verapamil ↑iii ↑iii ↑ ↑ ↑iii ↓ ↓E ↓ E E E ↔ ↑ ↔ ↔ ↔ ↔ E E
warfarin ↑ ↑ or ↓ ↑ ↓ ↓ ↑ or ↓ ↑ ↑ or ↓ ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
C
N
S 
dr
ug
s
diazepam ↑ ↑ ↑ ↑ ↑ ↓ ↑ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
midazolam (oral) ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
triazolam ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
citalopram ↑iii ↑iii ↑ ↑ ↑iii ↓ ↓ ↓ ↔iv ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
mirtazapine ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
paroxetine ↑↓? ↑↓? ↑↓? ↓39% ↑↓? ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑↓? ↔ ↔ ↔ ↔ ↔ ↔
sertraline ↑ ↓ ↑ ↓49% ↓ ↓39% ↓ ↓ ↔ ↔ ↔ ↔ ↓7% ↔ ↔ ↔ ↔ ↔ ↔
bupropion ↔ ↓ ↔ ↓ ↓57% ↓55% ↔ ↓ ↔ ↔ ↔ ↔ ↑? ↔ ↔ ↔ ↔ ↔ ↔
pimozide ↑iii ↑iii ↑ ↑ ↑iii ↑ ↓ ↓ ↔iv ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
carbamazepine ↑D ↑D ↑D ↑ ↑D ↓27%D36% D ↓D D D D D D Dxii ↑ ↔ ↔ D ↔
lamotrigine ↔ ↓32%ii ↔ ↓ii ↓50% ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
phenytoin D ↓D D ↓D ↓D ↓D D ↓D D D D D D Dxii D ↔ ↔ D ↔
A
nt
i-i
nf
ec
tiv
es
clarithromycin ↑Eiii ↑iii ↑ ↑ ↑iii ↓ ↓E ↓ E E E ↔ ↑E ↔ ↔ ↔ ↔ E E
fluconazole ↑? ↔ ↑? ↔ ↔ ↔ E86% E100% E ↔ ↔ ↔ ↑? ↔ ↔ ↔ ↔ E? ↔
itraconazole ↑E ↑E ↑E ↑E ↑E ↓ ↓E ↓61% E E E ↔ ↑E ↔ ↔ ↔ ↔ E E
rifabutin ↑D ↑ ↑D ↑E50% ↑ ↓38% D37% ↑17% D * D ↔ ↑D ↔ ↔ ↔ ↔ Dxi ↔
rifampicin D D72% D D D D26% D D58% D80% D D D54%x D D40%xii D ↔ ↔ Dxi ↔
voriconazole ↑E ↓ ↑E ↓ ↓ ↓E ↑E ↓E E E E ↔ ↑E ↔ ↔ ↔ ↔ ↔ ↔
M
is
ce
lla
ne
ou
s
antacids D D ↔ ↔ ↔ ↔ ↔ ↔ D ↔ D D D Dxiii ↔ ↔ ↔ ↔ ↔
PPIs D D ↔ ↔ ↔ ↔ ↔ ↔ D ↔ ↔ ↔ ↔ E ↔ ↔ ↔ ↔ ↔
H2 blockers D D ↔ ↔ ↔ ↔ ↔ ↔ D ↔ ↔ ↔ ↔ E ↔ ↔ ↔ ↔ ↔
alfuzosin ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
beclometasone 
inhal.
↑v ↑v ↑?v ↓11% ↑v ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑v ↔ ↔ ↔ ↔ ↔ ↔
buprenorphine ↑ ↑67% ↑ ↑vi ↔ ↓50% ↓25% ↔ ↔ ↔ ↔ ↔ ↑35% ↔ ↔ ↔ ↔ ↔ ↔
budesonide inhal. ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
ergot derivatives ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↓ E ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
ethinylestradiol ↔ ↓19% vii ↑30% ↓44% ↓ 42% ↔viii ↑22% ↓20% ↑14% ↔ ↔ ↑3% ↓25% ↔ ↔ ↔ ↔ ↔ ↔
fluticasone inhal. ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
methadone ↑? iii ↓ii, iii ↑? ↓16% ↓53%iii ↓52% ↑6% ↓≈50% ↓16% ↔ ↔ ↔ ↑7% ↔ ↓ ↔ ↔ ↔ ↔
salmeterol inhal. ↑iii ↑iii ↑ ↑ ↑iii ↓ ↓ ↓ ↔iv ↔ ↔ ↔ ↑iii ↔ ↔ ↔ ↔ ↔ ↔
sildenafil (erec. 
dys.)
↑ ↑ ↑ ↑ ↑ ↓ ↓37% ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
St John's wort D D D D D D D D D D D D D D ↔ ↔ ↔ D ↔
varenicline ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Comments      
i This table summarises the drug-drug interactions between HIV therapy and some commonly 
prescribed co-medicines as well as the drug-drug interactions of particular clinical relevance. 
This table is not exhaustive. For additional drug-drug interactions and for more detailed phar-
macokinetic interaction data and dosage adjustments, see http://www.hiv-druginteractions.org 
(University of Liverpool).
Legend      
↑  potential elevated exposure of non-ARV drug
↓  potential decreased exposure of non-ARV drug
↔ no significant effect     
E potential elevated exposure of ARV
D potential decreased exposure of ARV      
Numbers refer to decreased/increased AUC of non-ARV/ARV drugs as observed in drug interac-
tions studies.  
ATV/c  ATV co-formulated with COBI (300/150 mg qd);  
DRV/c DRV co-formulated with COBI (800/150 mg qd)
ii no PK changes with unboosted PI
iii  ECG monitoring is recommended
iv RPV manufacturer recommends caution when co-administering with another drug susceptible 
to prolong QT interval
v increase in concentration of active metabolite observed with RTV 100 mg bid alone but with-
out significant effect on adrenal function. Caution is still warranted, use the lowest possible 
corticosteroid dose and monitor for corticosteroid side effects. 
vi concentration of parent drug unchanged but concentration of metabolite increased 
vii  increase in ethinylestradiol with unboosted ATV  
viii  no effect on ethinylestradiol but ↓ progestin 
ix  potential haematological toxicity
        
x   administer DTG at a dose of 50 mg bid in treatment-naïve or INSTI-naïve HIV-positive persons.  
Alternative to rifampicin should be used where possible for INSTI-experienced HIV-positive 
persons with certain INSTI-associated resistance substitutions or clinically suspected INSTI 
resistance
xi interaction can be overcome by administering TAF 25 mg bid; 
xii  co-administration of RAL 1200 mg qd is not recommended with strong inducers. If co-adminis-
tration is unavoidable, RAL should be used 400 mg bid with monitoring of response,
xiii  Al, Mg containing antacids: not recommended with RAL 400 mg bid or RAL 1200 mg qd. If 
co-administration with antacid is unavoidable, calcium carbonate antacids can be used but only 
with RAL 400 mg bid
*  no dose adjustment for MVC in absence of PI. With PI (except TPV/r; FPV/r), give MVC 150 mg 
bid
Note: interactions with ZDV: clarithromycin, rifampicin (decrease in ZDV exposure), fluconazole, 
rifampicin (increase in ZDV exposure), carbamazepine (increase in carbamazepine exposure), 
phenytoin (decrease in phenytoin exposure)      
 
Colour legend 
 no clinically significant interaction expected
 these drugs should not be co-administered
 potential clinically significant interaction that is likely to require additional monitoring, altera-
tion of drug dosage or timing of administration 
 potential interaction likely to be of weak intensity. Additional action/monitoring or dosage 
adjustment is unlikely to be required
Comment 
For additional drug-drug interactions and for more detailed pharmacokinetic interaction data and 
dosage adjustments, please refer to http://www.hiv-druginteractions.org (University of Liverpool). 
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Antidepressants ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL
SSRI citalopram ↑a ↑a ↑ ↑ ↑a ↓ ↓ ↓ ↔b ↔ ↔ ↔ ↑ ↔
escitalopram ↑a ↑a ↑ ↑ ↑a ↓ ↓ ↓ ↔b ↔ ↔ ↔ ↑ ↔
fluvoxamine ↑ ↑ ↑ ↑ ↑ ↔ ↔ E ↔ ↔ ↔ ↔ ↑ ↔
fluoxetine ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
paroxetine ↑↓? ↑↓? ↑↓? ↓39% ↑↓? ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑↓? ↔
sertraline ↑ ↓ ↑ ↓49% ↓ ↓39% ↓ ↓ ↔ ↔ ↔ ↔ ↓7% ↔
SNRI duloxetine ↑ ↑↓ ↑ ↑↓ ↑↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
venlafaxine ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ D ↔ ↔ ↑ ↔
TCA amitriptyline ↑a ↑a ↑ ↑ ↑a ↔ ↔ ↔ ↔b ↔ ↔ ↔ ↑ ↔
clomipramine ↑a ↑a ↑a ↑a ↑a ↓ ↓ ↓ ↔b ↔ ↔ ↔ ↑a ↔
desipramine ↑a ↑a ↑ ↑ ↑5%a ↔ ↔ ↔ ↔b ↔ ↔ ↔ ↑ ↔
doxepin ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
imipramine ↑a ↑a ↑a ↑a ↑a ↓ ↓ ↓ ↔b ↔ ↔ ↔ ↑a ↔
nortriptyline ↑a ↑a ↑ ↑ ↑a ↔ ↔ ↔ ↔b ↔ ↔ ↔ ↑ ↔
trimipramine ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
TeCA maprotiline ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
mianserine ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔
mirtazapine ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔
Oth-
ers
bupropion ↔ ↓ ↔ ↓ ↓57% ↓55% ↔ ↓ ↔ ↔ ↔ ↔ ↑? ↔
lamotrigine ↔ ↓32% ↔ ↓ ↓50% ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
nefazodone ↑ ↑ ↑ ↑ ↑ ↓E ↓E ↓E E E E ↔ ↑ ↔
St John's wort D D D D D D D D D D D Dc D D
trazodone ↑a ↑a ↑ ↑ ↑a ↓ ↓ ↓ ↔b ↔ ↔ ↔ ↑ ↔
Legend
↑  potential elevated exposure of the antidepressant       
↓  potential decreased exposure of the antidepressant
↔  no significant effect     
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
ATV/c   ATV co-formulated with COBI (300/150 mg qd);  
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a  ECG monitoring is recommended       
b  caution as both drugs can induce QT interval prolongation
c           the US Prescribing Information recommends that co-administration 
should be avoided as there are insufficient data to make dosing 
recommendations
Numbers refer to decreased AUC of the antidepressant as observed in drug-
drug interactions studies.
Note: no clinically relevant interactions expected between ZDV (or any other 
NRTI) and antidepresssants
SSRI  selective serotonin reuptake inhibitors 
SNRI serotonin and norepinephrine reuptake inhibitors
TCA  tricyclic antidepressants    
TeCA  tetracyclic antidepressants
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion  
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required 
Comment
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).    
       
Drug-drug Interactions between Antidepressants and ARVs
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Antihypertensives ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
A
C
E 
in
hi
bi
to
rs
captopril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
cilazapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
enalapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
lisinopril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
perindopril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
quinapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
ramipril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
trandolapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
A
ng
io
te
ns
in
 
an
ta
go
ni
st
s
candesartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
eprosartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
irbesartan ↔ ↓ ↔ ↓ ↓ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
losartan ↔ ↓a ↔ ↓a ↓a ↑b ↑b ↔ ↔ ↔ ↔ ↔ ↓a ↔ ↔ ↔ ↔ ↔ ↔
olmesartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
telmisartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
valsartan ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
β 
bl
oc
ke
rs
atenolol ↔d ↔d ↔ ↔ ↔d ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
bisoprolol ↑d ↑d ↑ ↑ ↑d ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
carvedilol ↑d ↑↓d ↑ ↑↓ ↑↓d ↑↓ ↑↓ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
metoprolol ↑d ↑d ↑ ↑ ↑d ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
propranolol ↑d ↑d ↑ ↑ ↑d ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
C
al
ci
um
 c
ha
nn
el
 b
lo
ck
er
s amlodipine ↑c ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
diltiazem ↑c ↑c ↑ ↑ ↑e ↓69% ↓E ↓ E E E ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
felodipine ↑c ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
lacidipine ↑c ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
lercanidipine ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
nicardipine ↑c ↑c ↑ ↑ ↑e ↓ ↓E ↓ E E ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
nifedipine ↑c ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
nisoldipine ↑c ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
verapamil ↑c ↑c ↑ ↑ ↑e ↓ ↓E ↓ E E E ↔ ↑ ↔ ↔ ↔ ↔ E E
D
iu
re
tic
s
amiloride ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
bendroflumethiazide ? ? ? ? ? ? ? ? ↔ ↔ ↔ ↔ ? ↔ ↔ ↔ ↔ ↔ ↔
chlortalidone ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
furosemide ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ E
indapamide ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
hydrochlorothiazide ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
torasemide ↔ ↓ ↔ ↓ ↓ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
O
th
er
s doxazosin ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
sacubitril ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ E ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑
spironolactone ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Drug-drug Interactions between Antihypertensives and ARVs
Legend
↑  potential elevated exposure of the antihypertensive     
↓  potential decreased exposure of the antihypertensive
↔  no significant effect     
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
ATV/c   ATV co-formulated with COBI (300/150 mg qd);  
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a  [parent drug] decreased but [active metabolite] increased    
b  [parent drug] increased but [active metabolite] decreased
c  ECG monitoring recommended   
d  risk of PR interval prolongation
e use with caution as both LPV and calcium channel blockers prolong 
the PR interval. Clinical monitoring is recommended.
Numbers refer to decreased AUC of the antihypertensive as observed in 
drug-drug interactions studies.
Note: no clinically significant interactions expected between ZDV and anti-
hypertensives
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion 
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required
 there are no clear data, actual or theoretical, to indicate whether an 
interaction will occur 
Note: although some drug interactions are predicted to potentially require a 
dosage adjustment based on the drug's metabolic pathway, clinical 
experience with a particular antihypertensive and ARV drug may indicate 
that dosage adjustments are not an a priori requirement.    
Comment
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).     
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Analgesics ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
N
on
-o
pi
oi
d 
an
al
ge
si
cs
aspirin ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ g
celecoxib ↔ ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ g
diclofenac ↔ ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ Eg
ibuprofen ↔ ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ Eg
mefenamic acid ↔ ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ Eg
naproxen ↔ ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ Eg
nimesulide ↔ ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ g
paracetamol ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
piroxicam ↔ ↔ ↔ ↔ ↔ ↑a ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ g
O
pi
oi
d 
an
al
ge
si
cs
alfentanil ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
buprenorphine ↑ ↑67% ↑ ↑b ↔ ↓50% ↓25% ↔ ↔ ↔ ↔ ↔ ↑35% ↔ ↔ ↔ ↔ ↔ ↔
codeine ↑d ↑d ↑d ↑d ↑d ↓d ↓ d ↓ d ↔ ↔ ↔ ↔ ↑d ↔ ↔ ↔ ↔ ↔ ↔
dihydrocodeine ↑ ↓↑ ↑ ↓↑ ↓↑ ↓↑ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
fentanyl ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
methadone ↑?c ↓c ↑? ↓16% ↓53%c ↓52% ↑6% ↓≈50% ↓16% ↔ ↔ ↔ ↑7% ↔ ↓ ↔ ↔ ↔ ↔
morphine ↔h ↓h ↔h ↓h ↓h ↑ ↔h ↔ ↔ ↔ ↔ ↔ ↔h ↔ ↔ ↔ ↔ ↔ ↔
oxycodone ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
pethidine ↑ ↓e ↑ ↓e ↓e ↓e ↓e ↓e ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
sufentanil ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
tramadol ↑d ↑d ↑d ↑d ↑d ↓f ↔ ↔ ↔ ↔ ↔ ↔ ↑d ↔ ↔ ↔ ↔ ↔ ↔
Drug-drug Interactions between Analgesics and ARVs
Legend
↑   potential elevated exposure of the analgesic   
↓   potential decreased exposure of the analgesic
↔   no significant effect     
D   potential decreased exposure of ARV drug
E   potential elevated exposure of ARV drug
ATV/c  ATV co-formulated with COBI (300/150 mg qd);  
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a      clinical significance unknown. Use the lowest recommended dose  
particularly in individuals with risk factors for CVD, those indviduals 
at risk of developing gastrointestinal complications, persons with 
hepatic or renal impairment, and in elderly persons
b   [parent drug] unchanged but [metabolite] increased
c   both drugs can potentially prolong the QT interval, ECG monitoring 
recommended
d   potential decrease of the analgesic effect due to the reduced conver-
sion to the active metabolite
e   [parent drug] decreased and increased [neurotoxic metabolite]
f   [parent drug] decreased but no change in [more active metabolite] 
g      potential risk of nephrotoxicity which is increased if NSAID is used 
for a long duration, if the person has a pre-existing renal dysfunction,  
a low body weight or receives other drugs that may increase TDF 
exposure. Concurrent use of NSAIDs with TDF warrants monitoring 
of renal function
h      inhibition of P-gp by RTV and COBI could potentiate the effect of 
opiate in the CNS    
Numbers refer to increased or decreased AUC of the analgesic as observed 
in drug-drug interactions studies
Note: interactions with ZDV: ibuprofen, naproxen (potential additive hema-
tological toxicity); methadone (moderate increase in ZDV exposure, monitor 
for toxicity)
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion 
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required
Comment             
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).
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ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
A
nt
ic
oa
gu
la
nt
s
acenocoumarol ↔ ↓ ↔ ↓ ↓ ↓ ↑ ↓ ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
apixaban ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
dabigatran ↑ ↑ ↑ ↑ ↑? ↔ ↑ ↔ ↑? ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
dalteparin ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
edoxaban ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
enoxaparin ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
fondaparinux ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
heparin ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
phenprocoumon ↑ ↑or↓a ↑ ↑or↓ ↑or↓ ↓ ↑or↓ ↓ ↔ ↔ ↔ ↔ ↑or↓ ↔ ↔ ↔ ↔ ↔ ↔
rivaroxaban ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
warfarin ↑ ↑or↓a ↑ ↓ ↓ ↑or↓ ↑ ↑or↓ ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
A
nt
ip
la
te
le
t 
ag
en
ts
aspirin ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
clopidogrel ↓b ↓b ↓b ↓b ↓b ↓b ↓b ↑c ↔ ↔ ↔ ↔ ↓b ↔ ↔ ↔ ↔ ↔ ↔
dipyridamole ↑ ↓d ↔ ↓ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
prasugrel ↓e ↓e ↓e ↓e ↓e ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↓e ↔ ↔ ↔ ↔ ↔ ↔
ticagrelor ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
Drug-drug Interactions between Anticoagulants/Antiplatelet Agents 
and ARVs
Legend
↑  potential elevated exposure of the anticoagulant/antiplatelet agent     
↓  potential decreased exposure of the anticoagulant/antiplatelet agent
↔  no significant effect     
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
ATV/c  ATV co-formulated with COBI (300/150 mg qd);  
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a  unboosted ATV predicted to increase the anticoagulant, monitor INR 
and adjust the anticoagulant dosage accordingly    
b  decreased conversion to active metabolite leading to non-respon-
siveness to clopidogrel. An alternative to clopidogrel should be 
considered   
c  increase in amount of active metabolite via induction of CYP3A4 and 
CYP2B6
d unboosted ATV predicted to increase dipyridamole exposure due to 
UGT1A1 inhibition
e reduced active metabolite, but without a significant reduction in 
prasugrel activity
Note: no clinically significant interactions expected between ZDV and antico-
agulants or platelet agents
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion 
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required 
Comment
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).     
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Drug-drug Interactions between Bronchodilators (for COPD) and ARVs 
Bronchodilators ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
LA
M
A
aclidinium bromide ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
glycopyrronium 
bromide
↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
tiotropium bromide ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
umeclidinium 
bromide
↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
SA
M
A ipratropium ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
LA
B
A
formoterol ↔a ↔a ↔ ↔ ↔a ↔ ↔ ↔ ↔a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
indacaterol ↑d ↑d ↑d ↑d ↑d ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑d ↔ ↔ ↔ ↔ ↔ ↔
olodaterol ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
salmeterol ↑b ↑b ↑b ↑b ↑b ↓ ↓ ↓ ↔a ↔ ↔ ↔ ↑b ↔ ↔ ↔ ↔ ↔ ↔
vilanterol ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
SA
B
A salbutamol (alb-
uterol)
↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
M
X aminophylline ↔ ↓ ↔ ↓ ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
theophylline ↔ ↓ ↔ ↓ ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
PD
E4 roflumilast ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
IC
S
beclometasone ↑c ↑c ↑?c ↓11% ↑c ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
budesonide ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
fluticasone ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
Legend
↑  potential elevated exposure of the bronchodilator     
↓  potential decreased exposure of the bronchodilator
↔  no significant effect     
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
ATV/c  ATV co-formulated with COBI (300/150 mg qd);  
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a  caution as both drugs can induce QT interval prolongation    
b  ECG monitoring is recommended
c  increase in concentration of active metabolite observed with RTV 
100 mg bid alone but without significant effect on adrenal function. 
Caution is still warranted, use the lowest possible corticosteroid dose 
and monitor for corticosteroid side effects    
d  exposure can be increased up to 2-fold however this increase does 
not raise any concerns based on indacaterol's safety data
ICS   inhaled corticosteroids 
LABA  long-acting β2 agonists 
LAMA  long-acting muscarinic antagonists    
MX   methylxanthines
PD4     phosphodiesterase 4 inhibitors  
SABA  short-acting β2 agonists
SAMA short-acting muscarinic antagonists
Note: no clinically significant interactions expected between ZDV and bron-
chodilators
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion 
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required
Comment             
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).
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Drug-drug Interactions between Contraceptives and ARVs
ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
Es
ethinylestradiol 
(COC, TS, VR)
↔ ↓19%a ↓30% ↓44%b ↓42%b ↔c ↑22% ↓20% ↑14% ↔ ↔ ↑3% ↓25%d ↔ ↔ ↔ ↔ ↔ ↔
Pr
og
es
tin
s
desogestrel (COC) ↑ ↑e,a ↑ ↑f ↑f ↓g ↓ ↓ ↔ ↔ ↔ ↔ ↑d,e ↔ ↔ ↔ ↔ ↔ ↔
desogestrel (POP) ↑ ↑ ↑ ↑ ↑ ↓g ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
drospirenone (COC) ↑ ↑e,a ↑f ↑f ↑f ↓g ↓ ↓ ↔ ↔ ↔ ↔ ↑d,e ↔ ↔ ↔ ↔ ↔ ↔
etonogestrel (IP) ↑ ↑ ↑ ↑ ↑52% ↓63%g ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
etonogestrel (VR) ↑ ↑≈80%h ↑ ↑h ↑h ↓g ↓ ↓ ↔ ↔ ↔ ↔ ↑h ↔ ↔ ↔ ↔ ↔ ↔
gestodene (COC) ↑ ↑e,a ↑ ↑f ↑f ↓g ↓ ↓ ↔ ↔ ↔ ↔ ↑d,e ↔ ↔ ↔ ↔ ↔ ↔
levonorgestrel (COC) ↑ ↑e,a ↑ ↑f ↑f ↓g ↓ ↑ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
levonorgestrel (IP) ↑ ↑ ↑ ↑ ↑ ↓47%g ↓ ↑14% ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
levonorgestrel (POP) ↑ ↑ ↑ ↑ ↑ ↓g ↓ ↑ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
levonorgestrel (IUD) ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
medroxyprogester-
one (POI)
↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
norelgestromin (TS) ↑ ↑e,a ↑ ↑f ↑83%f ↓g ↓ ↓ ↔ ↔ ↔ ↔ ↑d,e ↔ ↔ ↔ ↔ ↔ ↔
norethisterone (COC) ↑ ↑e,a,i ↑ ↓14%f ↓17%f ↓g ↓5% ↓19% ↓11% ↔ ↔ ↔ ↑d,e ↔ ↔ ↔ ↔ ↔ ↔
norethisterone (POI) ↔ ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
norethisterone (POP) ↑ ↑50% ↑ ↑50% ↑50% ↓g ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
norgestimate (COC) ↑ ↑85%e,a ↑ ↑f ↑f ↓64%g ↓ ↓ ↔ ↔ ↔ ↔ ↑126%d,e ↑14% ↔ ↔ ↔ ↔ ↔
norgestrel (COC) ↑ ↑e,a ↑ ↑f ↑f ↓g ↓ ↑ ↔ ↔ ↔ ↔ ↑d,e ↔ ↔ ↔ ↔ ↔ ↔
O
th
er
levonorgestrel (EC) ↑j ↑j ↑j ↑j ↑j ↓58%k ↔ ↔ ↔ ↔ ↔ ↔ ↑j ↔ ↔ ↔ ↔ ↔ ↔
mifepristone ↑j ↑j ↑j ↑j ↑j ↓ ↓ ↓ Ej Ej ↔ ↔ ↑j ↔ ↔ ↔ ↔ ↔ ↔
ulipristal ↑j ↑j ↑j ↑j ↑j ↓l ↓l ↓l ↔ ↔ ↔ ↔ ↑j ↔ ↔ ↔ ↔ ↔ ↔
Legend
↑   potential increased exposure of the hormone  
↓   potential decreased exposure of the hormone
↔   no significant effect    
D   potential decreased exposure of ARV drug
E   potential elevated exposure of ARV drug
ATV/c  ATV co-formulated with COBI (300/150 mg qd);  
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a     unboosted ATV increased ethinylestradiol AUC by 48%. Use no more  
than 30 µg of ethinylestradiol if co-administered with unboosted ATV and 
at least 35 µg of ethinylestradiol if co-administered with ATV/r
b  alternative or additional contraceptive measures are recommended or, 
if used for hormone replacement therapy, monitor for signs of oestrogen 
deficiency
c     depending on the contraceptive method, ethinylestradiol levels are either 
not significantly changed (COC) or significantly decreased (VR).  Levels 
of coadministered progestin are markedly decreased. Use with EFV is 
not recommended as it may impair contraceptive efficacy
d  European SPC states a hormonal contraceptive should contain at least 
30 ug ethinylestradiol
e  when used in a combination pill, the estrogen component is reduced to a 
small extent 
f  when used in a combination pill, the estrogen component is significantly 
reduced, caution is recommended and additional contraceptive meas-
ures should be used  
g     EFV is expected to decrease the progestin exposure and thereby impair 
the efficacy of the contraceptive method. A reliable method of barrier 
contraception must be used in addition to hormonal contraceptives
h     used in combination with ethinylestradiol (0.015 mg/d) which is predicted 
to be decreased. Since there is no possibility to adjust ethinylestradiol, 
caution is recommended and additional contraceptive measures should 
be used
i      unboosted ATV increased norethisterone AUC by 110%
j      unlikely to have clinical consequences as hormone is administered as 
single dose    
k     use 3 mg as a single dose for emergency contraception. Of note, the 
doubling  of the standard dose is outside the product license and there is 
limited evidence in relation to efficacy 
l      not recommended, non hormonal emergency contraception (Cu-IUD) 
should be considered     
Es = estrogens     
Contraceptive options: COC - combined oral contraceptive, EC - emergency 
contraception, IP - implant, IUD - intrauterine device, POI - progestin only in-
jectable, POP - progestin only pill, TS - transdermal patch, VR - vaginal ring
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion  
 potential interaction likely to be of weak intensity or unlikely to impair 
contraceptive efficacy. Additional action/monitoring or dosage adjust-
ment is unlikely to be required 
Note: no clinically significant interactions expected between ZDV and con-
traceptives
Comment             
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).
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Drug-drug Interactions between Corticosteroids and ARVs 
Corticosteroids ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
In
ha
le
d,
 o
ra
l, 
to
pi
c 
an
d/
or
 in
je
ct
ed
 c
or
tic
os
te
ro
id
s
beclometasone 
(inhalation)
↑a ↑a ↑?a ↓b ↑a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑a ↔ ↔ ↔ ↔ ↔ ↔
betamethasone ↑c ↑c ↑c ↑c ↑c ↓ ↓ ↓ D D D ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
budesonide 
(inhalation)
↑c ↑c ↑c ↑c ↑c ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
clobetasol 
(topical)
↑c,d ↑c,d ↑c,d ↑c,d ↑c,d ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑c,d ↔ ↔ ↔ ↔ ↔ ↔
dexamethasone ↑c D ↑c D ↑c D ↑c D ↑c D ↓ D ↓ D ↓ D D D D ↔ ↑c D ↔ ↔ ↔ ↔ ↔ ↔
fluocinolone 
(topical)
↑c,d ↑c,d ↑c,d ↑c,d ↑c,d ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑c,d ↔ ↔ ↔ ↔ ↔ ↔
fluticasone 
(inhalation)
↑c ↑c ↑c ↑c ↑c ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
hydrocortisone 
(oral)
↑c ↑c ↑c ↑c ↑c ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
hydrocortisone 
(topical)
↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
methylpredni-
solone
↑c ↑c ↑c ↑c ↑c ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
mometasone 
(inhalation)
↑c ↑c ↑c ↑c ↑c ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
prednisolone 
(oral)
↑c ↑c ↑c ↑c ↑c ↓ 40% ↓ ↓ ↔ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
prednisone ↑c ↑c ↑c ↑c ↑c ↓ 40% ↓ ↓ ↔ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
triamcinolone ↑c ↑c ↑c ↑c ↑c ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
Legend
↑   potential increased exposure of the corticosteroid 
↓   potential decreased exposure of the corticosteroid
↔   no significant effect    
D   potential decreased exposure of ARV drug
E   potential elevated exposure of ARV drug
ATV/c  ATV co-formulated with COBI (300/150 mg qd);
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a     co-administration of RTV (100 mg bid) increased the concentrations of 
the active metabolite (beclometasone-17-monopropionate) but no signifi-
cant effect on adrenal function was seen. Caution is still warranted, use 
the lowest possible corticosteroid dose and monitor for corticosteroid 
side effects
b  DRV/r decreased the exposure of active metabolite (beclometa-
sone-17-monopropionate), no significant effect on adrenal function was 
seen
c  risk of having elevated corticosteroid levels, Cushing's syndrome and 
adrenal suppression. This risk is present for oral, injected but also for 
topical, inhaled or eye drops corticosteroid
d  the extent of percutaneous absorption is determined by many factors 
such as degree of inflammation and alteration of the skin, duration, 
frequency and surface of application, use of occlusive dressings
 
Note: no clinically significant interactions expected between ZDV and corti-
costeroids
Colour legend
 no clinically significant interaction expected 
 these drugs should not be co-administered 
 potential interaction which may require a dosage adjustment or close 
monitoring
Comment             
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).       
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Drug-drug Interactions between Antimalarial Drugs and ARVs 
Antimalarial drugs ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
Fi
rs
t l
in
e 
an
d 
se
co
nd
 li
ne
 d
ru
gs
amodiaquine ↔ ↑ ↔ ↑ ↑ ↑c ↓? ↓29%c ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
artemisinin ↑ ↑ ↑ ↑ ↑ ↓ ≈50% ↓D ↓D D D D ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
atovaquone ↔ ↓46%a ↔ ↓a ↓74%a ↓75%a ↓E55%a ↓a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
chloroquine ↔b ↔b ↔ ↔ ↔b ↔ ↔ ↔ ↔e ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
clindamycin ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
doxycycline ↔ ↔ ↔ ↔ ↔ ↓? ↓? ↓? ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
lumefantrine ↑b ↑b ↑ ↑ ↑b ↓ ≈40% ↓ ↓D46% ↔e ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
mefloquine ↑b ↑b ↑ ↑ ↑b ↓ ↓ ↓ ↔e ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
primaquine ↔ ↔ ↔ ↔ ↔ ↔d ↔d ↔d ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
proguanil ↔ ↓41%a ↔ ↓a ↓38%a ↓44%a ↓E55%a ↓a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
pyrimethamine ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ E E ↔ ↔
quinine ↑b ↑b ↑ ↑ ↑b ↓ ↓ ↓ ↔e E ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
sulfadoxine ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ E E ↔ ↔
Legend
↑   potential increased exposure of the antimalarial drug 
↓   potential decreased exposure of the antimalarial drug
↔   no significant effect    
D   potential decreased exposure of ARV drug
E   potential elevated exposure of ARV drug
ATV/c  ATV co-formulated with COBI (300/150 mg qd);
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a     take with high fat meal, consider dose increase
b  ECG monitoring is recommended
c  liver toxicity
d  increase of haemotoxic metabolites
e     both drugs can induce QT interval prolongation (only at supratherapeutic 
dose for RPV)
 
Note: interactions with ZDV: amodiaquine, atovaquone, primaquine, py-
rimethamine, sulfadoxine (potential additive hematological toxicity)
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion  
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required  
Comment             
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).
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Drug-drug Interactions between Pulmonary Antihypertensives and ARVs 
Pulmonary antihyperten-
sives
ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
ER
A
ambrisentan ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
bosentan ↑a ↑a ↑a ↑a ↑a ↓ ↓ ↓b D D D D ↑a ↔ ↔ ↔ ↔ ↔ ↔
macitentan ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
PD
E5 sildenafil ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
tadalafil ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
sG
C riociguat ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
PA
epoprostenol ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
iloprost ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
treprostinil ↔ ↑ ↔ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
IP
r selexipag ↔c ↔c ↔c ↔c ↔c ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔c ↔ ↔ ↔ ↔ ↔ ↔
Legend
↑   potential increased exposure of the pulmonary antihypertensive 
↓   potential decreased exposure of the pulmonary antihypertensive
↔   no significant effect    
D   potential decreased exposure of ARV drug
E   potential elevated exposure of ARV drug
ATV/c  ATV co-formulated with COBI (300/150 mg qd);
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a     when starting bosentan in individuals already on PI/r, PI/c or EVG/c 
use a bosentan dose of 62.5 mg qd or every other day. Discontinue 
bosentan at least 36 h prior to starting PI/r, PI/c or EVG/c and restart 
after at least 10 days at 62.5 mg qd or every other day  
b  potential additive liver toxicity
c  exposure of parent drug increased but exposure of active metabolite 
unchanged
ERA    endothelin receptor antagonists  
IPr       IP receptor agonists   
PA       prostacyclin analogues   
PDE5  phosphodiesterase type 5 inhibitors    
sGC   soluble guanylate cyclase stimulators    
       
Note: no clinically significant interactions expected between ZDV and pulmo-
nary antihypertensives 
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion  
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required 
Comment             
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).
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Drug-drug Interactions between Immunosuppressants (for SOT) and ARVs 
Immunosuppressants ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
C
S prednisone ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
A
M azathioprine ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
mycophenolate ↔ ↓ ↔ ↓ ↓ ↓ ↔ ↓D13% ↔ ↔ ↔ ↔ ↔ ↔ ↓? ↔ ↔ ↔ ↑ Eb
C
N
I cyclosporine ↑a ↑a ↑a ↑a ↑a ↓a ↓a ↓a E E E ↔ ↑a ↔ ↔ ↔ ↔ E Eb
tacrolimus* ↑a ↑a ↑a ↑a ↑a ↓a ↓a ↓a ↔ ↔ ↔ ↔ ↑a ↔ ↔ ↔ ↔ ↔ ↔b
m
TO
R everolimus ↑ ↑ ↑ ↑ ↑ ↓a ↓a ↓a ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
sirolimus ↑ ↑ ↑ ↑ ↑ ↓a ↓a ↓a ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔b
O
th
er
anti-thymocyte 
globulin
↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
basiliximab ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
belatacept ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Legend
↑   potential increased exposure of the immunosuppressant 
↓   potential decreased exposure of the immunosuppresant
↔   no significant effect    
D   potential decreased exposure of ARV drug
E   potential elevated exposure of ARV drug
ATV/c  ATV co-formulated with COBI (300/150 mg qd);
DRV/c DRV co-formulated with COBI (800/150 mg qd)
* available as prolonged release formulation  
Numbers refer to decreased/increased AUC of the immunosuppressant as 
observed in drug-drug interaction studies
a     TDM of immunosuppressant is recommended
b  monitor renal function
AM   antimetabolite    
CNI   calcineurin inhibitors   
CS   corticosteroids   
mTOR  mTOR inhibitors      
   
Note: interactions with ZDV: azathioprine (potential risk of additive hemato-
toxicity); mycophenolate (potential decrease in mycophenolate level, monitor 
plasma level)
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion  
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required 
Comment             
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).
EACS   European
AIDS Clinical Society
34EACS Guidelines 9.1 PART II
NRTIs
ABC Child-Pugh Class A: 200 mg bid (use oral solution)
Child-Pugh Class B or C: contraindicated
ddI Contraindicated
If used no dosage adjustment
d4T Contraindicated
If used no dosage adjustment
FTC No dosage adjustment
3TC No dosage adjustment
TAF No dosage adjustment
TAF/FTC No dosage adjustment
TDF No dosage adjustment
TDF/FTC No dosage adjustment
ZDV Reduce dose by 50% or double the interval between
doses if Child-Pugh Class C
NNRTIs
EFV No dosage adjustment; use with caution in persons 
with hepatic impairmentTDF/FTC/EFV
ETV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
NVP Child-Pugh Class B or C: contraindicated
RPV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
TAF/FTC/RPV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
TDF/FTC/RPV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
PIs
ATV Child-Pugh Class A: no dose adjustment
Child-Pugh Class B: 300 mg qd (unboosted)
Child-Pugh Class C: not recommended
ATV/c Child-Pugh Class A: no dosage adjustment
Child-Pugh Class B or C: not recommended
COBI Refer to recommendations for the primary PI
DRV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
DRV/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
TAF/FTC/DRV/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
FPV PI-naïve persons:
Child-Pugh Class A or B: 700 mg bid
Child-Pugh Class C: 350 mg bid
PI-experienced persons:
Child-Pugh Class A: 700 mg bid + RTV 100 mg qd
Child-Pugh Class B: 450 mg bid + RTV 100 mg qd
Child-Pugh Class C: 300 mg bid + RTV 100 mg qd
IDV Child-Pugh Class A or B: 600 mg q8h
Child-Pugh Class C: no data
LPV/r No dosage recommendation; use with caution in
persons with hepatic impairment
RTV Refer to recommendations for the primary PI
SQV Child-Pugh Class A or B: use with caution
Child-Pugh Class C: contraindicated
TPV Child-Pugh Class A: use with caution
Child-Pugh Class B or C: contraindicated
FI
ENF No dosage adjustment
CCR5 Inhibitor
MVC No dosage recommendations. Concentrations will
likely be increased in persons with hepatic impairment
INSTI
RAL No dosage adjustment
EVG Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
DTG Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
TAF/FTC/EVG/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
TDF/FTC/EVG/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
ABC/3TC/DTG Use separate compounds and refer to those adjust-
ments 
TAF/FTC/BIC Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
Note: Hepatic dysfunction is a good indication for TDM as clinical experience 
with these dose adjustments is very limited.
Dose Adjustment of ARVs  for Impaired Hepatic Function
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Dose Adjustment of ARVs for Impaired Renal Function
i  eGFR:  Use CKD-EPI formula; the abbreviated modification of diet in renal disease 
 (aMDRD) or the Cockcroft-Gault (CG) equation may be used as an alternative; see https://
www.chip.dk/Tools-Standards/Clinical-risk-scores
ii  Dose reduction if combined with TDF 
iii  150 mg loading dose 
iv  After dialysis
v  TDF and (boosted) PIs are associated with nephrotoxicity; consider alternative ART if 
pre-existing CKD, risk factors for CKD and/or decreasing eGFR, see ARV-associated 
Nephrotoxicity and Kidney Disease: Definition, Diagnosis and Management
 
vi  Limited data available in persons with renal impairment; pharmacokinetic analysis suggests 
no dose adjustment required
vii  See summary of product characteristics for specific recommendations; use with caution if 
eGFR ≤ 30 mL/min
viii In certain countries TDF is labelled as 245 mg rather than 300 mg to reflect the amount of 
the prodrug (tenofovir disoproxil) rather than the fumarate salt (tenofovir disoproxil fumara-
te)
ix 10 mg if co-administered with a boosting agent (inhibition of P-glycoprotein, P-gp)
eGFR(i) (mL/min)
Haemodialysis
≥ 50 30-49 10-29 < 10
NRTIs
ABC  300 mg q12h No dose adjustment required  
ddI(ii) ≥ 60 kg 400 mg q24h 200 mg q24h 150 mg q24h 100 mg q24h 100 mg q24h(iv)
< 60 kg 250 mg q24h 125 mg q24h 100 mg q24h 75 mg q24h 75 mg q24h(iv)
d4T                   ≥ 60 kg 40 mg q12h 20 mg q12h 20 mg q24h 20 mg q24h 20 mg q24h(iv)
< 60 kg 30 mg q12h 15 mg q12h 15 mg q24h 15 mg q24h 15 mg q24h(iv)
FTC 200 mg q24h 200 mg q48h 200 mg q72h 200 mg q96h 200 mg q96h(iv)
3TC 300 mg q24h 150 mg q24h 100 mg q24h(iii) 50-25 mg q24h(iii) 50-25 mg q24h(iii), (iv)
TDF(v)
300(viii) mg q24h 300(viii) mg q48h
Not recommended Not recommended
300(viii) mg q7d(iv)(300(viii) mg q72-96h, 
if no alternative)
(300(viii) mg q7d, if 
no alternative)
ZDV 300 mg q12h No dose adjustment 
required
100 mg q8h 100 mg q8h(iv)
ABC/3TC 600/300 mg q24h
Use individual drugsZDV/3TC 300/150 mg q12h
ABC/3TC/ZDV 300/150/300 mg 
q12h
TAF/FTC 25(ix)/200 mg q24h Not recommended
TDF/FTC 300(viii)/200 mg q24h 300(viii)/200 mg q48h Use individual drugs
NNRTIs
EFV 600 mg q24h              No dose adjustment required
ETV 200 mg q12h              No dose adjustment required
NVP 200 mg q12h              No dose adjustment required
TAF/FTC/RPV 25/200/25 mg q24h Not recommended
TDF/FTC/RPV 300(viii)/200/25 mg 
q24h
Do not use
eGFR(i) (mL/min)
Haemodialysis
≥ 50 30-49 10-29 < 10
PIs(v)
ATV/c 300/150 mg q24h No dose adjustment required(vi)
ATV/r 300/100 mg q24h No dose adjustment required(vi)
DRV/r 800/100 mg q24h
600/100 mg q12h No dose adjustment required
(vi)
DRV/c 800/150 mg q24h No dose adjustment required(vi)
TAF/FTC/DRV/c 10/200/800/150 mg q24h Not recommended
FPV/r 700/100 mg q12h No dose adjustment required(vi)
LPV/r 400/100 mg q12h No dose adjustment required(vi)
SQV/r 1000/100 mg q12h No dose adjustment required(vi)
TPV/r 500/200 mg q12h No dose adjustment required(vi)
Other ART
RAL 1 x 400 mg tablet q12h or
2 x 600 mg tablets q24h
No dose adjustment required(vi)
DTG 50 mg q24h No dose adjustment required(vi) No clinical data; PK 
data suggest safety
ABC/3TC/DTG 600/300/50 mg q24h Use individual drugs
TAF/FTC/BIC 20/200/75 mg q24h Not recommended
TAF/FTC/EVG/c 10/200/150/150 mg q24h                         Not recommended
TDF/FTC/EVG/c Do not initiate if eGFR < 70 mL/min Do not use
MVC: co-administered
without CYP3A4
inhibitors(vii)
300 mg q12h No dose adjustment required(vi)
MVC: co-administered 
with CYP3A4 inhibitors(vii)
If eGFR < 80 mL/min 150 mg q24h(vii) except: 150 mg q12h if co-administered with FPV/r
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Drug Formulation Crushtablets
Open 
capsules Comment
NRTIs
ABC tablet (300 mg)
solution (20 mg/mL)
yes Bitter taste. Crushed tablets can be added to small amount of semi-solid 
food or liquid, all of which should be consumed immediately
d4T capsule (20, 30, 40 mg)
oral solution (1 mg/mL)
no yes Take on empty stomach
FTC capsule (200 mg)
solution (10 mg/mL)
no yes Dissolve in ≥ 30 mL of water, contains Na 460 µmol/mL
Bioequivalence: 240 mg solution = 200 mg capsule; adjust dosage 
accordingly
3TC tablet (150, 300 mg)
solution (10 mg/mL)(vii)
yes Crushed tablets can be added to small amount of semi-solid food or liquid, 
all of which should be consumed immediately
TDF tablet (300(i) mg) yes Better: dissolve in ≥ 1 dL of water/orange or grape juice (bitter taste)
ZDV capsule (250 mg) no no Sticky, bitter taste
syrup (10 mg/mL) Better: use syrup or iv 6 mg/kg per day in glucose 5%
TAF/FTC tablet (25/200 mg and 
10/200 mg)(v)
yes Crushing of tablets is not recommended in the product information. However 
based on data with the fixed-dose combination tablet (TAF/FTC/DRV/c/), 
crushing of tablets does not impact significantly TAF/FTC pharmacokinetics  
(of note: TAF bioavailability is reduced by 20% (crushing) but this decrease 
is unlikely to be clinically significant)(viii)
TDF/FTC tablet (300(i)/200 mg) yes Better: dissolve in ≥ 1 dL of water/orange or grape juice (bitter taste)
ABC/3TC tablet (600/300 mg) no Use solution of individual compounds
ZDV/3TC tablet (300/150 mg) yes Disperse in ≥ 15 mL water, alternative: use solution of individual compounds
ABC/3TC/ZDV tablet (300/150/300 mg) no Use solution of individual compounds
NNRTIs
EFV tablet (600 mg) yes Difficult to dissolve; solution has lower bioavailability; if > 40 kg use 720 mg
capsule (50, 100, 200 mg) no yes
solution (30 mg/mL)
ETV tablet (200 mg) no Disperse in ≥ 5 mL water. The glass should be rinsed with water several
times and each rinse completely swallowed to ensure the entire dose is 
consumed.
NVP tablet (200, 400 mg)(ii)
suspension (10 mg/mL)
yes(ii) Dissolve in water
RPV tablet (25 mg) no Crushing of tablets and dispersion into a liquid is not recommended. RPV is 
insoluble in water over a wide pH range
TDF/FTC/EFV tablet (300(i)/200/600 mg) no
TAF/FTC/RPV tablet (25/200/25 mg)(v) no Tablets should be swallowed whole and should not be chewed, crushed or 
split
TDF/FTC/RPV tablet (300(i)/200/25 mg) no Crushing of tablets and dispersion into a liquid is not recommended. RPV is 
insoluble in water over a wide pH range.
PIs
ATV capsule (150, 200, 300 mg) no no Do not open the capsule, swallow whole
ATV/c tablet (300/150 mg) no Tablets should be swallowed whole and should not be chewed, broken, cut 
or crushed
DRV tablet (75,150, 400, 600, 
800 mg)
solution (100 mg/mL)
yes Take with food. Crushed tablets can be added to small amount of semi-solid 
food or liquid, all of which should be consumed immediately
DRV/c tablet (800/150 mg) yes Crushing of tablets is not recommended in the product information. However, 
based on data with the fixed-dose combination tablet (/TAF/FTC/ DRV/c), 
crushing of tablets does not impact significantly DRV/c pharmacokinetics(viii)
FPV tablet (700 mg)
suspension (50 mg/mL)
Bitter taste; adults take suspension on empty stomach
LPV/r tablet (200/50 mg)
solution (80/20 mg/mL)
no 42% alcohol, do not dilute with water (risk of precipitation), rinse with milk
(no water); take with food, bitter taste: dilute with chocolate milk
RTV tablet (100 mg)
solution (80 mg/mL)
no 43% alcohol, do not dilute solution (risk of precipitation), rinse with milk (no
water); bitter taste; take with food
SQV tablet (500 mg) no
TAF/FTC/DRV/c tablet (10/200/800/150 mg)(v) yes Crushing of tablets has no significant effect on the pharmacokinetics of the 
components of the tablet (of note: TAF bioavailability is reduced by 20% 
(crushing) but this decrease is unlikely to be clinically significant. TAF bio-
availability is not changed when splitting the pill)(viii)
Others
DTG tablet (50 mg) yes Tablets may be split or crushed and added to a small amount of semi-solid 
food or liquid, all of which should be consumed immediately
MVC tablet (150, 300 mg) yes While the company does not have any specific kinetic information, crushing 
the tablet is not expected to negatively affect the bioavailability
RAL(iii) tablet (400 mg)
chewable tablets (25, 100 
mg)
yes The bioavailability of the chewable tablet is higher: 300 mg chewable tablet 
(= 400 mg film-coated tablet)
Administration of ARVs in Persons with Swallowing Difficulties
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Drug Formulation Crushtablets
Open 
capsules Comment
RPV/DTG tablet (25/50 mg) no Tablets should be swallowed whole and should not be chewed, crushed or 
split
TAF/FTC/BIC tablet (25/200/50 mg)(v) no Tablets should be swallowed whole and should not be chewed, crushed or 
split
TAF/FTC/EVG/c tablet (10/200/150/150 mg)(v) yes Crushing of tablets is not recommended in the product information. However, 
based on data with the fixed-dose combination tablet (TAF/FTC/DRV/c/), 
crushing of tablets does not impact significantly TAF/FTC pharmacokinetics 
(of note: TAF bioavailability is reduced by 20% (crushing) but this decrease 
is unlikely to be clinically significant)(viii). Similarly, crushing of /TDF/FTC/ 
EVG/c did not have a significant effect of the pharmacokinetics of EVG/c(iv)
TDF/FTC/EVG/c tablet (300(i)/200/150/150 
mg)
yes Crushing of tablets does not significantly modify the pharmacokinetic pro-
files(iv)
ABC/3TC/DTG(vi) tablet (600/300/50 mg) yes Tablets may be split or crushed and added to a small amount of semi-solid 
food or liquid, all of which should be consumed immediately
Prophylaxis/treatment of opportunistic infections
azithromycin tablet (250, 500 mg)
suspension (40 mg/mL)
no
cotrimoxazole tablet (400/80 mg, forte
800/160 mg)
solution (40/8 mg/mL)
yes; forte 
difficult
Dilute solution 3-5 times with water (high osmolality)
fluconazole capsule (50, 200 mg)
suspension (40 mg/mL)
no yes
pyrimethamine tablet (25 mg) yes Take with food
valganciclovir tablet (450 mg)
solution (50 mg/mL)
no no Difficult to dissolve
rifampicin tablet (450, 600 mg) yes Take on empty stomach
capsule (150, 300 mg) no yes
suspension (20 mg/mL)
rifabutin capsule (150 mg) no yes Mix with apple sauce, syrup (insoluble in water)
isoniazid tablet (100, 150 mg) yes Take on empty stomach
pyrazinamide tablet (500 mg) yes
ethambutol tablet (100, 400 mg) yes Difficult to dissolve
Better: use iv solution
rifampicin/isoniazid tablet (150/100, 150/75 mg) yes Take on empty stomach
Rifater (rifampicin,
isoniazid,
pyrazinamide)
tablet (120/50/300 mg) yes Take on empty stomach
Rimstar (rifampicin,
isoniazid,
pyrazinamide,
ethambutol)
tablet (150/75/400/275 mg) yes Take on empty stomach
ribavirin capsule (200 mg) no yes Disperse in orange juice, take with food
For recommendations on prophylaxis/treatment of opportunistic infections, 
see Part V Opportunistic Infections
i In certain countries TDF is labelled as 245 mg rather than 300 mg to 
reflect the amount of the prodrug (tenofovir disoproxil) rather than the 
fumarate salt (tenofovir disoproxil fumarate).
ii Extended release effect lost. Note: NVP 400 mg qd (immediate release) 
can lead to sub-therapeutic trough levels in individuals with higher body 
weight (≥ 90 kg) compared to NVP 200 mg bid. Therefore, NVP bid ad-
ministration should be preferred in individuals with higher body weight. 
iii     Crushing tablets is not recommended in the product information, howev-
er absorption of RAL was not compromised when the drug was crushed, 
dissolved in 60 mL warm water and administered by gastrostomy tube 
[10]. In addition, RAL drug absorption has been shown to be higher in 
HIV-positive persons taking RAL 400 mg bid by chewing the tablets as 
compared to swallowing the intact tablets [11].
iv Crushing tablets is not recommended in the product information howev-
er the pharmacokinetic profiles of TDF/FTC/EVG/c were not significantly 
modified when the fixed-dose combination tablet (Stribild) was crushed 
and administered with food or with drip feed compared to the administra-
tion of the whole tablet [12].
v TAF is used at 10 mg when co-administered with drugs that inhibit P-gp. 
TAF is used at 25 mg when co-administered with drugs that do not inhib-
it P-gp.
vi    The pharmacokinetic profiles of ABC/3TC/DTG were not modified to a
       clinically significant extent when the fixed-dose combination tablet 
       (Triumeq) was crushed and administered suspended in water or in
       enteral nutrition (of note: crushing leads to a 26% increase in DTG 
 exposure) [14]. 
vii   The bioavailability of 3TC solution has been shown to be significantly
       reduced in a dose dependent manner by sorbitol present in other liquid
       formulations (e.g. ABC, NVP, cotrimoxazole) [15]. 
viii Crushing of tablets is not recommended in the product information, how-
ever the individual pharmacokinetic profiles of TAF/FTC/ DRV/c were not 
significantly modified when the fixed-dose combination tablet (Symtuza) 
was administered crushed or split compared to the whole tablet [16].
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Part III   Prevention and Management of
  Co-morbidities in HIV-positive Persons
The appropriate management of co-morbidities, which include cardiovascu-
lar, pulmonary, hepatic, metabolic, neoplastic, renal, bone, central nervous 
system disorders as well as sexual dysfunction, has increasingly become 
an integral part of the overall management of individuals living with HIV. 
Potential contributors to co-morbidity pathogenesis include a higher prev-
alence of recognised risk factors, ART-exposure and toxicity, HIV itself as 
well as immune dysfunction/dysregulation and chronic immune activation/
inflammation, associated with HIV or other co-infections (e.g. CMV, HCV).
Health care professionals other than HIV specialists, who are involved in 
the care of HIV-positive persons and who are not familiar with the use of 
ART, should consult their HIV specialist colleagues before introducing or 
modifying any type of medicines for co-morbidity. As intervals between visits 
to HIV-clinics are increasingly extended, HIV-positive persons can be ex-
pected to seek care more frequently with their primary care doctor. In these 
situations, it is important to ensure some level of shared-care arrangement.   
Conversely, many HIV doctors are not specialists in managing co-morbidi-
ties, and should seek expert advice where appropriate in the prevention and 
management of such conditions. Situations where consultation is generally 
recommended are indicated elsewhere in this document. 
As individuals with treated HIV age, complex multiple co-morbidities often 
co-exist in the same person and may be associated with frailty and disa-
bility. Such circumstances may require a comprehensive “geriatric-type” 
multidimensional, multidisciplinary assessment aimed at appropriately 
capturing the composite of medical, psychosocial and functional capabilities 
and limitations of elderly HIV-positive persons. 
Depending on future clinical research findings, these recommendations will 
be regularly updated as required. The online version at http://www.eacso-
ciety.org and the EACS Guidelines App contain more detailed information 
and links to other relevant websites; these will be regularly updated. 
The current recommendations highlight co-morbidities that are seen 
frequently in the routine care of HIV-positive persons and those for which 
specific issues should be considered. 
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Drug Dependency and Drug Addiction
Characteristics of drugs used as opioid substitution therapy (OST)(i)
Feature Methadone Buprenorphine
Dose required to prevent withdrawal  
symptoms according to degree of opioid 
dependency
Linear relationship (from 10-300 mg per day) Linear relationship for persons with less opioid 
dependency only – ceiling effect (max daily dose 
24 mg)
Interaction with ARVs Methadone plasma concentrations are reduced if 
used together with NNRTIs or PIs:
• NVP & EFV: ↓ 50%
• ETV: ↓ < 10%(ii)
• LPV/r: ↓ 50%
• SQV/r, DRV/r, FPV/r: ↓ 15-25%
• ATV, IDV: ↓ < 10%
Buprenorphine (B) and active
metabolite norbuprenorphine (N)
plasma concentrations are reduced if
combined with NNRTIs and increased
if combined with some PIs or INSTIs
• EFV: ↓ up to 50% (B) and 70% (N)
• ETV: ↓ 25% (B)
• ATV/r, IDV, SQV/r: ↑ 50-100% (B&N)
• DRV/r: ↑ 50% (N)
• CAVE: B reduces ATV; do not use without 
RTV or COBI boosting
• EVG/c, ↑ 35-42% (B&N)
(BIC, DTG, RAL, RPV & LPV/r do not affect B & N 
metabolism)
CAVE: withdrawal symptoms if combined with ARV that decreases plasma concentration and risk of 
drug toxicity if such ARVs are interrupted – reverse if ARVs increase plasma concentration
Risk of overdose Yes No, if used as a co-formulation with naloxone 
Causing QT prolongation on ECG Yes (dose-response relationship)(iii) No
Risk of obstipation High High
Type of administration Tablet or liquid Tablet applied sublingual
Risk of further impairment in persons with 
existing liver impairment
Yes Yes
i  See Drug-drug Interactions between Analgesics and ARVs 
ii  Note that despite ETV causes a decrease in the plasma concentration of 
methadone, the active methadone enantiomer is in fact increased 6% by 
ETV. 
iii  ECG recommended for daily methadone doses exceeding 50 mg; 
special caution with concomitant use of other drugs known to cause QT 
prolongation (e.g. certain PIs such as SQV/r as well as albuterol (USAN) 
or salbutamol (INN), amiodarone, amitriptyline, astemizole, chloroquine, 
clomipramine and moxifloxacin).
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Cancer: Screening Methods(i)
Problem Persons Procedure Evidence of benefit Screening interval Additional comments
Anal cancer MSM and persons 
with HPV-associated 
dysplasia(ii)
Digital rectal exam
± anal cytology 
Unknown; advocated by 
some experts
1-3 years If anal cytology abnor-
mal, anoscopy
Breast cancer Women 50-70 years Mammography ↓ Breast cancer mor-
tality 
1-3 years
Cervical cancer HIV-positive women 
> 21 years or within 1 
year after sexual debut
Liquid based cervical 
cytology test
↓ Cervical cancer 
mortality 
1-3 years HPV testing may aid 
screening
Colorectal cancer Persons 50-80 years 
with a life expectancy > 
10 years
Faecal occult blood test 
annually or sigmoidos-
copy every 5 years or  
colonoscopy every 10 
years
↓ Colorectal cancer 
mortality 
1-3 years 
HepatoCellular  
Carcinoma (HCC) 
Persons with cirrhosis, 
persons with HBV co-in-
fection at high risk of 
HCC or those who ever 
had chronic hepatitis(iii)
Ultrasound (and alpha- 
foetoprotein)
Earlier diagnosis allow-
ing for improved ability 
for surgical eradication
Every 6 months See pages 58 and 81
Prostate cancer Men > 50 years with 
a life expectancy >10 
years
PSA(iv) Use of PSA is contro-
versial 
2-4 years Pros: ↑ early diagnosis 
and modest ↓ prostate 
cancer specific mortali-
ty. Cons: overtreatment, 
adverse effects of treat-
ment on quality of life
i   Screening recommendations derived from the general population.
 These screenings should preferably be done as part of national general popula-
tion-screening programmes. 
 Careful examination of skin should be performed regularly to detect cancers such 
as Kaposi’s sarcoma, basal cell carcinoma and malignant melanoma.
ii  Includes Anal Intraepithelial Neoplasia (AIN), Penile Intraepithelial Neoplasia 
(PIN), Cervical Intraepithelial Neoplasia (CIN), Vaginal Intraepithelial Neoplasia 
(VAIN) and Vulval Intraepithelial Neoplasia (VIN).
iii  HCC screening is indicated in all cirrhotic HBV or HCV co-infected persons (even 
if HCV infection has been cured and HBV replication is medically suppressed) in 
a setting where treatment for HCC is available.  Although the cost-effectiveness of 
HCC screening in persons with F3 fibrosis is uncertain, surveillance may be con-
sidered based on an individual risk assessment (www.easl.eu/research/our-contri-
butions/clinical-practice-guidelines/detail/easl-clinical-practice-guidelines-on-hepa-
tocellular-carcinoma). In HBV-positive non-cirrhotics, HCC screening should 
follow current EASL guidelines. Risk factors for HCC in this population include 
family history of HCC, ethnicity (Asians, Africans), HDV and age. EASL guidelines 
propose using the PAGE-B score in Caucasians to assess the HCC risk, however 
this score has not been validated in HIV-positive persons, see pages 58 and 81.
iv  Whilst prostate cancer screening with PSA can reduce prostate cancer specific 
mortality, the absolute risk reduction is very small. Given limitations in the design 
and reporting of the randomized trials, there remain important concerns that the 
benefits of screening are outweighed by the potential harms to quality of life, 
including the substantial risks for over-diagnosis and treatment complications.
 See online video lectures Epidemiology of cancers and HIV-Part 1, Epidemiology 
of cancers and HIV-Part 2, Clinical Management of cancers and HIV-Part 1 and  
Clinical Management of cancers and HIV-Part 2 from the EACS online course 
Clinical Management of HIV.
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Dietary  
counselling
• Dietary intervention should not interfere with the dietary 
requirements necessary for appropriate absorption of 
ART drugs
• Keep caloric intake balanced with energy expenditure
• Limit intake of saturated fat, cholesterol and refined 
carbohydrates
• Reduce total fat intake to < 30% and dietary cholesterol 
to < 300 mg/day
• Emphasise intake of vegetables, fruit and grain products 
with fibre
• Cut back on beverages and foods with added sugar 
• Choose and prepare foods with little or no salt. Aim to 
eat less than 1,500 mg of sodium per day 
• Emphasise consumption of fish, poultry (without skin) 
and lean meat
• Consider referral to dietician, one-week food and drink 
diary to discover ‘hidden’ calories
• Avoid binge eating (‘yo-yo dieting’)
• In persons with HIV-related wasting and dyslipidaemia, 
address wasting first and consider referral to dietician
• Persons who are obviously overweight should be motiva-
ted to lose weight. Starvation diets are not recommended 
(immune defence mechanisms potentially decreased). 
Malnutrition has to be addressed where observed. 
Normal BMI range: 18.5-24.9; Overweight: 25.0-29.9, 
Obesity: > 30.0 kg/m2
Lifestyle Interventions(i)
• The following questions are helpful to determine average 
alcohol intake 
1.  How often do you drink alcohol: never, ≤ 1/month, 
 2-4x/month, 2-3x/week, > 4x/week 
2. If you drink alcohol, how much typically at a time:  
 1-2, 3-4, 5-6, 7-9, > 10 drinks 
3. How many times do you have 6 or more alcoholic  
 drinks at one occasion: never, < 1/month, 1x/month,  
 1x/week, more or less daily.
• Intake of alcohol should be restricted to no more than 
one drink per day for women and two drinks per day for 
men (< 20-40 g/day).
• In particular, persons with hepatic disease, see NAFLD, 
adherence problems, inadequate CD4 count increa-
se, tumours, past tuberculosis, diarrhoea and other 
conditions associated with high alcohol intake should be 
motivated to decrease or stop alcohol intake.    
Exercise 
promotion
• Promote active lifestyle to prevent and treat obesity, 
hypertension and diabetes
• Encourage self-directed moderate level physical activity 
(take the stairs, cycle or walk to work, cycling, swimming, 
hiking, etc.) 
• Emphasise regular moderate-intensity exercise rather 
than vigorous exercise 
• Achieve cardiovascular fitness (e.g. 30 minutes brisk 
walking > 5 days a week) 
• Maintain muscular strength and joint flexibility 
i  Based on recommendations by the US Preventive Services Task Force 
 
Is the HIV-positive person an active smoker?
Yes No
Brief clear statement about the need to 
stop smoking
Explain the health consequences of smok-
ing and the benefits of quitting
Encourage con-
tinued abstinence
Is the person willing to quit?
Yes No
Pharmacotherapy(i) Cognitive-behavioural 
counselling(ii)
Motivational strat-
egy(iii). Encourage 
smoking reduction
Adapted from [1] and [2] 
i  Pharmacotherapy: Nicotine replacement therapy: nicotine substitution (patch, chewing gum, spray), varenicline and bupropion are approved by the EMA. 
Bupropion is contraindicated with epilepsy and varenicline may induce depression. Bupropion  may interact with PIs and NNRTIs, see Drug-drug Interac-
tions between ARVs and Non-ARVs 
ii  Cognitive-behavioral counselling: Use specific available resources. Either individual or group interventions to better suit and satisfy the HIV-positive per-
son. The programme should consist of four or more sessions lasting 30 minutes for 3-4 months. 
iii  Motivational strategy: Identify potential health risks of the smoker and to stratify both acute (e.g. exacerbations of COPD) and long-term (e.g. infertility, 
cancer) risks. Show the HIV-positive person the personal benefits of stopping smoking. Identify the barriers or obstacles that might impede the success 
of a quit attempt. Smoking cessation interventions should be delivered repeatedly, as long as the HIV-positive person is not willing/ready enough to quit 
smoking.
Smoking cessation 
HIV-positive tobacco users should be made aware of the substantial health benefits of smoking cessation which include reducing the risk of tobacco-related 
diseases, slowing the progression of existing tobacco related disease, and improving life expectancy by an average of 10 years.
Regularly consider the following algorithm with two major questions:
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Prevention of CVD
i Use the Framingham equation or whatever system local National Guid-
ance recommends; a risk equation developed from HIV populations is 
available: see https://www.chip.dk/Tools-Standards/Clinical-risk-scores. 
This assessment and the associated considerations outlined in this 
figure should be repeated annually in all persons under care, see pages 
6-8, to ensure that the various interventions are initiated in a timely way. 
ii Options for ART modification include: 
(1) Replace with NNRTI, INSTI or another PI/r known to cause less 
metabolic disturbances and/or lower CVD risks, see pages 21-22 
(2) Consider replacing ZDV or ABC with TDF or use an NRTI-sparing 
regimen 
iii Of the modifiable risk factors outlined, drug treatment is reserved for 
certain subgroups where benefits are considered to outweigh potential 
harm. Of note, there is a combined benefit of various interventions in tar-
get groups identified. Per 10 mmHg reduction in systolic blood pressure, 
per 1 mmol/L (39 mg/dL) reduction in TC and with use of acetylsalicylic 
acid, each reduces risk of IHD by 20-25%; the effect is additive. Obser-
vational studies suggest that smoking cessation results in about 50% 
less risk of IHD – and this is additive to other interventions.
Assess CVD risk in next 10 years(i)
Advise on diet and lifestyle in all 
persons
Consider ART modification if 10-
year CVD risk ≥ 20%(ii)
Smoking (see page 41) Identify key modifiable risk factors(iii)
Blood pressure Coagulation Glucose Lipids
Drug treatment if: SBP ≥ 140 or 
DBP ≥ 90 mmHg (especially if 10-
year CVD risk ≥ 20%)
Drug treatment if: established CVD 
or age ≥ 50 and 10-year CVD risk 
≥ 20%
Confirm DM and treat with drugs
Drug treatment(iv) if: established 
CVD or type 2 diabetes or 10-year 
CVD risk ≥ 10%
Target(v) Target - N/A
Consider treating with acetylsali-
cylic acid 75-150 mg(vii)
Target 
HbA1C  6.5-7.0%
Treatment (see page 47)
Target(vi)
SBP < 140 mmHg Optimal Standard
DBP < 90 mmHg TC ≤ 4 (155) ≤ 5 (190)
LDL ≤ 2 (80) ≤ 3 (115)
Treatment (see page 43-45) 
Treatment (see page 48) 
Principles: The intensity of efforts to prevent CVD depends on the underly-
ing risk of CVD, which can be estimated(i). The preventive efforts are diverse 
in nature and require involvement of a relevant specialist, in particular if the 
risk of CVD is high and always in persons with a history of CVD.
iv See discussion on drug treatment of persons with lower CVD risk at  
https://www.nhlbi.nih.gov/files/docs/guidelines/atp3xsum.pdf 
v For higher risk individuals (e.g. diabetes) where resources allow target 
SBP < 130 and DBP < 80 mmHg. 
vi    Target levels are to be used as guidance and are not definitive – ex-
pressed as mmol/L with mg/dL in parenthesis. In case LDL cannot be 
calculated because of high triglyceride levels, the non-HDL-c (TC minus 
HDL-c) target should be used which is 0.8 mmol/L (30 mg/dL) higher 
than the corresponding LDL-c target. Target levels for TG are not listed 
because an independent contribution from TG to CVD risk is uncertain, 
and hence whether this condition should be treated, see page 48. 
vii Evidence for benefit when used in persons without a history of CVD (in-
cluding diabetics) is less compelling. BP should be reasonably controlled 
before aspirin use in such a setting. 
See online video lecture CVD, CKD, Endocrinology from the EACS online 
course Clinical Management of HIV.  
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Other risk factors, asymp-
tomatic organ damage or 
disease
Blood pressure (mmHg) Blood pressure (mmHg) Blood pressure (mmHg) Blood pressure (mmHg)
High normal SBP  
130-139  
or DBP 85-89
Grade 1 hypertension
SBP 140-159
or DBP 90-99
Grade 2 hypertension
SBP 160-179
or DBP 100-109
Grade 3 hypertension
SBP ≥ 180  
or DBP ≥ 110
No other risk factors • Lifestyle changes(i)
• No BP drug intervention
• Lifestyle changes(i) for  
several months
• Then add BP drugs  
targeting < 140/90
• Lifestyle changes(i) for  
several weeks
• Then add BP drugs  
targeting < 140/90
• Lifestyle changes(i)
• Immediate BP drugs 
targeting < 140/90
1-2 risk factors • Lifestyle changes(i)
• No BP drug intervention
• Lifestyle changes(i) for  
several weeks
• Then add BP drugs  
targeting < 140/90
• Lifestyle changes(i) for  
several weeks
• Then add BP drugs  
targeting < 140/90
• Lifestyle changes(i)
• Immediate BP drugs  
targeting < 140/90
≥ 3 risk factors • Lifestyle changes(i)
• i.e. no BP drug intervention
• Lifestyle changes(i) for  
several weeks
• Then add BP drugs  
targeting < 140/90
• Lifestyle changes(i)
• BP drugs targeting  
< 140/90
• Lifestyle changes(i)
• Immediate BP drugs  
targeting < 140/90
Organ damage, CKD stage 
3 or diabetes
• Lifestyle changes(i)
• Consider blood pressure 
drugs targeting < 130/80
• Lifestyle changes(i)
• BP drugs targeting  
< 140/90(ii)
• Lifestyle changes(i)
• BP drugs targeting  
< 140/90(ii)
• Lifestyle changes(i)
• Immediate BP drugs  
targeting < 140/90(ii)
Symptomatic CVD, CKD 
stage ≥ 4 or diabetes with 
organ damage/risk factors
• Lifestyle changes(i)
• Consider blood pressure 
drugs targeting < 130/80
• Lifestyle changes(i)
• BP drugs targeting  
< 140/90(ii)
• Lifestyle changes(i)
• BP drugs targeting  
< 140/90(ii)
• Lifestyle changes(i)
• Immediate BP drugs  
targeting < 140/90(ii)
Hypertension: Diagnosis, Grading and Management
BP blood pressure
DBP   diastolic blood pressure
SBP  systolic blood pressure
Repeated blood pressure measurements should be used for stratification
i  Recommended lifestyle interventions, see page 41
ii   Consider targeting < 130/80 when resources allow
Table adapted from [3].
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Hypertension: Drug Sequencing Management
Choosing drugs(i) for persons newly diagnosed with hypertension
< 55 years ≥ 55 years or black(ii)
person of any age
A(iii) C(iii)
A + C(iii)
A + C +D(iii) + spironolactone (12.5 to 50 mg)
Add(iv) α-blocker (e.g. doxazosin [slow release]) or β-blocker (e.g. bisopro-
lol). Refer to specialist.
Abbreviations + details
A ACE inhibitor (e.g. perindopril, lisinopril or ramipril) or low cost angioten-
sin receptor blockers (ARB) (e.g. losartan, candesartan) 
C Dihydropyridine calcium-channel blocker (e.g. amlodipine). If not 
tolerated or if deemed at high risk of heart failure, ’D’ drugs can be used 
instead. Where a C drug is preferred but not tolerated, verapamil or 
diltiazem may be used (note: dose with caution with PIs as these may 
increase plasma concentrations of these calcium-channel blockers, 
potentially leading to toxic reactions) 
D Thiazide-type diuretic* e.g. indapamide or chlorthalidone as a first 
choice
i Some calcium-channel blockers interact marginally with the pharmacoki-
netics of ARVs, see Drug-drug Interactions between Antihypertensives 
and ARVs 
ii Black persons are those of African or Caribbean descent, and not mixed 
race, Asian or Chinese persons. Single tablet combinations of antihyper-
tensive drugs (where available) are increasingly recommended both as 
first-line therapy (A + C or A + D) and second-line therapy 
iii Wait 4-6 weeks to assess whether target, see page 42, is achieved; if 
not, go to next step 
iv Requirement of 4-5 drugs to manage hypertension needs specialist 
training 
* This excludes thiazides (e.g. hydrochlorothiazide (HCTZ), bendroflu-
methiazide etc.). However, if thiazide-type diuretics are not available 
low-dose thiazides may be used as a treatment alternative. 
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Antihypertensives ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
A
C
E 
in
hi
bi
to
rs
captopril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
cilazapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
enalapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
lisinopril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
perindopril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
quinapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
ramipril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
trandolapril ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
A
ng
io
te
ns
in
 
an
ta
go
ni
st
s
candesartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
eprosartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
irbesartan ↔ ↓ ↔ ↓ ↓ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
losartan ↔ ↓a ↔ ↓a ↓a ↑b ↑b ↔ ↔ ↔ ↔ ↔ ↓a ↔ ↔ ↔ ↔ ↔ ↔
olmesartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
telmisartan ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
valsartan ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
β 
bl
oc
ke
rs
atenolol ↔d ↔d ↔ ↔ ↔d ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
bisoprolol ↑d ↑d ↑ ↑ ↑d ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
carvedilol ↑d ↑↓d ↑ ↑↓ ↑↓d ↑↓ ↑↓ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
metoprolol ↑d ↑d ↑ ↑ ↑d ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
propranolol ↑d ↑d ↑ ↑ ↑d ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
C
al
ci
um
 c
ha
nn
el
 b
lo
ck
er
s amlodipine ↑c ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
diltiazem ↑c ↑c ↑ ↑ ↑e ↓69% ↓E ↓ E E E ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
felodipine ↑c ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
lacidipine ↑c ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
lercanidipine ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
nicardipine ↑c ↑c ↑ ↑ ↑e ↓ ↓E ↓ E E ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
nifedipine ↑c ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
nisoldipine ↑c ↑c ↑ ↑ ↑e ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
verapamil ↑c ↑c ↑ ↑ ↑e ↓ ↓E ↓ E E E ↔ ↑ ↔ ↔ ↔ ↔ E E
D
iu
re
tic
s
amiloride ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
bendroflumethiazide ? ? ? ? ? ? ? ? ↔ ↔ ↔ ↔ ? ↔ ↔ ↔ ↔ ↔ ↔
chlortalidone ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
furosemide ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ E
indapamide ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
hydrochlorothiazide ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
torasemide ↔ ↓ ↔ ↓ ↓ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔
O
th
er
s doxazosin ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
sacubitril ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ E ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑
spironolactone ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Drug-drug Interactions between Antihypertensives and ARVs
Legend
↑  potential elevated exposure of the antihypertensive     
↓  potential decreased exposure of the antihypertensive
↔  no significant effect     
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
ATV/c   ATV co-formulated with COBI (300/150 mg qd);  
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a  [parent drug] decreased but [active metabolite] increased    
b  [parent drug] increased but [active metabolite] decreased
c  ECG monitoring recommended   
d  risk of PR interval prolongation
e use with caution as both LPV and calcium channel blockers prolong 
the PR interval. Clinical monitoring is recommended.
Numbers refer to decreased AUC of the antihypertensive as observed in 
drug-drug interactions studies.
Note: no clinically significant interactions expected between ZDV and anti-
hypertensives
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion 
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required
 there are no clear data, actual or theoretical, to indicate whether an 
interaction will occur 
Note: although some drug interactions are predicted to potentially require a 
dosage adjustment based on the drug's metabolic pathway, clinical 
experience with a particular antihypertensive and ARV drug may indicate 
that dosage adjustments are not an a priori requirement.    
Comment
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).     
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Type 2 Diabetes: Diagnosis
Diagnostic criteria(i)
Fasting plasma 
glucose mmol/L 
(mg/dL)(ii)
Oral glucose 
tolerance test 
(OGTT) 2-h 
value mmol/L 
(mg/dL)(iii)
HbA1c(iv)  
(mmol/mol)
Diabetes ≥ 7.0 (126) OR→ ≥ 11.1 (200) ≥ 6.5%  (≥ 48)
Impaired  
glucose
tolerance (IGT) 
< 7.0 (126) AND→ 7.8 – 11.0  
(140-199) 
Prediabetes
5.7-6.4% (39-47)
Impaired fasting 
glucose (IFG)
5.7– 6.9 AND 
(100-125) 
< 7.8 (140) 
i  As defined by WHO, [4] and [5]
ii  An abnormal finding should be repeated before confirming the diagnosis
iii  Recommended in persons with fasting blood glucose of 5.7 - 6.9 mmol/L 
(100-125 mg/dL) as it may identify persons with overt diabetes
iv  Do not use HbA1c in presence of haemoglobinopathies, increased 
erythrocyte turnover and severe liver or kidney dysfunction. Falsely high 
values are measured under supplementation with iron, vitamin C and E 
as well as older age (age > 70: HbA1c + 0.4%). HbA1c values in treated 
HIV-positive persons, particularly when on ABC, tend to underestimate 
type 2 diabetes. Both IGT and IFG increase CVD morbidity and mortality, 
and increase the risk of developing diabetes by 4-6 fold. These persons 
should be targeted for lifestyle intervention, and their CVD risk factors 
must be evaluated and treated.
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Type 2 Diabetes(i): Management
If modification of lifestyle measures is insufficient
Metformin(ii) start dose (500-850 mg qd), increase to maximum tolerated 
dose of 2(-3) g/day over 4-6 weeks(iii)
HbA1c > 6.5-7% (> 48-53 mmol/mol)
Metformin(ii) + sulfonylureas or thiazolidinedione or 
DPP-4 inhibitor or SGLT-2 inhibitor
or GLP-1 agonist or insulin
HbA1c > 6.5-7% (> 48-53 mmol/mol)
Refer to specialist for triple therapy – use insulin
Treatment goals: 
Prevention of hyper-/hypoglycaemia, glucose control (HbA1c < 6.5-7% 
without hypoglycaemia, fasting plasma glucose 4-6 mmol/L (73-110 mg/dL), 
prevention of long-term complications.
• Normal blood lipids, see pages 42 and 48, and blood pressure < 130/80 
mmHg, see page 43. 
• Acetylsalicylic acid (75-150 mg qd) considered in diabetics with elevated 
underlying CVD risk, see page 42. 
• Nephropathy, polyneuropathy and retinopathy screening should be 
performed as in diabetic persons without HIV 
• Consultation with a specialist in diabetology is recommended 
i Type 1 diabetes should be treated according to national guidelines. 
ii Metformin may worsen lipoatrophy.
 No data for any oral antidiabetic agents in terms of CVD prevention in 
HIV-positive persons. Incretins  (DDP-4 inhibitors [e.g. linagliptin, saxag-
liptin (reduce dose when given with a booster), sitagliptin and vildaglip-
tin], GLP-1 agonists [liraglutide, exenatide], and SGLT-2 inhibitors [e.g. 
dapagliflozin, canagliflozin, empagliflozin] have not been evaluated in 
HIV-positive persons, but some (e.g empagliflozin, liraglutide) have 
shown to reduce mortality from CVD; choice of drugs dependent on a 
variety of individual-  & disease-specific factors; no clinically significant 
drug-drug-interaction or adverse effects on CD4 counts expected; clini-
cal use of pioglitazone questioned by its side effects; HbA1c targets up 
to 7.5% can be considered for older persons with long-standing type 2 
diabetes and evidence of CVD.
iii   Consider lower dose in individuals with mild to moderate CKD or indivi- 
duals receiving DTG.
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Dyslipidaemia
Drugs used to lower LDL-c
Drug class Drug Dose Side effects Advise on use of statin together with ART
use with PI/r use with NNRTIs
Statin(i,ix) atorvastatin(ii) 10-80 mg qd Gastrointestinal
symptoms,
headache, insomnia,
rhabdomyolysis (rare)
and toxic hepatitis
Start with low dose(v) 
(max: 40 mg) 
Consider higher dose(vi) 
fluvastatin(iii) 20-80 mg qd Consider higher dose(vi) Consider higher dose(vi)
pravastatin(iii) 20-80 mg qd Consider higher 
dose(vi,vii)
Consider higher dose(vi)
rosuvastatin(ii) 5-40 mg qd Start with low dose(v) 
(max: 20 mg) 
Start with low dose(v) 
simvastatin(ii) 10-40 mg qd Contraindicated
Intestinal cholesterol 
absorption inhibitor↓(i,viii)
ezetimibe(iv) 10 mg qd Gastrointestinal
symptoms
No known drug-drug interactions with ART
PCSK9-inhibitor(x) evolocumab 140 mg 2 weekly or 
420 mg monthly
Nil No drug-drug interactions anticipated
i  A statin is preferred first-line therapy; different statins have variable 
intrinsic LDL-c lowering ability
ii, iii, iv  Target levels for LDL-c, see page 42. In persons where LDL-c 
targets are difficult to achieve, consult/refer to specialist
  Expected range of reductions of LDL-c: ii 1.5-2.5 mmol/L (60-100 
mg/dL), iii 0.8-1.5 mmol/L (35-60 mg/dL), iv 0.2-0.5 mmol/L (10-20 
mg/dL)
v, vi  The ARV may v inhibit (statin toxicity, ↓ dose) or vi induce (=less 
effect of statin, ↑ dose gradually to achieve expected benefit  ii, iii) 
the excretion of the statin
vii Exception: If used with DRV/r, start with lower dose of pravastatin
viii This agent can be used for HIV-positive persons intolerant of statins 
or added to a statin when LDL reduction is inadequate despite maxi-
mally tolerated statin
ix Pitavastatin has as yet no morbidity/mortality trial data to support its 
use but may have advantages of fewer drug-drug interactions, more 
HDL increase and less adverse glucose effect than other statins
x Consider for highest risk individuals inadequately controlled on top 
statin dose or for statin intolerant individuals
Principles: Higher LDL-c levels increase risk of CVD and reduction dimin-
ishes this risk (see table below for drugs used on this indication); the reverse 
is probably true for HDL-c but trial data are less compelling. The CVD risk 
implications from higher than normal TG levels are even less clear, as TG 
has not consistently been shown to independently predict the risk of CVD. 
Furthermore, the clinical benefit of treating moderate hypertriglyceridaemia 
is uncertain; very high TG (> 10 mmol/L or > 900 mg/dL) increase risk of 
pancreatitis.
Less calories, more exercise, reducing bodyweight, and stopping smoking 
tend to improve (increase) HDL. Eating fish, reducing calories, saturated fat 
and alcohol intake reduce triglyceride levels. Reducing dietary saturated fat 
intake improves LDL-levels; if not effective, consider change of ART, then 
consider lipid-lowering medicine, see page 42. Statins should be used by 
all those with established vascular disease and among those with type 2 
diabetes or at high risk of CVD, irrespective of lipid levels.
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Bone Disease: Screening and Diagnosis
Condition Characteristics Risk factors Diagnostic tests
Osteoporosis 
• Postmenopausal women and men 
aged ≥ 50 years with BMD T-score 
≤ -2.5 
• Premenopausal women and men 
aged < 50 years with BMD Z-score 
≤ -2 and fragility fracture 
• Reduced bone mass 
• Increased incidence of fractures in 
HIV-positive persons 
• Asymptomatic until fractures occur 
Common in HIV
• Up to 10-15% prevalence of 
osteoporosis 
• Aetiology multifactorial 
• Loss of BMD observed with  
ART initiation
• Greater loss of BMD with initiation 
of certain ARVs(i)
Consider classic risk factors(ii) and 
estimate fracture risk using FRAX.
Consider DXA in any person  
with ≥ 1 risk of:(iii)                    
1. Postmenopausal women 
2. Men ≥ 50 years 
3. Those between 40-50 years with 
high fracture risk (> 20% 10-year 
major osteoporotic fracture risk 
based on FRAX assessment 
without DXA)
4. History of low impact fracture
5. High risk for falls(iv) 
6. Clinical hypogonadism (sympto-
matic, see Sexual  
Dysfunction)
7. Oral glucocorticoid use (minimum 
5 mg/qd prednisone equivalent for 
> 3 months) 
Preferably perform DXA in those 
with above risk factors prior to 
ART initiation. Assess effect of risk 
factors on fracture risk by including 
DXA results in the FRAX® score 
(http://www.shef.ac.uk/FRAX) 
• Only use if > 40 years 
• May underestimate risk in HIV- 
positive persons 
• Consider using HIV as a cause of 
secondary osteoporosis(v)
DXA scan 
Rule out causes of secondary 
osteoporosis if BMD low(vi) 
Lateral spine X-rays (lumbar and 
thoracic) if low spine BMD, osteopo-
rosis on DXA, or significant height 
loss or kyphosis develops. (DXA-
based vertebral fracture assessment 
can be used as an alternative to 
lateral spine X-ray).
  
Osteomalacia • Defective bone mineralisation
• Increased risk of fractures and 
bone pain 
• Vitamin D deficiency may cause 
proximal muscle weakness 
• High prevalence (> 80%) of 
vitamin D insufficiency in some 
HIV cohorts and in the general 
population
• Dark skin
• Dietary deficiency
• Avoidance of sun exposure 
• Malabsorption
• Obesity 
• Renal phosphate wasting(vii)
Measure 25(OH) vitamin D 
in all persons at presentation
ng/mL nmol/L
Deficiency < 10 < 25
Insufficiency < 20 < 50
If deficient or insufficient, check PTH 
levels
Consider vitamin D replacement if 
clinically indicated, see page 50
Osteonecrosis • Infarct of epiphyseal plate of long 
bones resulting in acute bone pain 
• Rare but increased prevalence 
in HIV 
Risk factors: 
• Low CD4 count
• Glucocorticoid exposure 
• IVDU
MRI
i Greater loss of BMD observed with initiation of regimens containing TDF 
and some PIs. Additional loss and gains in BMD observed with switch 
to and away from TDF-containing ARV regimens, respectively. Clinical 
relevance to fracture risk not determined. TAF is associated with less 
bone loss than TDF.
       Consider replacing TDF* by non-tenofovir drug or TAF** if:
 •   Osteoporosis / progressive bone loss
 •   History of fragility fracture
 •   FRAX score for major osteoporotic fracture > 10%
 •   Use of a PI/r as third agent
 *   Expert opinion, pending clinical data
 **  There is limited data on use of TAF with eGFR ≤ 30 mL/min and  
longer term outcomes are unknown.
ii Classic risk factors: older age, female gender, hypogonadism, family 
history of hip fracture, low BMI (≤ 19 kg/m2), vitamin D deficiency, smo-
king, physical inactivity, history of low trauma fracture, alcohol excess (> 
3 units/day), glucocorticoid exposure (minimum prednisone 5 mg/qd or 
equivalent for > 3 months) 
iii If T-score normal, repeat after 3-5 years in risk groups 1, 2 and 5; no 
need for re-screening with DXA in risk groups 3 and 4 unless risk factors 
change and only rescreen group 6 if glucocorticoid use ongoing. 
iv Falls Risk Assessment Tool (FRAT), see https://www2.health.vic.gov.au/
ageing-and-aged-care/wellbeing-and-participation/healthy-ageing/falls-
prevention/falls-prevention-tools
v If including BMD within FRAX, entering yes in the secondary cause box  
will not be considered in the FRAX algorithms, as it is assumed that se-
condary osteoporosis affects fracture risk solely through BMD. However, 
if the contribution of HIV infection to fracture risk is partially independent 
of BMD, fracture probability may be underestimated by FRAX.  
vi  Causes of secondary osteoporosis include hyperparathyroidism, 
hyperthyroidism, malabsorption, hypogonadism/amenorrhoea, diabetes 
mellitus, and chronic liver disease.
vii For diagnosis and management of renal phosphate wasting,  
see Indications and Tests for Proximal Renal Tubulopathy (PRT).
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Vitamin D Test Therapy(i)
Deficiency:
< 10 ng/mL (< 25 nmol/L)(ii)
Insufficiency:
< 20 ng/mL (< 50 nmol/L)
Serum 25-hydroxy vitamin D  
(25(OH) vitamin D)
If deficient, consider checking par-
athyroid hormone (PTH), calcium, 
phosphate(iii), alkaline phosphatase
If vitamin D deficient, replacement recommended. Various regimens 
suggested(iv)
Consider re-checking 25(OH) vitamin D levels 3 months after replacement.
After replacement, maintenance with 800-2,000 IU vitamin D daily.
Vitamin D deficiency prevalent in 
both HIV-positive and HIV-neg-
ative populations – may not be 
directly associated with HIV.
Factors associated with lower 
vitamin D:
• Dark skin
• Dietary deficiency
• Avoidance of sun exposure
• Malabsorption
• Obesity
• Chronic kidney disease
• Some ARVs(v)
Check vitamin D status in persons 
with history of:
• low bone mineral density and/or 
fracture
• high risk for fracture
Consider assessment of vitamin D 
status in persons with other factors 
associated with lower vitamin D 
levels (see left column)
Replacement and/or supplementation of vitamin D is  
recommended for persons with both vitamin D insufficiency(vi) and one of 
the following:
• osteoporosis
• osteomalacia
• increased PTH (once the cause has been identified)
Consider re-testing after 6 months of vitamin D intake
Vitamin D Deficiency: Diagnosis and Management
i Can be provided according to national recommendations/availability of 
preparations (oral and parenteral formulations). Combine with calcium 
where there is insufficient dietary calcium intake. Consider that in some 
countries food is artificially fortified with vitamin D. 
ii Some experts consider a value of ≤ 30 ng/mL as vitamin D deficiency. 
Low vitamin D has a prevalence of up to 80% in HIV cohorts and was 
associated with increased risk for osteoporosis, type 2 diabetes, morta-
lity and AIDS events. Consider seasonal differences (in winter approxi-
mately 20% lower than in summer). 
iii Consider that hypophosphataemia can be associated with TDF therapy. 
This phosphate loss through proximal renal tubulopathy may be inde-
pendent of low vitamin D, see page 54. A combination of low calcium + 
low phosphate +/- high alkaline phosphatase may indicate osteomalacia 
and vitamin D deficiency. 
iv Expect that 100 IU vitamin D daily leads to an increase in serum 25(OH) 
vitamin D of approximately 1 ng/mL. Some experts prefer a loading dose 
of e.g. 10,000 IU vitamin D daily for 8-10 weeks in persons with vitamin 
D deficiency. The principal goal is to achieve a serum level > 20 ng/mL 
(50 nmol/L) and to maintain normal serum PTH levels. Combine with 
calcium where potential for insufficient dietary calcium intake. The thera-
peutic aim is to maintain skeletal health; vitamin D supplementation has 
not been proven to prevent other co-morbidities in HIV-positive persons. 
v The role of HIV-therapy or specific drugs remains unclear. Some studies 
suggest an association of EFV with reductions in 25(OH)D but not 
1.25(OH)D. PIs may also affect vitamin D status by inhibiting conversion 
of 25(OH)D to 1.25(OH)D. 
vi The implications of vitamin D levels that are below the physiological 
reference range but not markedly reduced and the value of supplemen-
tation are not completely understood. 
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Reducing risk  
of fractures 
• Aim to decrease falls by addressing fall risks(i)
• Ensure sufficient dietary calcium (1-1.2 g daily) and 
vitamin D (800-2,000 IU daily) intake(ii)
• Where appropriate, screen for osteoporosis(iii) and 
refer to national/regional guidelines on treatment of 
osteoporosis 
 – If no guidelines available, consider bisphosphonate(iv) 
treatment in all osteoporotic postmenopausal women 
and men > 50 years old (BMD T-score ≤ -2.5) and 
those with a history of fragility fracture. Consider 
treatment based on BMD alongside consideration of 
other risk factors for fracture, especially age.
 – Use bisphosphonate and ensure adequate calcium 
and vitamin D intake 
 – No significant interactions between bisphosphonates 
and antiretrovirals
 – If antiretroviral-naïve, consider options for ART that 
preserve BMD(v)
 – If diagnosed with osteoporosis and requiring therapy, 
consider optimising ART to preserve or improve BMD
• In complicated cases (e.g. young men, premenopausal 
women, recurrent fracture despite bone protective thera-
py), refer to osteoporosis specialist
• If on bisphosphonate treatment, repeat DXA after 2 
years and reassess need for continued treatment after 
3-5 years
Approach to Fracture Reduction in HIV-positive Persons
i  Falls Risk Assessment Tool (FRAT), see https://www2.health.vic.gov.au/
ageing-and-aged-care/wellbeing-and-participation/healthy-ageing/falls-
prevention/falls-prevention-tools  
ii  See page 50 for diagnosis and management of vitamin D deficiency.
iii  See page 49 for screening and diagnosis of bone disease in HIV.
iv  Bisphosphonate treatment with either of: alendronate 70 mg once  
weekly po; risedronate 35 mg once weekly po; ibandronate 150 mg  
po once a month or 3 mg iv every 3 months; zoledronic acid 5 mg iv  
once yearly.
v BMD loss is greatest in the first year after ART initiation, with more BMD 
loss with ART regimens containing TDF and some PIs. Consider relative 
risk/benefit of using these agents in persons with high fracture risk. 
Reduced BMD loss is seen in those with optimised vitamin D status.
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Kidney Disease: Definition, Diagnosis and Management
Management of HIV-associated kidney disease(vi)
Prevention of progressive  
renal disease
Comment
1. ART Start ART immediately where 
HIV-associated nephropathy (HIVAN)
(vii) or HIV immune complex disease 
strongly suspected. Immunosup-
pressive therapy may have a role in 
immune complex diseases. Renal 
biopsy to confirm histological diag-
nosis recommended 
Consider replacing TDF** by 
non-tenofovir drug or TAF*** if:
•  UP/C 20-50 mg/mmol
•  eGFR > 60 mL/min, but decrease 
in eGFR by 5 mL/min per year for 
at least 3 consecutive years or 
confirmed 25% eGFR decline from 
baseline
•  co-morbidities with a high risk of 
CKD (i.e. diabetes and hyperten-
sion) 
•  body weight < 60 kg
•  use of a PI/r as a third agent
Replace TDF** by non-tenofovir 
drug or TAF*** if:
•  eGFR ≤ 60 mL/min
•  UP/C > 50 mg/mmol
•  nephrotoxic comedication
•  previous TDF toxicity (proximal 
renal tubulopathy)
** Expert opinion pending clinical 
data
***There are limited data on use 
of TAF with eGFR ≤ 30 mL/min, 
and longer term outcomes are 
unknown. 
2. Start ACE inhibitors or angio-
tensin-II receptor antagonists 
if:
a. Hypertension and/or
b. Proteinuria
Monitor eGFR and K+ level 
closely on starting treatment or 
increasing dose
a. Blood pressure target: < 130/80 
mmHg
3.  General measures:
a.  Avoid nephrotoxic drugs
b.  Lifestyle measures (smoking, 
weight, diet)
c.  Treat dyslipidaemia(viii) and diabe-
tes(ix)
d.  Adjust drug dosages where nec-
essary(v)
CKD and proteinuria are independ-
ent risk factors for CVD
i For eGFR: Use CKD-EPI formula based on serum creatinine, gender, 
age and ethnicity because eGFR quantification is validated > 60 mL/
min. The abbreviated modification of diet in renal disease  (aMDRD) or 
the Cockcroft-Gault (CG) equation may be used as an alternative; see   
https://www.chip.dk/Tools-Standards/Clinical-risk-scores. 
 Definition CKD: eGFR ≤ 60 mL/min for ≥ 3 months (see http://www.
kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_
GL.pdf). If not previously known to have CKD, confirm pathological 
eGFR within 2 weeks. Use of DTG, COBI and RTV boosted PIs is 
associated with an increase in serum creatinine/reduction of eGFR due 
to inhibition of proximal tubular creatinine transporters without impairing 
actual glomerular filtration: consider new set point after 1-2 months 
ii Urinalysis: use urine dipstick to screen for haematuria. To screen for 
proteinuria, use urine dipstick and if ≥ 1+ check urine protein/creatinine 
(UP/C), or screen with UP/C. Proteinuria defined as persistent if con-
firmed on ≥ 2 occasions > 2-3 weeks apart. If UP/C not available, use 
urine albumin/creatinine (UA/C), see(iii) 
iii UP/C in spot urine is preferred to UA/C as detects total urinary protein 
secondary to glomerular and tubular disease. UA/C largely detects glo-
merular disease and can be used for screening for HIV-associated renal 
disease where UP/C is not available, but is not appropriate for screening 
for tubular proteinuria secondary to drug nephrotoxicity (e.g. TDF). If 
both UP/C and UA/C are measured, UP/C > UA/C suggests tubular 
proteinuria. Screening values for UA/C are: < 30, 30-70 and > 70. UA/C 
should be monitored in persons with diabetes. UPC ratio is calculated as 
urine protein (mg/L) / urine creatinine (mmol/L); may also be expressed 
as mg/mg. Conversion factor for mg to mmol creatinine is x 0.000884 
iv Repeat eGFR and urinalysis as per screening table, see page 7 
v See Dose Adjustment of ARVs for Impaired Renal Function 
vi Joint management with a nephrologist 
vii HIVAN suspected if black ethnicity & UP/C > 100 mg/mmol & no haema-
turia 
viii See page 48 
ix See page 46-47 
x Different models have been developed for calculating a 5-years CKD 
risk score while using different nephrotoxic ARVs integrating HIV-inde-
pendent and HIV-related risk factors [6], [7]  
 See online video lecture CVD, CKD and Endocrinology from the EACS 
online course Clinical Management of HIV. 
Diagnosis of kidney disease
eGFR(i)
> 60 mL/min > 60 mL/min, but 
accelerated decline of 
eGFR*
 > 30 - ≤ 60 mL/
min
≤ 30 mL/min 
Pr
ot
ei
nu
ria
(ii
)
UP/C(iii) < 50 Regular follow-up • Check risk factors for CKD and nephrotoxic  
medicines including ART(iv)
• Discontinue or adjust drug dosages where appropriate(v) 
• Perform renal ultrasound 
• Urgent referral to nephrologist 
UP/C(iii) 50-100 • Check risk factors for CKD(x) and nephrotoxic 
medicines including ART(iv, x)
• Discontinue or adjust drug dosages where 
appropriate(v) 
• Perform renal ultrasound 
• If haematuria present with any level of proteinu-
ria refer to nephrologist
• Refer to nephrologist if new CKD or progressive 
decline in eGFR
UP/C(iii) > 100 
 
* Defined as decrease in eGFR of 5 mL/min per year for ≥3 consecutive years or confirmed 25% eGFR decline from baseline
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ARV-associated Nephrotoxicity
Renal abnormality* ARV Management
Proximal tubulopathy with any combination of:
1. Proteinuria: urine dipstick ≥ 1, or confirmed increase in 
UP/C > 30 mg/mmol(i)
2. Progressive decline in eGFR and eGFR ≤ 90 mL/min(ii)
3. Phosphaturia(iii): confirmed hypophosphataemia secon-
dary to increased urine phosphate leak
4. Glucosuria in non-diabetics
TDF** Assessment:
• Tests for proximal renal tubulopathy/renal Fanconi syndrome(iii)
• Consider renal bone disease if hypophosphataemia of renal origin: mea-
sure 25(OH) vitamin D, PTH, DXA 
Replace TDF by non-tenofovir drug or TAF*** if:
• Documented tubular proteinuria and/or glucosuria 
• Progressive decline in eGFR and no other cause
• Confirmed hypophosphataemia of renal origin and no other cause
• Osteopenia/osteoporosis in the presence of increased urine  
phosphate leak 
Nephrolithiasis:
1. Crystalluria
2. Haematuria(iv)
3. Leukocyturia
4. Loin pain
5. Acute renal insufficiency
IDV
ATV
(DRV)
Assessment:
• Urinalysis for crystalluria/stone analysis
• Exclude other cause for nephrolithiasis
• Renal tract imaging including CT scan
Consider stopping IDV/ATV if:
• Confirmed renal stones
• Recurrent loin pain +/- haematuria
Interstitial nephritis:
1. Progressive decline in eGFR(ii)
2. Tubular proteinuria(iii)/ haematuria
3. Eosinophiluria (if acute)
4.  Leukocyte casts
IDV
ATV
Assessment:
• Renal ultrasound
• Refer to nephrologist
Consider stopping IDV/ATV if:
• Progressive decline in eGFR and no other cause
Progressive decline in eGFR, but none of the above(v) TDF**
PI/r
Complete assessment:
•   Risk factors for CKD(v) (see Kidney Disease: Definition, Diagnosis and 
Management)
•   PRT, UA/C, UP/C (see Kidney Disease: Definition, Diagnosis and Man-
gement and Indications and Tests for Proximal Renal Tubulopathy (PRT)
• Renal tract ultrasound
Consider stopping ARVs with potential nephrotoxicity if:
• Progressive decline in eGFR and no other cause(v)
* Use of COBI, DTG, RPV, but also PI/r is associated with an increase in 
serum creatinine/reduction of eGFR due to inhibition of proximal tubular 
creatinine transporters without impairing actual glomerular filtration: 
consider new set point after 1-2 months 
** TAF has shown lower tenofovir-related renal adverse effects due to 
lower systemic tenofovir exposure. Switch-studies from TDF to TAF and 
certain PIs suggest potential reversion of renal toxicity, however, long-
term experience with TAF is lacking
*** Particularly if eGFR > 30 mL/min, as there are limited data to on use of 
TAF with eGFR ≤ 30 mL /min, and longer term outcomes are unknown
i UP/C in spot urine detects total urinary protein including protein of 
glomerular or tubular origin. The urine dipstick analysis primarily detects 
albuminuria as a marker of glomerular disease and is inadequate to 
detect tubular disease. 
ii For eGFR: use CKD-EPI formula based on serum creatinine, gender, 
age and ethnicity because eGFR quantification is validated > 60 mL/
min. The abbreviated modification of diet in renal disease (aMDRD) or 
the Cockcroft-Gault (CG) equation may be used as an alternative; see 
https://www.chip.dk/Tools-Standards/Clinical-risk-scores.
iii See Indications and Tests for Proximal Renal Tubulopathy (PRT) 
iv Microscopic haematuria is usually present. 
v Different models have been developed for calculating a 5-years CKD 
risk score while using different nephrotoxic ARVs integrating HIV-inde-
pendent and HIV-related risk factors [6], [7].
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Indications and Tests for Proximal Renal Tubulopathy (PRT)
Indications for proximal renal tubulopathy tests Proximal renal tubulopathy tests(iv), including Replace TDF by non-tenofovir 
drug or TAF* alternative drug if:
• Progressive decline in eGFR(i) 
& eGFR ≤ 90 mL/min & no other cause and/or
• Confirmed hypophosphataemia(ii) and/or
• Confirmed increase in UP/C(iii)
• Renal insufficiency even if stable (eGFR ≤ 60 mL/min)
• Tubular proteinuria(v)
• Blood phosphate and urinary phosphate excretion(vi)
• Blood glucose and glucosuria
• Serum bicarbonate and urinary pH(vii)
• Blood uric acid level and urinary uric acid excretion(viii)
• Serum potassium and urinary potassium excretion
• Confirmed proximal renal tubulo-
pathy with no other cause
i For eGFR: use CKD-EPI formula. The abbreviated MDRD (Modification 
of Diet in Renal Disease) or the Cockcroft-Gault (CG) equation may be 
used as an alternative, see https://www.chip.dk/Tools-Standards/Clini-
cal-risk-scores.
ii Serum phosphate < 0.8 mmol/L or according to local thresholds; con-
sider renal bone disease, particularly if alkaline phosphatase increased 
from baseline: measure 25(OH) vitamin D, PTH. 
iii  UP/C in spot urine, detects total urinary protein, including protein of 
glomerular or tubular origin. The urine dipstick analysis primarily detects 
albuminuria as a marker of glomerular disease and is inadequate to 
detect tubular disease.
iv  It is uncertain which tests discriminate best for TDF renal toxicity.  
Proximal tubulopathy is characterised by: proteinuria, hypophospha-
taemia, hypokalaemia, hypouricaemia, renal acidosis, glucosuria with 
normal blood glucose level. Renal insufficiency and polyuria may be 
associated. Most often, only some of these abnormalities are observed
v  Tests for tubular proteinuria include retinol binding protein, α1- or β2-mi-
croglobulinuria, urine cystatin C, aminoaciduria.
vi  Quantified as fractional excretion of phosphate (FEPhos): (PO4(urine) 
/ PO4(serum) / (Creatinine(urine) / Creatinine(serum) in a spot urine 
sample collected in the morning in fasting state. Abnormal > 0.2 (> 0.1 
with serum phosphate < 0.8 mmol/L).
vii  S-bicarbonate < 21 mmol/L and urinary pH > 5.5 suggests renal tubular 
acidosis.
viii  Fractional excretion of uric acid (FEUricAcid): (UricAcid(urine) / Uri-
cAcid(serum) / (Creatinine(urine) / Creatinine(serum) in a spot urine 
sample collected in the morning in fasting state; abnormal > 0.1.
* Particularly if eGFR > 30 mL/min, as there are limited data on use of 
TAF with eGFR ≤ 30 mL/min.
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Dose Adjustment of ARVs for Impaired Renal Function
i  eGFR:  Use CKD-EPI formula; the abbreviated modification of diet in renal disease 
 (aMDRD) or the Cockcroft-Gault (CG) equation may be used as an alternative; see https://
www.chip.dk/Tools-Standards/Clinical-risk-scores
ii  Dose reduction if combined with TDF 
iii  150 mg loading dose 
iv  After dialysis
v  TDF and (boosted) PIs are associated with nephrotoxicity; consider alternative ART if 
pre-existing CKD, risk factors for CKD and/or decreasing eGFR, see ARV-associated 
Nephrotoxicity and Kidney Disease: Definition, Diagnosis and Management
 
vi  Limited data available in persons with renal impairment; pharmacokinetic analysis suggests 
no dose adjustment required
vii  See summary of product characteristics for specific recommendations; use with caution if 
eGFR ≤ 30 mL/min
viii In certain countries TDF is labelled as 245 mg rather than 300 mg to reflect the amount of 
the prodrug (tenofovir disoproxil) rather than the fumarate salt (tenofovir disoproxil fumara-
te)
ix 10 mg if co-administered with a boosting agent (inhibition of P-glycoprotein, P-gp)
eGFR(i) (mL/min)
Haemodialysis
≥ 50 30-49 10-29 < 10
NRTIs
ABC  300 mg q12h No dose adjustment required  
ddI(ii) ≥ 60 kg 400 mg q24h 200 mg q24h 150 mg q24h 100 mg q24h 100 mg q24h(iv)
< 60 kg 250 mg q24h 125 mg q24h 100 mg q24h 75 mg q24h 75 mg q24h(iv)
d4T                   ≥ 60 kg 40 mg q12h 20 mg q12h 20 mg q24h 20 mg q24h 20 mg q24h(iv)
< 60 kg 30 mg q12h 15 mg q12h 15 mg q24h 15 mg q24h 15 mg q24h(iv)
FTC 200 mg q24h 200 mg q48h 200 mg q72h 200 mg q96h 200 mg q96h(iv)
3TC 300 mg q24h 150 mg q24h 100 mg q24h(iii) 50-25 mg q24h(iii) 50-25 mg q24h(iii), (iv)
TDF(v)
300(viii) mg q24h 300(viii) mg q48h
Not recommended Not recommended
300(viii) mg q7d(iv)(300(viii) mg q72-96h, 
if no alternative)
(300(viii) mg q7d, if 
no alternative)
ZDV 300 mg q12h No dose adjustment 
required
100 mg q8h 100 mg q8h(iv)
ABC/3TC 600/300 mg q24h
Use individual drugsZDV/3TC 300/150 mg q12h
ABC/3TC/ZDV 300/150/300 mg 
q12h
TAF/FTC 25(ix)/200 mg q24h Not recommended
TDF/FTC 300(viii)/200 mg q24h 300(viii)/200 mg q48h Use individual drugs
NNRTIs
EFV 600 mg q24h              No dose adjustment required
ETV 200 mg q12h              No dose adjustment required
NVP 200 mg q12h              No dose adjustment required
TAF/FTC/RPV 25/200/25 mg q24h Not recommended
TDF/FTC/RPV 300(viii)/200/25 mg 
q24h
Do not use
eGFR(i) (mL/min)
Haemodialysis
≥ 50 30-49 10-29 < 10
PIs(v)
ATV/c 300/150 mg q24h No dose adjustment required(vi)
ATV/r 300/100 mg q24h No dose adjustment required(vi)
DRV/r 800/100 mg q24h
600/100 mg q12h No dose adjustment required
(vi)
DRV/c 800/150 mg q24h No dose adjustment required(vi)
TAF/FTC/DRV/c 10/200/800/150 mg q24h Not recommended
FPV/r 700/100 mg q12h No dose adjustment required(vi)
LPV/r 400/100 mg q12h No dose adjustment required(vi)
SQV/r 1000/100 mg q12h No dose adjustment required(vi)
TPV/r 500/200 mg q12h No dose adjustment required(vi)
Other ART
RAL 1 x 400 mg tablet q12h or
2 x 600 mg tablets q24h
No dose adjustment required(vi)
DTG 50 mg q24h No dose adjustment required(vi) No clinical data; PK 
data suggest safety
ABC/3TC/DTG 600/300/50 mg q24h Use individual drugs
TAF/FTC/BIC 20/200/75 mg q24h Not recommended
TAF/FTC/EVG/c 10/200/150/150 mg q24h                         Not recommended
TDF/FTC/EVG/c Do not initiate if eGFR < 70 mL/min Do not use
MVC: co-administered
without CYP3A4
inhibitors(vii)
300 mg q12h No dose adjustment required(vi)
MVC: co-administered 
with CYP3A4 inhibitors(vii)
If eGFR < 80 mL/min 150 mg q24h(vii) except: 150 mg q12h if co-administered with FPV/r
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Identify potential cause of increased liver enzymes, using the following steps:
ST
EP
 1
Does the person take any potentially hepatotoxic medication/
herbal products/illicit drugs? No
GO TO STEP 2
Yes
Stop the drug or replace if feasible; if ARV potentially involved,  
do not impair efficacy of the regimen 
Yes
Disappearance of liver abnormalities? No
Yes
Adapt treatment regimen accordingly
Can you identify recent/chronic alcohol intake? No
Yes
Recommend stopping alcohol intake and follow ALT/AST 
(4-8 weeks may be needed for improvement) 
ST
EP
 2
Exclude viral hepatitis test for:
• Hepatitis A (HAV IgM), if status unknown or person non-immune 
previously
Neg
GO TO STEP 3
Manage accordingly
• Acute/chronic HBV (HBsAg) or HCV (HCV-Ab, HCV-RNA),  
if status unknown or person non-immune/negative previously Neg
see page 81-87
ST
EP
 3
Identify other causes of increased ALT/AST Identify other causes of increased ALT/AST
Steatosis 
NASH(i) (metabolic 
syndrome, diabetes) 
HCV-associated 
steatosis
Nodular regenerative 
hyperplasia (more 
frequent in HIV-posi-
tive persons)
Other viral diseases 
(CMV, EBV, Hepa-
titis E)
Non-hepatic causes of  
increased ALT/AST
• Coeliac disease
• Myopathy
• Portal hypertension
• Heart failure
Rare disorders
• Autoimmune hepatitis
• Haemochromatosis
• Wilson’s disease 
• Alpha-1 antitrypsin deficiency
IN ALL CASES PERFORM: • liver ultrasonography
• liver biopsy
If all causes of increased ALT/AST have been reasonably 
excluded, consider high HIV-VL as a potential explanation
See pages 57-58 and 60-61     Cirrhotic persons
i  Non-Alcoholic SteatoHepatitis, see NAFLD
Work-up and Management of HIV-positive Persons with Increased ALT/AST
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Liver Cirrhosis: Classification and Surveillance
Child-Pugh classification of the severity of cirrhosis
Points(i)
1 2 3
Total bilirubin, 
mg/dL (μmol/L)
< 2 (< 34) 2-3 (34-50) > 3 (> 50)
Serum albumin, 
g/L (μmol/L) 
> 35 (> 507) 28-35 (406-507) < 28 (< 406)
INR < 1.7 1.7-2.20 > 2.20
Ascites None Mild/Moderate 
(diuretic respon-
sive)
Severe
(diuretic refrac-
tory)
Hepatic enceph-
alopathy 
None Grade I-II
(or suppressed 
with medicine)
Grade III-IV
(or refractory)
i  5-6 points:    Class A
 7-9 points:    Class B
  10-15 points:  Class C
Algorithm for surveillance for varices and primary prophylaxis
Diagnosis of cirrhosis
Upper GI endoscopy
No varices Grade I varices Grade II/III varices
Re-endoscope
3-4 years
Re-endoscope
1 year
propranolol
80-160 mg/day
or
carvedilol
6.25-50 mg/day
intolerant
Variceal band ligation
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Liver Cirrhosis: Management
Management of HIV-positive persons with cirrhosis should be done in col-
laboration with experts in liver diseases. More general management guid-
ance is described below.
For dosage adjustment of antiretrovirals, see Dose Adjustment of ARVs for 
Impaired Hepatic Function.
In end-stage liver disease (ESLD), use of EFV may increase risk of  
CNS symptoms.
ART, if otherwise indicated, also provides net benefit to cirrhotic persons. 
See Diagnosis and Management of Hepatorenal Syndrome (HRS).
Management of hypervolaemic 
hyponatraemia
Management strategy of hepatic 
encephalopathy (HE)
1. Fluid restriction: 1000-1500 mL/
day (consumption of bouillon 
allowed ad libitum)
2. If fluid restriction is ineffective, 
consider use of oral tolvaptan
a. To be started in hospital at 
15 mg/day for 3-5 days, then 
titrated to 30-60 mg/day until 
normal s-Na; duration of treat-
ment unknown (efficacy/safety 
only established in short-term 
studies (1 month))
b. S-Na should be monitored 
closely, particularly after 
initiation, dose modification or if 
clinical status changes
c. Rapid increases in s-Na 
concentration (> 8 mmol/day) 
should be avoided to prevent 
osmotic demyelination  
syndrome
d. Persons may be discharged 
after s-Na levels are stable and 
without need to further adjust 
dose
General management
1. Identify and treat precipitating 
factor (GI haemorrhage, infection, 
pre-renal azotaemia, constipation, 
sedatives)
2. Short-term (< 72 hours) protein 
restriction may be considered if 
HE is severe
Specific therapy
Lactulose 30 cm³ po every 1-2h 
until bowel evacuation, then adjust 
to a dosage resulting in 2-3 formed 
bowel movements per day (usually 
15-30 cm³ po bid)
Lactulose enemas (300 cm³ in 1L of 
water) in persons who are unable to 
take it po. Lactulose can be
discontinued once the precipitating 
factor has resolved
Management strategy in uncomplicated ascites
General  
management
• Treat ascites once other complications have been 
treated
• Avoid NSAIDs
• Norfloxacin prophylaxis (400 mg po, qd) in persons with 
1) an ascites protein level of < 1.5 mg/dL,  
2) impaired renal function (serum creatinine level > 1.2 
mg/dL, BUN > 25 mg/dL), 3) s-Na level < 130mE g/L), 
or 4) severe liver failure (Child-Pugh score > 9 points 
with s-bilirubin level > 3 mg/dL)
Specific  
management
• Salt restriction: 1-2 g/day. Liberalise if restriction results 
in poor food intake
• Large volume paracentesis as initial therapy only in 
persons with tense ascites
• Administer iv albumin (= 6-8 g/L ascites removed)
Follow-up  
and goals
• Adjust diuretic dosage every 4-7 days
• Weigh the person at least weekly and BUN,  
s-creatinine, and electrolytes measured every  
1-2 weeks while adjusting dosage
• Double dosage of diuretics if: weight loss < 2 kg a week 
and BUN, creatinine and electrolytes are stable
• Halve the dosage of diuretics or discontinue if: weight 
loss ≥ 0.5 kg/day or if there are abnormalities in BUN, 
creatinine or electrolytes
• Maximum diuretic dosage: spironolactone (400 mg qd) 
and furosemide (160 mg qd)
Nutrition of cirrhotic persons
Caloric requirements
• 25-30 Kcal/kg/day of normal body 
weight
Protein requirements
• Protein restriction is not recom-
mended (see above for exception 
if HE)
• Type: rich in branched chain (non-
aromatic) amino acids
• Some studies support that paren-
teral proteins carry less risk of en-
cephalopathy since not converted 
by colonic bacteria into NH3
Micronutrients
• Mg and Zn
Analgesia in persons with hepatic failure
• Acetaminophen can be used; 
caution on daily dose (max 2 g/day).
• NSAIDs generally avoided; 
predispose persons with cirrhosis 
to develop GI bleeding. Persons 
with decompensated cirrhosis are 
at risk for NSAID-induced renal 
insufficiency.
• Opiate analgesics are not contra-
indicated but must be used with 
caution in persons with pre-exis-
ting hepatic encephalopathy.
Screening for HepatoCellular Carcinoma (HCC)
• HCC screening is indicated in all cirrhotic HBV or HCV co-infected 
persons (even if HCV infection has been cured and HBV replication is 
medically suppressed) in a setting where treatment for HCC is available.  
• Although the cost-effectiveness of HCC screening in persons with F3 
fibrosis is uncertain, surveillance may be considered based on an individ-
ual risk assessment (http://www.easl.eu/research/our-contributions/clini-
cal-practice-guidelines/detail/easl-clinical-practice-guidelines-on-hepato-
cellular-carcinoma).
• In HBV-positive non-cirrhotics, HCC screening should follow current 
EASL guidelines. Risk factors for HCC in this population include family 
history of HCC, ethnicity (Asians, Africans), HDV and age. EASL guideli-
nes propose using the PAGE-B score in Caucasians to assess the HCC 
risk, however this score has not been validated in HIV-positive persons.
• F4 diagnosis made by transient elastography measurement should be 
validated by a biomarker score, signs of cirrhosis in liver in sonography or 
at least repetition of transient elastography after 6 months. F3 diagnosis 
made by transient elastography measurement should be confirmed by 
a second measurement after 6 months. Cut-offs for F4 (cirrhosis): 13.0 
kPa, for F3: 10.0 kPa (http://www.easl.eu/research/our-contributions/
clinical-practice-guidelines/detail/easl-recommendations-on-treatment-of-
hepatitis-c-2018).
• Ultrasound (US) every 6 months. 
Alpha-foetoprotein is a suboptimal surveillance tool because of low 
sensitivity and specificity.
 
When to refer for liver transplantation
Best to refer early as disease progresses rapidly
= MELD(i) score 10-12 (listing at 15)
Decompensated cirrhosis (at least one of the following complications) 
• Ascites
• Hepatic encephalopathy
• Variceal bleeding
• Spontaneous bacterial peritonitis
• Hepatorenal syndrome
• Hepatopulmonary syndrome
• HCC
See Solid Organ Transplantation (SOT) in HIV-positive Persons
 
i  Unit for both S-creatinine and S-bilirubin is mg/dL. 
 MELD score = 10 {0,957 Ln (serum creatinine (mg/dL)) + 0.378 Ln (total 
bilirubin (mg/dL)) + 1.12 Ln (INR) + 0.643}, see http://www.mdcalc.com/
meld-score-model-for-end-stage-liver-disease-12-and-older/
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Non-Alcoholic Fatty Liver Disease (NAFLD)
The prevalence of NAFLD is higher in individuals with HIV infection (30- 40% 
in the US) than in the general population [9]. Nearly half of the HIV-positive 
persons that undergo evaluation for unexplained liver test abnormalities are 
found to have NAFLD. The diagnosis of NAFLD requires the exclusion of 
both secondary causes and of a daily alcohol consumption ≥ 30 g for men 
and ≥ 20 g for women.
Spectrum of NAFLD
Often associated with components of the metabolic syndrome:
Non-Alcoholic Fatty Liver (NAFL)
•  Pure steatosis
NAFLD  
•  Steatosis and mild lobular inflammation
Non-Alcoholic SteatoHepatitis (NASH)
•  Early NASH: no or mild (F0-F1) fibrosis
•  Fibrotic NASH: significant (≥ F2) or advanced (≥ F3, bridging) fibrosis
•  NASH-cirrhosis (F4)
•  HCC (can occur in the absence of cirrhosis and histological evidence of 
NASH)
Most common concurrent diseases
•  AFLD-alcoholic fatty liver disease
•  Drug-induced fatty liver disease
•  HCV-associated fatty liver (GT 3)
Diagnosis
•  Ultrasound is the preferred first-line diagnostic procedure for imaging of 
NAFLD.
•  Whenever imaging tools are not available or feasible, serum biomarkers 
and scores are an acceptable alternative for the diagnosis. Fibroscan is not 
validated for this purpose.
•  A quantitative estimation of liver fat can only be obtained by 1H-MRS. 
This technique is of value in clinical trials and experimental studies, but is 
expensive and not recommended in the clinical setting.
•  NASH has to be diagnosed by a liver biopsy showing steatosis, hepatocyte 
ballooning and lobular inflammation.
Treatment of NAFLD
•  Lifestyle modification and weight reduction is the cornerstone of treatment
•  Pharmacotherapy should be reserved for individuals with NASH, particu-
larly for those with significant fibrosis ≥ F2 and individuals with less severe 
disease, but at high risk of faster disease progression (i.e. with diabetes, 
metabolic syndrome, persistently increased ALT, high necroinflammation).
•  Management and treatment of NASH should be discussed with hepatol-
ogists. Options with proven efficacy include pioglitazone, vitamin E and 
bariatric surgery.
•  Statins may be safely used but have demonstrated no impact on liver 
disease. The same is true for n-3 polyunsaturated fatty acids.
Consideration on ARV drugs
•  d-drugs (ddi, d4T) are contraindicated in individuals at risk of or with 
NAFLD
•  Consider use of lipid neutral regimens in individuals at risk of or with 
NAFLD
Diagnostic flow-chart to assess and monitor disease severity in case of suspected NAFLD and metabolic risk factors
Metabolic syndrome Defined as ≥ 3 of the 5 following features associated with insulin resistance: 
- Impaired fasting glucose or type 2 diabetes
- Hypertriglyceridemia
- Low HDL cholesterol
- Increased waist circumference
- High blood pressure
Liver ultrasound
Liver enzymes
Steatosis present Steatosis absent
Normal liver enzymes Abnormal liver enzymes Normal liver enzymes
Serum fibrosis marker(i)
Low risk Medium/high risk
Follow-up/2 years Specialist referral Follow-up/3-5 years
Liver enzymes, fibrosis 
biomarkers
Identify other chronic liver 
diseases
In-depth assessment of 
disease severity
Decision to perform liver 
biopsy
Initiate monitoring/therapy
Ultrasound/liver enzymes
i Serum fibrosis markers: NAFLD-Fibrosis Score, FIB-4, Commercial tests (FibroTest, FibroMeter, ELF)
These recommendations are largely inspired by the EASL–EASD–EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver 
Disease: European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the 
Study of Obesity (EASO) [8].  
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Diagnosis Consider HRS in a person with cirrhosis and ascites and a creatinine level of > 1.5 mg/dL. It is a diagnosis of exclu-
sion. Before making the diagnosis, the following need to be ruled out and treated:
• Sepsis (person needs to be pancultured)
• Volume depletion (haemorrhage, diarrhoea, overdiuresis)
• Vasodilatators
• Organic renal failure (urine sediment; kidney ultrasound)
Diuretics should be discontinued and intravascular volume expanded with iv albumin.
If renal dysfunction persists despite above, diagnose HRS.
Recommended therapy Liver transplant (priority dependent on MELD score, see page 58). If person is on transplant list, MELD score should 
be updated daily and communicated to transplant centre, see Solid Organ Transplantation (SOT) in HIV-positive 
Persons.
Alternative (bridging therapy) Vasoconstrictors octreotide 100-200 µg sc tid
→ Goal to increase mean arterial 
pressure by 15 mmHg
+ midodrine 5-15 mg po tid
or terlipressin 0.5-2.0 mg iv every 4-6 hours
and iv albumin  
(both for at least 7 days)
50-100 g iv qd
Diagnosis and Management of Hepatorenal Syndrome (HRS)
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NRTIs
ABC Child-Pugh Class A: 200 mg bid (use oral solution)
Child-Pugh Class B or C: contraindicated
ddI Contraindicated
If used no dosage adjustment
d4T Contraindicated
If used no dosage adjustment
FTC No dosage adjustment
3TC No dosage adjustment
TAF No dosage adjustment
TAF/FTC No dosage adjustment
TDF No dosage adjustment
TDF/FTC No dosage adjustment
ZDV Reduce dose by 50% or double the interval between
doses if Child-Pugh Class C
NNRTIs
EFV No dosage adjustment; use with caution in persons 
with hepatic impairmentTDF/FTC/EFV
ETV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
NVP Child-Pugh Class B or C: contraindicated
RPV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
TAF/FTC/RPV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
TDF/FTC/RPV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
PIs
ATV Child-Pugh Class A: no dose adjustment
Child-Pugh Class B: 300 mg qd (unboosted)
Child-Pugh Class C: not recommended
ATV/c Child-Pugh Class A: no dosage adjustment
Child-Pugh Class B or C: not recommended
COBI Refer to recommendations for the primary PI
DRV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
DRV/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
TAF/FTC/DRV/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
FPV PI-naïve persons:
Child-Pugh Class A or B: 700 mg bid
Child-Pugh Class C: 350 mg bid
PI-experienced persons:
Child-Pugh Class A: 700 mg bid + RTV 100 mg qd
Child-Pugh Class B: 450 mg bid + RTV 100 mg qd
Child-Pugh Class C: 300 mg bid + RTV 100 mg qd
IDV Child-Pugh Class A or B: 600 mg q8h
Child-Pugh Class C: no data
LPV/r No dosage recommendation; use with caution in
persons with hepatic impairment
RTV Refer to recommendations for the primary PI
SQV Child-Pugh Class A or B: use with caution
Child-Pugh Class C: contraindicated
TPV Child-Pugh Class A: use with caution
Child-Pugh Class B or C: contraindicated
FI
ENF No dosage adjustment
CCR5 Inhibitor
MVC No dosage recommendations. Concentrations will
likely be increased in persons with hepatic impairment
INSTI
RAL No dosage adjustment
EVG Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
DTG Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
TAF/FTC/EVG/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
TDF/FTC/EVG/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
ABC/3TC/DTG Use separate compounds and refer to those adjust-
ments 
TAF/FTC/BIC Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
Note: Hepatic dysfunction is a good indication for TDM as clinical experience 
with these dose adjustments is very limited.
Dose Adjustment of ARVs  for Impaired Hepatic Function
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Lipodystrophy: Prevention and Management
Lipoatrophy Lipohypertrophy(i)
Prevention
• Avoid d4T and ZDV or pre-emptively switch away from them. No evidence 
of benefit by switching other antiretrovirals.
• Avoid excessive weight loss due to diet and exercise.
• In ART-naïve persons, limb fat usually increases with initiation of ART not 
containing d4T or ZDV, reflecting “return-to-health” type of response.
Prevention
• No proven strategy
• No current antiretroviral drug has been specifically associated with increa-
sed visceral adiposity
• An excess of visceral fat has been reported in HIV vs. non-HIV non-obese 
persons for the same body mass index
• Weight reduction or avoidance of weight gain may decrease visceral fat
• Avoid corticosteroids with RTV or COBI-boosted drugs as it may cause 
Cushing syndrome or adrenal insufficiency (see Drug-Drug Interactions 
between Corticosteroids and ARVs)
Management
• Modification of ART: Switch away from d4T or ZDV
    –– Increase in total limb fat ~400-500 g/year (in the first two years)
    –– Risk of toxicity from new drug, see Adverse Effects of ARVs & Drug
         Classes
• Surgical intervention
       –– Offered for cosmetic relief of (facial) lipoatrophy only
Management
• Diet and exercise may reduce visceral adiposity;
  –– Limited data, but not consistently associated with improvement in insulin    
sensitivity and blood lipids
  –– No prospective trials in HIV-positive persons to definitely indicate degree
       of diet and/or exercise needed to maintain reduction in visceral fat
• Pharmacological interventions to treat lipohypertrophy have not been pro-
  ven to provide long-term effects and may introduce new complications;
• Growth hormone (not approved for this indication in Europe) 
  –– Decreases visceral adipose tissue
  –– May worsen insulin resistance
• Tesamorelin (not approved in Europe; approved for this indication by FDA)(ii) 
• Metformin (not approved for this indication in Europe)
  –– Decreases visceral adipose tissue in insulin resistant persons
  –– May worsen subcutaneous lipoatrophy
• Surgical therapy can be considered for localised lipomas/buffalo humps
  –– Duration of effect variable
i  Lipohypertrophy may occur as localised  lipomas in the subcutaneous 
region or as increased visceral adiposity, both intraabdominally and/or in 
the epicardium. 
ii  Tesamorelin (growth hormone releasing factor) was shown to reduce 
visceral adipose tissue volume but this effect was lost on discontinuation.
 See online video lecture CVD, CKD and Endocrinology from the EACS 
online course Clinical Management of HIV. 
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Hyperlactataemia and Lactic Acidosis: Diagnosis, Prevention and Management
Risk factors Prevention/Diagnosis Symptoms
• Use of ddI > d4T > ZDV
• HCV/HBV co-infection
• Use of ribavirin
• Liver disease
• Low CD4 count
• Pregnancy
• Female sex
• Obesity
• Avoid d4T + ddI combination
• Routine monitoring of serum lactate levels not 
recommended - does not predict risk of lactic 
acidosis
• Measurement of serum lactate, bicarbonate & 
arterial blood gases + pH indicated in case of 
symptoms suggestive of hyperlactataemia
• Close monitoring for symptoms if > 1 risk factor
• Hyperlactataemia: unexplained nausea, abdo-
minal pain, hepatomegaly, elevated ALT and/or 
AST, weight loss
• Acidaemia: asthenia, dyspnoea, arrhythmias
• Guillain-Barré-like syndrome
Management
Serum lactate (mmol/L) Symptoms Action
> 5(i) Yes/No • Repeat test under standardised conditions to confirm & obtain arterial pH 
and bicarbonate(i)
• If confirmed, exclude other causes
 – Arterial pH ↓ and/or bicarbonate ↓(i): Stop NRTIs 
 – Arterial pH and/or bicarbonate normal: Consider switch from high to 
low-risk NRTI & monitor carefully OR stop NRTIs
2-5 Yes Exclude other causes; if none found: watchfully follow up OR consider 
switch from high to low-risk NRTI, OR stop NRTI 
2-5 No Repeat test 
If confirmed, watchfully follow up
< 2  None 
i Lactic acidosis is a rare but life-threatening situation usually associated 
with symptoms; high risk if serum lactate > 5 and especially > 10 mmol/L.
Management of lactic acidosis  
(irrespective of serum-lactate level)
Admit the person. Stop NRTIs. Provide iv fluids. Vitamin supplementation 
can be used (vitamin B complex forte 4 mL bid, riboflavin 20 mg bid, thia-
mine 100 mg bid; L-carnitine 1000 mg bid), although benefit is not proven.
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Travel
General precautions • Delay travel until clinically stable and treatment 
established
• Provide drug prescription and referral letter for 
emergencies
• Provide medical certificate for import of perso-
nal medicines/syringes
• Carry antiretrovirals split between suitcase and 
hand luggage
• Beware of fake drugs
ART • Maintain hours of medicines (e.g. 23.00 local 
time) when switching time zones, shortening 
the interval to the next dose when flying east
Acknowledge in-
creased susceptibili-
ty(i) of HIV-positive
1. Observe food hygiene
• Bacterial enterocolitis 
e.g. diarrhoeagenic E. coli, Salmonella, Shigel-
la, Campylobacter
• Opportunistic intestinal parasitosis
Cryptosporidium, Cyclospora, Cystoisospora, 
Microsporidia
2. Prevent insect bites
• Repellents (DEET ≥ 30%), spray clothing with 
insecticide (permethrin)
• Sleep under bednet
• Malaria chemoprophylaxis/emergency stand-
by treatment(ii) 
• Yellow fever, see page 66 
• Leishmaniasis 
    beware of sand flies (dogs) 
Advice on travel restrictions, see http://www.hivtravel.org
i Higher susceptibility due to HIV-associated GALT destruction, low CD4 
count.
ii According to malaria risk at travel destination and national guidelines; 
adherence counselling is particularly important in persons visiting friends 
and relatives. See Drug-drug Interactions between Antimalarial Drugs 
and ARVs. 
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Drug-drug Interactions between Antimalarial Drugs and ARVs 
Antimalarial drugs ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
Fi
rs
t l
in
e 
an
d 
se
co
nd
 li
ne
 d
ru
gs
amodiaquine ↔ ↑ ↔ ↑ ↑ ↑c ↓? ↓29%c ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
artemisinin ↑ ↑ ↑ ↑ ↑ ↓ ≈50% ↓D ↓D D D D ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
atovaquone ↔ ↓46%a ↔ ↓a ↓74%a ↓75%a ↓E55%a ↓a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
chloroquine ↔b ↔b ↔ ↔ ↔b ↔ ↔ ↔ ↔e ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
clindamycin ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
doxycycline ↔ ↔ ↔ ↔ ↔ ↓? ↓? ↓? ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
lumefantrine ↑b ↑b ↑ ↑ ↑b ↓ ≈40% ↓ ↓D46% ↔e ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
mefloquine ↑b ↑b ↑ ↑ ↑b ↓ ↓ ↓ ↔e ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
primaquine ↔ ↔ ↔ ↔ ↔ ↔d ↔d ↔d ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
proguanil ↔ ↓41%a ↔ ↓a ↓38%a ↓44%a ↓E55%a ↓a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
pyrimethamine ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ E E ↔ ↔
quinine ↑b ↑b ↑ ↑ ↑b ↓ ↓ ↓ ↔e E ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
sulfadoxine ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ E E ↔ ↔
Legend
↑   potential increased exposure of the antimalarial drug 
↓   potential decreased exposure of the antimalarial drug
↔   no significant effect    
D   potential decreased exposure of ARV drug
E   potential elevated exposure of ARV drug
ATV/c  ATV co-formulated with COBI (300/150 mg qd);
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a     take with high fat meal, consider dose increase
b  ECG monitoring is recommended
c  liver toxicity
d  increase of haemotoxic metabolites
e     both drugs can induce QT interval prolongation (only at supratherapeutic 
dose for rilpivirine)
 
Note: interactions with ZDV: amodiaquine, atovaquone, primaquine, py-
rimethamine, sulfadoxine (potential additive hematological toxicity)
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion  
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required  
Comment             
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).
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Vaccination
• Vaccinate according to national guidelines for healthy population, prefe-
rably after having achieved suppressed viraemia and immune reconsti-
tution (CD4 count > 200 cells/μL)
• Consider repeating vaccinations performed at CD4 count < 200 cells/μL 
(< 14%) or unsuppressed viraemia once adequate immune reconstituti-
on is achieved (HIV-VL undetectable and CD4 count > 200 cells/μL)
• As vaccine responses may be significantly lower in HIV-positive persons 
(i.e. lower seroconversion rates, faster titer decline), consider antibody 
titers to assess their effectiveness
• Avoid polysaccharide vaccination
• For background data, see http://www.bhiva.org/vaccination-guidelines.
aspx.
• For attenuated live vaccines(i) 
(in addition to restrictions for general population):
•  *Varicella, measles, mumps, rubella, yellow fever 
Contraindicated if CD4 count < 200 cells/μL (14%) and/or AIDS.
Impaired protection after vaccination with unsuppressed viraemia.
• Oral live typhoid 
Contraindicated if CD4 count < 200 cells/μL (14%): give inactivated 
parenteral polysaccharide vaccine. Preferred if CD4 count > 200 cells/
μL (> 14%).
Infection Vaccination rationale in HIV-positive 
persons
Comment
Influenza Virus Higher rate of pneumonia. Explicitly rec-
ommended in all HIV-positive persons 
Yearly
Human Papilloma Virus (HPV) Shared risk with HIV of contracting
infection. Higher rate of cervical and anal
cancer
Vaccinate with 3 doses for all HIV-positive persons up to age 26 / age 40 if 
MSM (health insurance coverage differs by country according to age, sex, 
sexual orientation). Use 9-valent vaccine if available.
If HPV infection is established, efficacy of vaccine is questionable
Hepatitis B Virus (HBV) Shared risk with HIV of contracting
infection. HIV accelerates liver disease
progression
Vaccinate if seronegative. Repeat doses until anti-HBs antibodies ≥ 10 IU/L 
/ ≥ 100 IU/L according to national guidelines. In order to reach ≥ 100 IU/L 
in non-responders repeat 3 doses if anti-HBs < 10 IU/L, 1 dose if anti-HBs 
< 100 IU(ii); consider double dose (40 μg) in particular with low CD4 count 
and high HIV-VL. See page 81
Hepatitis A Virus (HAV) According to risk profile (travel, MSM,
IVDU, active hepatitis B or C infection)
Vaccinate if seronegative. Consider checking antibody titres in individuals 
with high risk. Weaker immune response expected with HAV/HBV co-vac-
cine. See page 81
Neisseria meningitidis As general population Use conjugated(iii) vaccine (2 doses 1-2 months apart) if available. Booster 
every five years if exposure continues. Polysaccharide vaccine not recom-
mended anymore.
Streptococcus pneumoniae Higher rate and severity of invasive
disease. Vaccine explicitly recommend-
ed for all HIV-positive persons
One dose of conjugated(iii) 13-valent vaccine (CPV-13) for all individuals, 
also if pre-vaccinated with PPV-23 polysaccharide vaccine. No general 
recommendation for any booster dose. Some national guidelines consider 
one dose of PPV-23 at least 2 months after CPV-13 for all individuals.
Varicella Zoster Virus (VZV) Higher rate and severity of both chicken-
pox and zoster
Perform serology if exposure history negative. Vaccinate if seronegative. 
For contraindications, see*
Yellow Fever Virus Mandatory for travel to selected coun-
tries (provide exemption letter if no true
risk of exposure)
Contraindicated if past or current haematological neoplasia or thymus 
affection (thymoma, resection/radiation) 
For other contraindications, see*. Booster q 10 years.
i Administer live vaccines simultaneously or with an interval of 4 weeks 
ii In case of non-response, ART should contain TDF or TAF
iii Conjugated vaccines are more immunogenic, induce memory cells, 
respond to boosting and reduce mucosal colonisation 
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Sexual and Reproductive Health of HIV-positive Women and Men
Screening questions about sexual and reproductive health and sexual func-
tioning should be routinely asked in every HIV consultation. 
Sexual transmission of HIV
Effective measures to reduce sexual transmission of HIV include:
Measure Comment
Male condom or 
female condom use
• Effective in treated and untreated HIV-positive 
persons
Post-exposure 
prophylaxis (PEP)
• Consider after situations of unprotected anal or
vaginal intercourse, if one partner has detectab-
le HIV-VL and the other partner is seronegative
• Start as soon as possible and within 48/72 
hours post sexual exposure
See Post-exposure prophylaxis (PEP)
Pre-exposure 
prophylaxis (PrEP)
• Effective in HIV-negative persons with high risk 
sexual situations, see Pre-exposure prophylaxis 
(PrEP)
ART for HIV-positive  
partner
• Considered effective from 6 months of fully 
suppressive ART if no active STIs
• Consider in e.g. serodifferent couples(i)
i See page 11
Reproductive health 
Reproductive health issues should be preferentially discussed with both 
partners, particularly in serodifferent couples. See Drug-drug Interactions 
between Contraceptives and ARVs  
Approaches for serodifferent couples who want to have children
Screening for STIs (and treatment, if required) of both partners is mandatory. 
For HIV-positive women wishing to conceive: 
(1) avoid using ddI, d4T or triple NRTIs, among PI/r, prefer ATV/r, already 
started NVP, EFV, DTG, RAL or DRV/r can be continued. Women on 
EVG/c need to be informed that monitoring of HIV-VL and drug levels 
may be necessary during pregnancy, see page 17;
(2) consider treating the HIV-positive partner to reduce risk of HIV transmis-
sion to the HIV-negative partner.
No single method is fully protective against transmission of HIV; the following 
list represents selected measures with increasing safety for serodifferent 
couples without active STIs:
• Unprotected intercourse during times of maximum fertility (determined by 
ovulation monitoring), if the HIV-positive partner has undetectable HIV-VL. 
• Vaginal syringe injection of seminal fluid during times of maximum fertility, 
if the male partner is HIV-negative. 
• Sperm washing, with or without intra-cytoplasmic sperm injection, is 
no longer necessary because of effectiveness of ART in avoiding HIV 
transmission at conception in HIV-positive male persons with undetectable 
HIV-VL.
Sexual dysfunction 
Guidelines for treatment of sexual dysfunction in the general population are 
available for men but not women. Refer to specialist where appropriate.
See Sexual Dysfunction and Treatment of Sexual Dysfunction in  
HIV-positive Men
Therapy Comment
Chlamydia infection Consider doxycycline (100 mg bid po 7-10 days, con-
traindicated in pregnancy) or azithromycin (1 g po as a 
single dose) for urethritis and cervicitis.
For Lymphogranuloma venereum (LGV) doxycycline 
(100 mg po bid for 21 days) or azithromycin (1 g po 
every week for 3 weeks).
Alternatives: 
erythromycin (500 mg/6 h po(i)) or levofloxacin (500 mg/
day) for 7 days (or 21 days in case of LGV)
• May cause therapy-resistant proctitis in HIV-positive MSM
• Consider co-infections with Neisseria gonorrhoeae
Gonorrhoea Ceftriaxone (500 mg im as a single dose) together with 
azithromycin (1 g po as a single dose).
• Can cause proctitis, prostatitis and epididymitis
• In women often asymptomatic
• Fluoroquinolone resistance is highly prevalent in all regions
HBV infection
HCV infection
See detailed information on HIV/HCV or HIV/HBV co-in-
fections, pages 82-87
• Interruption of TDF, 3TC or FTC can lead to HBV reactivation
• Clusters of acute HCV infection in HIV-positive MSM across Europe
HPV infection There are several treatment modalities for the manage-
ment of genital warts with no evidence to suggest one 
approach is better than another approach. Consider 
operative removal by laser surgery, infrared coagulation, 
cryotherapy, etc.
Management of both pre-invasive cervical lesions as 
well as peri- and intra-anal lesions should follow local or 
national guidelines
• Infection is mostly asymptomatic; relapse of genital warts is frequent
• Cervical PAP smear test recommended in all HIV-positive women
• Anal HPV screening and cytology should be considered in all HIV-positive persons 
practising anal sex
• Consider high resolution anoscopy in case of suspicious cytological findings (rectal 
palpation or external inspection is not sufficient)
HSV2 infection Primary infection: aciclovir (400–800 mg po tid) or valaci-
clovir (500 mg po bid) for 5 days, see page 93
• Treatment of HSV2 alone does not prevent HIV-transmission and only modestly 
prevents HIV disease progression
Syphilis Penicillin is the gold standard for the treatment of syphilis 
in both pregnant and non-pregnant individuals.
Primary/secondary syphilis: benzathine penicillin 
G (2.4 million IU im as single dose). In early syphilis 
adjunctive treatment with prednisolone (20–60 mg daily 
for 3 days) prevents optic neuritis, uveitis and Jarisch–
Herxheimer reaction.
Late latent syphilis and syphilis of unknown dura-
tion: benzathine penicillin (2.4 million IU im weekly on 
days 1, 8 and 15); the alternative doxycycline (100 mg 
po bid for 2 weeks) is considered less effective.
Neurosyphilis: penicillin G (6 x 3 - 4 million IU iv for at 
least 2 weeks). 
There is no evidence to give a general recommendation 
on prednisolone use in this condition.
• Expect atypical serology and clinical courses
• Consider cerebrospinal fluid (CSF) testing in persons with neurological symptoms 
(evidence for intrathecally-produced specific antibodies, pleocytosis, etc.)
• Successful therapy clears clinical symptoms and decreases VDRL test four-fold 
within 6-12 months
i Rarely used
STI screening and treatment
STI screening should be offered to all sexually active HIV-positive persons at 
the time of HIV diagnosis, annually thereafter or at any time STI symptoms 
are reported and during pregnancy. Diagnosis procedures should follow local 
or national guidelines. More comprehensive advice can be found at  
http://www.iusti.org/regions/Europe/euroguidelines.htm
The following STIs should be universally considered in HIV-positive persons 
and their sexual partner(s):
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When sexual 
complaints exist:
What is the exact nature of the 
problem? In which phase(s) of 
the sexual response cycle does 
the problem occur?
1. Desire (lack of sexual desire or libido; desire discrepancy with partner; aversion to sexual activi-
ty)
2.  Arousal (difficulties with physical and/or subjective sexual arousal; difficulties or inability to achie-
ve or sustain an erection of sufficient rigidity for sexual intercourse MEN; i.e. erectile dysfunction; 
lack or impaired nocturnal erections MEN; difficulties lubricating WOMEN; difficulties sustaining 
arousal)
3. Orgasm (difficulties experiencing orgasm) 
4. Pain (pain with sexual activity; difficulties with vaginal/anal penetration–anxiety, muscle tension; 
lack of sexual satisfaction and pleasure)
Self-assessment of sexual 
function (questionnaires):
MEN
International Index of Erectile Function (IIEF) -5, see https://www.hiv.va.gov/provider/manual-prima-
ry care/urology-tool2.asp) or IIEF-15, see http://files.sld.cu/urologia/files/2011/08/iief.pdf
WOMEN
Female Sexual Function Index (FSFI), see http://www.fsfiquestionnaire.com
Check for endo-
crine causes:
Signs of hypogonadism MEN
- Look for signs of testosterone insufficiency (main: decreased or 
absent nocturnal erections, decrease in testes size, decreased 
volume of ejaculate, hot flushes, sweats, reduction of body hair 
and beard; others: reduced sexual arousal and libido, de-
creased frequency of sexual thoughts and fantasies, decreased 
genital sensitivity, erectile dysfunction, loss of vitality; fatigue; 
loss of muscle mass and muscle strength)
- If signs or symptoms of hypogonadism are present ask for 
hormonal assessment: lutropin hormone (LH), follicle stimulating 
hormone (FSH), total testosterone; sex hormone-binding glob-
ulin evaluation to calculate free testosterone, see http://www.
issam.ch/freetesto.htm
If hypogonadism is present 
(total testosterone < 300 ng/dl 
or calculated free testosterone 
below normal): refer to endo-
crinologist or andrologist
If hypogonadism is not present: 
check for other causes
WOMEN
- Look for signs of estradiol insufficiency/menopause (amenor-
rhoea or missed menstrual periods, vaginal dryness, hot flash-
es, night sweats, sleep disturbances, emotional lability, fatigue, 
recurrent urogenital infections)
- If symptoms of menopause are present ask for hormonal as-
sessment: LH, FSH, estradiol
If symptoms of menopause are 
present: refer to endocrinologist 
or gynaecologist 
If hypogonadism is not present: 
check for other causes
Check for other 
causes:
Psychological or sociological 
problems
Stigma, body image alteration, depression, fear of infecting an 
HIV-negative partner, anxiety, awareness of a chronic disease, 
condom use
Refer to clinical psychologist
Infections MEN
- Urogenital infections (note: if complete sexual response pos-
sible, e.g. with another partner, with masturbation or nocturnal 
erections-then no major somatic factors are involved)
Refer to urologist, andrologist, 
cardiologist
WOMEN
- Urogenital infections
Refer to gynaecologist
Relevant medicines, drugs, 
lifestyle factors
Drugs associated with sexual dysfunction: 1) Psychotropics – 
MEN and WOMEN (antidepressants, antiepileptics, antipsychot-
ics, benzodiazepines), 2) Lipid-lowering drugs - MEN (statins, 
fibrates), 3) Antihypertensives - MEN (ACE-inhibitors, betablock-
ers, alfablockers), 4) Others – MEN and WOMEN (omeprazole, 
spironolactone, metoclopramide, finasteride, cimetidine); 5) MEN 
and WOMEN - contribution from ARVs is controversial and benefit 
from switching studies is not proven 
Consider therapy changes
Sexual Dysfunction
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Treatment of Sexual Dysfunction in HIV-positive Men
Treatment of erectile dysfunction Treatment of premature ejaculation
Primarily oral PDE5-inhibitors (sildenafil, tadalafil, vardenafil).
• All at least 30 minutes before initiation of sexual activity
• Use lower dose if on PI/r
  –– sildenafil (25 mg every 48 hours)
  –– tadalafil 5 mg initial dose with maximum dose 10 mg in 72 hours
  –– vardenafil 2.5 mg maximum dose in 72 hours
• Tadalafil also licensed for use as an everyday ongoing therapy
Consider behavioural interventions and/or psychosexual counselling,
SSRIs, tricylclic antidepressants, clomipramine and topical anaesthetics.
• Use lower dose of clomipramine and other tricyclic antidepressants if on 
PI/r 
• Dapoxetine, a short-acting SSRI, is the only drug approved for on-demand 
treatment of premature ejaculation in Europe.
• Treatment must be maintained as recurrence is highly likely following 
withdrawal of medicine
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Depression: Screening and Diagnosis
Significance
• Higher prevalence of depression reported in HIV-positive persons (20-40% 
versus 7% in general population) 
• Significant disability and poorer HIV treatment outcomes associated with 
depression
Screening and diagnosis
Who? How to screen? How to diagnose?
Screening of all HIV-positive per-
sons recommended in view of the 
high prevalence of depression
Populations at particularly high 
risk
• Positive history of depression in 
family
• Depressive episode in personal 
history
• Older age
• Adolescence
• Persons with history of drug ad-
diction, psychiatric, neurologic or
severe somatic co-morbidity
• Use of EFV
• Use of neurotropic and recreatio-
nal drugs
• As part of investigation of neuro-
cognitive impairment, see page 
74
• Screen every 1-2 years
• Two main questions: 
1. Have you often felt depressed, 
sad or without hope in the last few 
months? 
2. Have you lost interest in activi-
ties that you usually enjoy?
• Specific symptoms in men:
 – Stressed, burn out, angry 
outbursts, coping through work 
or alcohol
• Rule out organic cause (such as 
hypothyroidism, hypogonadism, 
Addison’s disease, non-HIV drugs, 
vitamin B12 deficiency)
Symptoms – evaluate regularly
A.  At least 2 weeks of depressed mood
OR
B.  Loss of interest 
OR
C.  Diminished sense of pleasure
PLUS 4 out of 7 of the following:
1.  Weight change of ≥ 5% in one month or a persistent change of appetite
2.  Insomnia or hypersomnia on most days
3.  Changes in speed of thought and movement
4.  Fatigue
5.  Feelings of guilt and worthlessness
6.  Diminished concentration and decisiveness
7.  Suicidal ideation or a suicide attempt(i)
i  EFV has been associated with a higher risk of suicidal ideation
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Depression: Management
Degree of  
depression
Number of 
symptoms                  
(see page 70:   
A, B or C + 4/7)
Treatment Consultation with expert
No < 4 No
Mild 4 • Problem-focused consultation
• Consider antidepressant 
treatment(i)   
• Recommend physical activity
• Always if treating doctor is unfamiliar with use of antidepressants
• If depression not responding to treatment
• If person has suicidal ideation
• In case of complex situations such as drug addiction, anxiety disorders, 
personality disorders, dementia, acute severe life eventsIntermediate 5-6 Start antidepressant treatment(i)  
Severe > 6 Refer to expert (essential)   
i See Drug-drug Interactions between Antidepressants and ARVs
 
If a person is diagnosed with depression switching off EFV to another third 
ARV drug according to switch rules is recommended.
EACS   European
AIDS Clinical Society
72EACS Guidelines 9.1 PART III
Classification, Doses, Safety and Adverse Effects of Antidepressants
Mechanisms & 
classification
Start dose Standard dose Lethality in 
overdose(ii)
Insomnia  
and agitation
Sedation Nausea or 
GI effects
Sexual  
dysfunction
Weight gain
mg/day
Selective serotonin-reuptake inhibitors (SSRIs)(i)
paroxetine 10-20 20-40 Low + - / + + ++ ++
sertraline 25-50 50-150 Low + - / + + + +
citalopram 10-20 20-40 Low + - / + + + +
escitalopram 5-10 10-20 Low + - / + + + +
Mixed or dual-action reuptake inhibitors
venlafaxine 37.5-75 75-225 Moderate ++ - / + + + - / +
Mixed-action newer agents
mirtazapine 30 30-60 Low - / + ++ - / + - / + ++
-  none
+  moderate
++ severe
i For many persons, SSRI induction may be associated with adverse 
effects (GI tract, dizziness, anxiety, panic attacks). Commencing at lower 
doses (i.e. 10, 25 & 10 mg for paroxetine, sertraline and citalopram, 
respectively) and increasing to the above starting doses after 4 to 7 days 
if tolerated may reduce such effects.
ii Insomnia is associated with DTG containing ART regimens and with the 
use of some antidepressants. Clinicians should be aware when prescri-
bing DTG and antidepressants together.
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Antidepressants ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL
SSRI citalopram ↑a ↑a ↑ ↑ ↑a ↓ ↓ ↓ ↔b ↔ ↔ ↔ ↑ ↔
escitalopram ↑a ↑a ↑ ↑ ↑a ↓ ↓ ↓ ↔b ↔ ↔ ↔ ↑ ↔
fluvoxamine ↑ ↑ ↑ ↑ ↑ ↔ ↔ E ↔ ↔ ↔ ↔ ↑ ↔
fluoxetine ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
paroxetine ↑↓? ↑↓? ↑↓? ↓39% ↑↓? ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑↓? ↔
sertraline ↑ ↓ ↑ ↓49% ↓ ↓39% ↓ ↓ ↔ ↔ ↔ ↔ ↓7% ↔
SNRI duloxetine ↑ ↑↓ ↑ ↑↓ ↑↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
venlafaxine ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ D ↔ ↔ ↑ ↔
TCA amitriptyline ↑a ↑a ↑ ↑ ↑a ↔ ↔ ↔ ↔b ↔ ↔ ↔ ↑ ↔
clomipramine ↑a ↑a ↑a ↑a ↑a ↓ ↓ ↓ ↔b ↔ ↔ ↔ ↑a ↔
desipramine ↑a ↑a ↑ ↑ ↑5%a ↔ ↔ ↔ ↔b ↔ ↔ ↔ ↑ ↔
doxepin ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
imipramine ↑a ↑a ↑a ↑a ↑a ↓ ↓ ↓ ↔b ↔ ↔ ↔ ↑a ↔
nortriptyline ↑a ↑a ↑ ↑ ↑a ↔ ↔ ↔ ↔b ↔ ↔ ↔ ↑ ↔
trimipramine ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
TeCA maprotiline ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔
mianserine ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔
mirtazapine ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔
Oth-
ers
bupropion ↔ ↓ ↔ ↓ ↓57% ↓55% ↔ ↓ ↔ ↔ ↔ ↔ ↑? ↔
lamotrigine ↔ ↓32% ↔ ↓ ↓50% ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
nefazodone ↑ ↑ ↑ ↑ ↑ ↓E ↓E ↓E E E E ↔ ↑ ↔
St John's wort D D D D D D D D D D D Dc D D
trazodone ↑a ↑a ↑ ↑ ↑a ↓ ↓ ↓ ↔b ↔ ↔ ↔ ↑ ↔
Legend
↑  potential elevated exposure of the antidepressant       
↓  potential decreased exposure of the antidepressant
↔  no significant effect     
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
ATV/c   ATV co-formulated with COBI (300/150 mg qd);  
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a  ECG monitoring is recommended       
b  caution as both drugs can induce QT interval prolongation
c           the US Prescribing Information recommends that co-administration 
should be avoided as there are insufficient data to make dosing 
recommendations
Numbers refer to decreased AUC of the antidepressant as observed in drug-
drug interactions studies.
Note: no clinically relevant interactions expected between ZDV (or any other 
NRTI) and antidepresssants
SSRI  selective serotonin reuptake inhibitors 
SNRI serotonin and norepinephrine reuptake inhibitors
TCA  tricyclic antidepressants    
TeCA  tetracyclic antidepressants
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion  
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required 
Comment
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).    
       
Drug-drug Interactions between Antidepressants and ARVs
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Algorithm for Diagnosis and Management of HIV-Associated Neurocognitive  
Impairment (NCI) in Persons without Obvious Confounding Conditions
Abbreviations
CSF cerebrospinal fluid
GDR genotypic drug resistance test
HAD HIV-associated dementia
MND mild neurocognitive disorder
MRI brain magnetic resonance imaging
NP neuropsychological
OIs opportunistic infections
HIV-positive person-
self or their relatives 
complaining of, or 
care giver noting 
cognitive problems - 
without obvious con-
founding conditions(i)
Initial assesments(ii)
Problems suspected
Evaluation for 
depression and pos-
sible treatment(iii)
Problems persisting but 
depression excluded or 
optimally managed
NP examination(iv)
NCI(v)
Neurological  
examination
Brain MRI
CSF examination(vi)
Additional causes of NCI 
other than HIV excluded
Diagnosis:
HIV-associated NCI
Off ART On ART
CSF viral escape(vii) Other situations(viii)
Start ART(ix), (refer to
general guidelines)
Consider inclusion of
potentially CNS-
active drugs(x)
Optimise ART(ix) by 
CSF
and plasma GDR
testing
Include potentially 
CNS-active drugs(x)
Continue or switch
ART(ix), (refer to 
general
guidelines)
Reconsider other
causes of NCI
Repeat CSF exam-
ination and other 
evaluations as by 
clinical judgement 
 
i  Obvious confounding conditions: 
1. Severe psychiatric conditions 
2. Abuse of psychotropic drugs 
3. Alcohol abuse 
4. Sequelae from previous CNS-OIs or other neurological diseases 
5. Current CNS-OIs or other neurological diseases 
ii  The following questions may be used to guide doctor assessment 
1. Do you experience frequent memory loss (e.g. do you forget the oc-
currence of special events even the more recent ones, appointments, 
etc.)? 
2. Do you feel that you are slower when reasoning, planning activities, or 
solving problems? 
3. Do you have difficulties paying attention (e.g. to a conversation, book 
or movie)? 
       Answering “yes” to one or more of these questions may suggest the 
presence of cognitive disorders, although not necessarily linked to HIV.
iii   See Depression: Screening and Diagnosis 
iv   NP examination will have to include tests exploring the following cogniti-
ve domains: fluency, executive functions, speed of information proces-
sing, attention/working memory, verbal and visual learning, verbal and 
visual memory, motor skills plus assessment of daily functioning. 
v    NCI is defined by impairment in cognitive function on the above neuro-
psychological test where performance is compared to age- and educa-
tion-matched appropriate controls and is considered clinically significant. 
vi   Neurological examination, brain MRI and CSF examination are 
required to exclude other pathologies and to further characterise HIV-
associated NCI by including assessment of CSF HIV-VL level and, where 
appropriate, evidence for genotypic drug resistance (GDR) in a paired 
CSF and plasma sample.  
vii  CSF escape definition: 
 either CSF HIV-VL detectable and plasma HIV-VL undetectable; or both 
CSF HIV-VL and plasma HIV-VL detectable, with CSF HIV-VL higher than 
plasma HIV-VL.
viii Including all situations that do not fulfill the CSF escape definition 
ix   Triple ART regimen
x    ART drugs with potential beneficial or detrimental effects on the   
CNS
Definition of potentially CNS-active drug
    ARV drugs with either: 
1. demonstrated clear CSF penetration when studied in healthy 
HIV-positive populations (concentration above the IC90 in > 90% 
examined persons) 
2. proven short-term (3-6 months) efficacy on cognitive function or 
CSF HIV-VL decay when evaluated as single agents or in cont-
rolled studies in peer-reviewed papers
    • Drugs with demonstrated clear CSF penetration: 
       ––NRTIs: ZDV, ABC* 
       ––NNRTIs: EFV**, NVP 
       ––PI/r: LPV/r, DRV/r* 
       ––INSTI: DTG
       ––Other classes: MVC 
   • Drugs with proven clinical efficacy: 
       ––NRTIs: ZDV, ABC 
       ––PI/r: LPV/r 
*  When administered bid. Once-daily administration of these drugs, although 
common in clinical practice, has not been studied extensively with regard 
to CNS effects/CSF penetration and may have different CNS activity. RTV 
is preferred as PI booster
** Avoid EFV because of its detrimental effects on neurocognitive function in 
a RCT and potentially confounding CNS effects due to neuropsychiatric 
effects.
See online video lectures CNS and HIV-Part 1 and CNS and HIV-Part 2 from 
the EACS online course Clinical Management of HIV. 
EACS   European
AIDS Clinical Society
75EACS Guidelines 9.1 PART III
Chronic Lung Disease in HIV
Screen for chronic lung disease:
- Are you 40 years or older?
- Have you smoked more than 10 pack years in your entire lifetime?
Then check for respiratory symptoms:
- Do you have ANY of the following on a regular basis: 1) shortness of breath when walking up a slight hill or hurrying on flat ground; 2) cough and/or 
sputum; 3) wheezing
"Yes" to all three questions “Yes” to "shortness of 
breath on light exercise 
or at rest"
“No” 
Repeat questions 
anually
Assess for airflow limitation with 
spirometry
Post-bronchodilator 
FEV1/FVC < 0.70
Make comprehensive assessment particularly for the risk of 
concomitant CVD including pulmonary hypertension
Post-bronchodilator FEV1/FVC > 
0.70, but reduced lung volumes and/
or altered CO diffusion capacity test
Diagnose COPD
Consider chest 
CT for structural 
changes and/
or referral to 
respiratory 
specialist(iii)
Assessment of symp-
toms/risk of 
exacerbations(i)
Assessment of 
concomitant 
chronic 
diseases(ii)
Treatment of COPD(iv)
Single bron-
chodilator
Symptom 
persistence 
no asthma
Frequent 
exacerba-
tions and/or 
asthma
LAMA or 
LAMA/LABA
LAMA or 
LABA/ICS
Symptoms/
exacerba-
tions persistence
Symptoms/
exacerba-
tions persistence
LAMA + LABA + ICS
Continued lack of 
control
Continued lack of 
control
Add roflu-
milast or 
macrolide
LABA:  long-acting β2-agonist
LAMA:  long-acting muscarinic antagonist
ICS:  inhaled corticosteroid
i  Assessment of either dyspnoea using mMRC, see https://www.verywell.
com/guidelines-for-the-mmrc-dyspnea-scale-914740 or symptoms using 
CAT™, see http://www.catestonline.org/ and history of exacerbations 
(including prior hospitalisations)
ii  COPD itself has significant extra-pulmonary (systemic) effects including 
weight loss, nutritional abnormalities and skeletal muscle dysfunction 
iii Based on expert opinion
iv Each pharmacological treatment should be individualised and guided 
by the severity of symptoms, risk of exacerbations, adverse effects, 
co-morbidities, drug availability and cost, and the individual’s response, 
preference and ability to use various drug delivery devices.
 Inhaler technique needs to be assessed regularly.
 Long-term use of oral glucocorticoids has no evidence of benefits in 
COPD. Because of the risk of pneumonia and because of proven su-
periority of LABA/LAMA over LABA/ICS, the addition of ICS to LABA is 
recommended only in individuals with history of frequent exacerbations 
and/or asthma or in individuals not adequately controlled by LAMA/LABA 
combination. Do not use inhaled glucocorticoids with boosted ART regi-
mens, see Drug-drug Interactions between Corticosteroids and ARVs.
 Influenza and pneumococcal vaccination decreases rates of lower respira-
tory tract infections, see Vaccination
There are 3 life saving interventions:
1. Smoking cessation        
2. Chronic oxygen when stable (non-exacerbated) resting SpO2 ≤ 88% (or 
PaO2 ≤ 55 mmHg)                          
3. Non-invasive ventilation (NIV) in individuals with acute hypercapnic 
respiratory failure
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Drug-drug Interactions between Bronchodilators (for COPD) and ARVs 
Bronchodilators ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
LA
M
A
aclidinium bromide ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
glycopyrronium 
bromide
↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
tiotropium bromide ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
umeclidinium 
bromide
↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
SA
M
A ipratropium ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
LA
B
A
formoterol ↔a ↔a ↔ ↔ ↔a ↔ ↔ ↔ ↔a ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
indacaterol ↑d ↑d ↑d ↑d ↑d ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑d ↔ ↔ ↔ ↔ ↔ ↔
olodaterol ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
salmeterol ↑b ↑b ↑b ↑b ↑b ↓ ↓ ↓ ↔a ↔ ↔ ↔ ↑b ↔ ↔ ↔ ↔ ↔ ↔
vilanterol ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
SA
B
A salbutamol (alb-
uterol)
↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
M
X aminophylline ↔ ↓ ↔ ↓ ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
theophylline ↔ ↓ ↔ ↓ ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
PD
E4 roflumilast ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
IC
S
beclometasone ↑c ↑c ↑?c ↓11% ↑c ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑c ↔ ↔ ↔ ↔ ↔ ↔
budesonide ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
fluticasone ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
Legend
↑  potential elevated exposure of the bronchodilator     
↓  potential decreased exposure of the bronchodilator
↔  no significant effect     
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
ATV/c  ATV co-formulated with COBI (300/150 mg qd);  
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a  caution as both drugs can induce QT interval prolongation    
b  ECG monitoring is recommended
c  increase in concentration of active metabolite observed with RTV 
100 mg bid alone but without significant effect on adrenal function. 
Caution is still warranted, use the lowest possible corticosteroid dose 
and monitor for corticosteroid side effects    
d  exposure can be increased up to 2-fold however this increase does 
not raise any concerns based on indacaterol's safety data
ICS   inhaled corticosteroids 
LABA  long-acting β2 agonists 
LAMA  long-acting muscarinic antagonists    
MX   methylxanthines
PD4     phosphodiesterase 4 inhibitors  
SABA  short-acting β2 agonists
SAMA short-acting muscarinic antagonists
Note: no clinically significant interactions expected between ZDV and bron-
chodilators
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion 
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required
Comment             
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).
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Drug-drug Interactions between Pulmonary Antihypertensives and ARVs 
Pulmonary antihyperten-
sives
ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
ER
A
ambrisentan ↑ ↑ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
bosentan ↑a ↑a ↑a ↑a ↑a ↓ ↓ ↓b D D D D ↑a ↔ ↔ ↔ ↔ ↔ ↔
macitentan ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
PD
E5 sildenafil ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
tadalafil ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
sG
C riociguat ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
PA
epoprostenol ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
iloprost ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
treprostinil ↔ ↑ ↔ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
IP
r selexipag ↔c ↔c ↔c ↔c ↔c ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔c ↔ ↔ ↔ ↔ ↔ ↔
Legend
↑   potential increased exposure of the pulmonary antihypertensive 
↓   potential decreased exposure of the pulmonary antihypertensive
↔   no significant effect    
D   potential decreased exposure of ARV drug
E   potential elevated exposure of ARV drug
ATV/c  ATV co-formulated with COBI (300/150 mg qd);
DRV/c  DRV co-formulated with COBI (800/150 mg qd)
a     when starting bosentan in individuals already on PI/r, PI/c or EVG/c 
use a bosentan dose of 62.5 mg qd or every other day. Discontinue 
bosentan at least 36 h prior to starting PI/r, PI/c or EVG/c and restart 
after at least 10 days at 62.5 mg qd or every other day  
b  potential additive liver toxicity
c  exposure of parent drug increased but exposure of active metabolite 
unchanged
ERA    endothelin receptor antagonists  
IPr       IP receptor agonists   
PA       prostacyclin analogues   
PDE5  phosphodiesterase type 5 inhibitors    
sGC   soluble guanylate cyclase stimulators    
       
Note: no clinically significant interactions expected between ZDV and pulmo-
nary antihypertensives 
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion  
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required 
Comment             
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).
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Prescribing in the Elderly
Age related co-morbidities
polypharmacy +
Age related physiological changes
  impact pharmacokinetic (PK)/ pharmacodynamic 
(PD) effects of drugs
Drug-drug interactions (DDI) Inappropriate drug/dosage use
         ↑ risk of adverse drug reactions; nonadherence; cognitive impairment; impaired balance and falls; morbidity and 
hospitalisation
Perform periodic medicines reviews(i)
Questions to consider when reviewing a prescription
• Is there an indication for the medicine?
• Is this medicine appropriate for elderly people?
• Is the dose correct (e.g. adjusted for the renal function)?
• Is there a significant drug-drug interaction?
• Is there a significant drug-disease interaction (e.g. delirium)?
• Is the duration of treatment acceptable?
• Is there any missing medicine?
• Is the person able to manage his/her own medicines or does he/she need assis-
tance?
 Check for DDI with HIV drugs: http://www.hiv-druginteractions.org
 Check for inappropriate drugs use: Beers(ii) and STOPP/START(iii) criteria
Adapted from [10], [11], [12]
i-iii  The  Beers and STOPP criteria are tools established by experts in geriatric pharmacotherapy to detect and reduce the burden of inappropriate prescrib-
ing in elderly. Inappropriate medicines include, for instance, those which in elderly persons with certain diseases can lead to drug-disease interactions, 
are associated with a higher risk of adverse drug reactions in the elderly, medicines that predictably increase the risk of falls in the elderly or those to be 
avoided in case of organ dysfunction. The START criteria consist of evidence-based indicators of potential prescribing omission in elderly with specific 
medical conditions.
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General features
•   HIV infection is not a contraindication for transplantation consideration. 
•   Experts in HIV medicine should preferably be members of the multi-
disciplinary team, responsible for the pre-transplant evaluation, and 
take primary responsibility for the management of the HIV infection 
and the prevention and treatment of OIs. 
Organ criteria for SOT
•   HIV-positive persons should be considered for organ transplantation 
using the same indications as used in HIV-negative persons. HIV-positive 
persons with HCC can be evaluated for liver transplantation if they fulfill 
the Milan criteria(i).
Organ donation
• HIV-positive persons can receive organs from living (renal) and deceased 
(all types of SOT) HIV-negative donors.
• The use of HIV-positive donor organs for HIV-positive recipients is being 
evaluated in the context of research studies.
HIV-infection criteria for SOT
According to most international guidelines, HIV-positive individuals should 
fulfill the following criteria to be considered for SOT
1. Clinical criteria. No active OIs or HIV-related cancers. Individuals 
with PML, chronic crypto/microsporidiosis, multi-drug resistant fungal 
or mycobacterial infections, NHL and visceral KS to be excluded. For 
non-HIV-related cancers same criteria apply as in the general HIV-nega-
tive population.
2. Immunological criteria. CD4 > 200 cells/µL for all SOT except for liver 
transplantation where CD4 > 100 cells/µL. Persons with previous oppor-
tunistic infections should have a CD4 > 200 cells/µL. 
3. Virological criteria. Full control of HIV replication prior to and after trans-
plantation should be confirmed/predicted in all cases.  
4. Drug abuse. Abstinence period: alcohol 6 months; heroin/cocaine 2 
years. Former IVDUs can be in methadone programme.
Preparing HIV-positive persons for transplantation
Antiretroviral therapy
•   Choice of ART components should avoid drugs known to cause organ 
dysfunction or drugs with a high potential for drug-drug interactions if at all 
possible, see Drug-drug Interactions between Immunosuppressants (for 
SOT) and ARVs. 
•   Using a pharmacological booster (RTV or COBI) and some of the NNRTIs 
are best avoided, see Drug-drug Interactions between Immunosuppres-
sants (for SOT) and ARVs.
•   For individuals nearing indication for transplantation, ART should be modi-
fied to ensure this if at all possible. 
•   RAL (and probably DTG) plus 2 NRTIs is the preferred regimen.
•   If the individual has not yet started ART and transplantation is considered, 
ART should be commenced as soon as possible and preferably before the 
transplantation is started. 
Viral hepatitis co-infection
In liver transplant candidates, every effort should be made to treat the 
underlying viral hepatitis independently of MELD score, see pages 81-82 
and 84-87. Use of DAAs in persons with HCV co-infection may improve their 
liver function, and possibly lead to them  being removed from the transplant 
waiting list. 
Prevention of infections
•  While screening and treatment for latent TB is recommended in all 
HIV-positive persons, see page 99, it is particularly important in persons 
pre-and post-transplantation due to the additional use of immunosuppres-
sants. Immunisation regimens and pre-transplant diagnostic protocols are 
the same as in HIV-negative SOT recipients.
Follow-up after transplantation
Antiretroviral therapy
•   Same recommendations in individuals under preparation for transplanta-
tion.
•   Additionally, ARVs may exacerbate immunosuppressive agents’ adverse 
drug effects (kidney impairment, bone marrow suppression, drug-induced 
liver injury, etc.). Therefore, careful consideration of which drugs to use is 
essential see Adverse Effects of ARVs & Drug Classes. 
•   Before starting or restarting abacavir containing ART the HLA-B*5701 
status of the donor should be assessed.
Primary and secondary disease-specific chemoprophylaxis
•   HIV-positive transplant recipients should receive the same surveillance, 
prophylaxis and immunisation regimens for OIs as HIV-negative SOT 
recipients.
•   Screening and treatment for latent TB is a priority, see page 99.
Viral hepatitis co-infection
•   The efficacy and safety of DAAs in liver transplant HIV-positive recipients 
with HCV recurrence is the same as in HIV-negative recipients. 
•   Anti HBV treatment should follow the same schedules of HIV-negative 
persons.
Immunosuppressive regimens 
•   Same as in HIV-negative transplant recipients. The risk of acute rejection 
is however double of that of HIV-negative SOT recipients and, therefore, 
requires close monitoring.
•   Special attention to interaction with ART, see Drug-drug Interactions 
between Immunosuppressants (for SOT) and ART. 
i  Milan criteria: solitary tumor smaller than 5 cm or 2–3 tumors of < 3 cm in 
the absence of macrovascular tumor invasion and extrahepatic metasta-
ses.
Solid Organ Transplantation (SOT) in HIV-Positive Persons
                  PART III
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Drug-drug Interactions between Immunosuppressants (for SOT) and ARVs 
Immunosuppressants ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
C
S prednisone ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
A
M azathioprine ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
mycophenolate ↔ ↓ ↔ ↓ ↓ ↓ ↔ ↓D13% ↔ ↔ ↔ ↔ ↔ ↔ ↓? ↔ ↔ ↔ ↑ Eb
C
N
I cyclosporine ↑a ↑a ↑a ↑a ↑a ↓a ↓a ↓a E E E ↔ ↑a ↔ ↔ ↔ ↔ E Eb
tacrolimus* ↑a ↑a ↑a ↑a ↑a ↓a ↓a ↓a ↔ ↔ ↔ ↔ ↑a ↔ ↔ ↔ ↔ ↔ ↔b
m
TO
R everolimus ↑ ↑ ↑ ↑ ↑ ↓a ↓a ↓a ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
sirolimus ↑ ↑ ↑ ↑ ↑ ↓a ↓a ↓a ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔b
O
th
er
anti-thymocyte 
globulin
↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
basiliximab ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
belatacept ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Legend
↑   potential increased exposure of the immunosuppressant 
↓   potential decreased exposure of the immunosuppresant
↔   no significant effect    
D   potential decreased exposure of ARV drug
E   potential elevated exposure of ARV drug
ATV/c  ATV co-formulated with COBI (300/150 mg qd);
DRV/c DRV co-formulated with COBI (800/150 mg qd)
* available as prolonged release formulation  
Numbers refer to decreased/increased AUC of the immunosuppressant as 
observed in drug-drug interaction studies
a     TDM of immunosuppressant is recommended
b  monitor renal function
AM   antimetabolite    
CNI   calcineurin inhibitors   
CS   corticosteroids   
mTOR  mTOR inhibitors      
   
Note: interactions with ZDV: azathioprine (potential risk of additive hemato-
toxicity); mycophenolate (potential decrease in mycophenolate level, monitor 
plasma level)
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential clinically significant interaction that is likely to require addi-
tional monitoring, alteration of drug dosage or timing of administra-
tion  
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required 
Comment             
For additional drug-drug interactions and for more detailed pharmacoki-
netic interaction data and dosage adjustments, please refer to http://www.
hiv-druginteractions.org (University of Liverpool).
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Part IV   Clinical Management and Treatment of HBV and  
HCV Co-infection in HIV-positive Persons
General Recommendations for Persons with Viral Hepatitis/HIV Co-infection
Screening
1. All HIV-positive persons should be screened for HCV at time of HIV diagnosis and 
annually thereafter. Screening should use an anti-HCV antibody test. A positive 
result should be followed by HCV-RNA and genotype determination. Alternatively, 
HCV core-antigen testing can be performed to establish chronic HCV infection. 
Persons with risk factors like ongoing IDU, “chem sex” (sex under the influence of 
recreational drugs taken predominantly intravenously immediately before and/or du-
ring sexual contacts), mucosal traumatic sex, ongoing unprotected anal intercourse, 
recent sexually transmitted infection) with unexplained increase in hepatic transa-
minases and a negative anti-HCV antibody test should be tested for HCV-RNA for 
early detection of a recent infection. HCV-RNA testing or HCV core antigen is also 
recommended in persons with high risk factors for HCV re-infection after successful 
treatment or spontaneous clearance at 6-monthly interval.
2. HIV-positive persons should be screened for HAV and HBV. Persons who are 
anti-HBc positive and HBsAg negative, in particular those with elevated liver transa-
minases, should be screened for HBV-DNA in addition to HBsAg to rule out occult 
HBV infection. 
3. Hepatitis Delta antibodies should be screened for in all HBsAg positive persons.
4.     HCC screening is indicated in all cirrhotic HBV or HCV co-infected persons (even 
if HCV infection has been cured and HBV replication is medically suppressed) in 
a setting where treatment for HCC is available.  Although the cost-effectiveness 
of HCC screening in persons with F3 fibrosis is uncertain, surveillance may be 
considered based on an individual risk assessment, see page 58. In HBV-positive 
non-cirrhotics, HCC screening should follow current EASL guidelines. Risk factors 
for HCC in this population include family history of HCC, ethnicity (Asians, Africans), 
HDV and age. EASL guidelines propose using the PAGE-B score in Caucasians 
to assess the HCC risk, however this score has not been validated in HIV-positive 
persons, see pages 8, 40 and 58. 
5. Routine screening is also advised for oesophageal varices in co-infected persons 
with liver cirrhosis, see page 57. 
Vaccination, see page 66
6. Persons lacking anti-HAV IgG antibodies or anti-HBs antibodies should be offered 
vaccination for the respective virus to prevent infection regardless of their CD4 
count. The response to the HBV vaccine is influenced by the CD4 count and level 
of HIV-VL. In persons with low CD4 count (< 200 cells/μL) and ongoing HIV repli-
cation, ART should be initiated first, prior to respective vaccination. Because of the 
lack of data on the impact of immunisation in isolated anti-HBc IgG positive persons 
(HBsAg negative, anti-HBc positive and anti-HBs negative profile), vaccination is 
not presently recommended in this population. Additional data awaited. However, if 
anti-HBc results are not available, HBV vaccination is recommended in all HBs-Ag 
negative persons.
7. In HIV-positive persons vaccinated for HBV with insufficient response (anti-HBs 
< 10 IU/L), re-vaccination should be considered. Double-dose (40 μg) at 3-4 time 
points (months 0, 1, 6 and 12) may help to improve response rates to the HBV 
vaccine. Persons who fail to seroconvert after HBV vaccination and remain at risk 
for HBV should have annual serological tests for evidence of HBV infection. TDF 
based cART has been associated with prevention of HBV infection in these persons 
and ART including TDF or TAF is recommended.
ART
8.   ART initiation is recommended in all HIV-positive persons with HBV and/or HCV 
co-infection irrespective of CD4 count. ART should contain TDF or TAF in HBV 
co-infected persons. Stopping ART has been associated with higher risk for AIDS 
and non-AIDS related events; indeed, the risk for non-AIDS events was particularly 
increased for persons with hepatitis co-infection. Stopping anti-HBV containing ART 
should be avoided in persons with HIV/HBV co-infection because of the high risk of 
severe hepatitis flares and decompensation following HBV reactivation hepatitis.
End Stage Liver Disease (ESLD)
9. HIV-positive persons with liver cirrhosis require the same measures for the treat-
ment of oesophageal varices, hepatorenal syndrome, hepatic encephalopathy or 
ascites as HIV-negative persons, see page 57-58 and Diagnosis and Management 
of Hepatorenal Syndrome (HRS). 
10. Persons with viral hepatitis/HIV co-infection suffering from ESLD warrant particular 
attention in the management of liver insufficiency; see Dose Adjustment of ARVs for 
Impaired Hepatic Function. Nevertheless, it is important to highlight that ART initia-
tion in cirrhotic persons generally improves overall survival and is therefore strongly 
recommended in these persons. 
11. Persons with HCC or a MELD-score > 15(i), CD4 count > 100 cells/μL and options 
for efficacious and durable ART should be evaluated for liver transplantation 
(OLTX), see Solid Organ Tranplantation (SOT) in HIV-positive Persons. 
12. Renal complications are frequent, see page 58 and Diagnosis and Management of 
Hepatorenal Syndrome (HRS). 
i MELD calculation, see page 58.
Prevention/Support
13. Psychiatric, psychological, social and medical support should be made available to 
persons with alcohol intake to stop drinking. 
14. Substitution therapy (opioid replacement therapy) in persons with active drug 
use as a step towards cessation of active drug use should be encouraged. Help 
provided (e.g. through needle and syringe exchange programme) reduces the risk 
of re-infection including parenteral viral transmission (harm reduction strategy), see 
Drug Dependency and Drug Addiction. 
15. Since HBV and HIV, and occasionally HCV, are transmitted sexually, adequate 
counselling including the use of condoms is advisable. Information on the risk of 
HCV transmission due to mucosal traumatic sexual practices associated with a high 
likelihood of blood contact or ongoing IDU, “chem sex” (sex under the influence of 
recreational drugs taken predominantly intravenously immediately before and/or 
during sexual contacts), should be provided and risk reduction should be discussed. 
16. In women of childbearing age, HCV treatment should be initiated prior to conception 
because of the lack of safety data in pregnancy and to reduce the risk of MTCT of 
HCV.
Hepatitis Delta Virus 
17. In persons with Delta virus co-infection and significant liver fibrosis (≥ F2), long-term 
(> 18 months) treatment with PEG-IFN might be considered in association with 
TDF-based ART. Because of its anti-HBV activity, TDF/TAF should be added to 
PEG-IFN in order to reduce HBV-DNA load. Treatment efficacy should be monitored 
with HBV-DNA and HDV-RNA measurements, when available, and with follow-up 
of biochemical and liver fibrosis estimates. Compassionate use of new drugs active 
against HDV should be encouraged in persons without response to PEG-IFN 
treatment. Persons with anti-HCV antibodies and detectable HCV-RNA should be 
offered anti-HCV treatment in order to eradicate HCV co-infection. Persistent off-
treatment HDV-RNA negativity and anti-HBs seroconversion are the ideal goals of 
antiviral treatment for hepatitis Delta even if they can only be obtained in a minority 
of persons. Histological remission of liver disease is a less ambitious but more likely 
achievable goal. In persons with Delta virus and ESLD or HCC, liver transplantation 
from HBsAg negative donor should be strongly considered especially in the ab-
sence of active HCV co-infection. Transplant with anti-HBV prophylaxis post-OLTX 
cures HBV and Delta virus infection.
Hepatitis E Virus 
18.  Screening in HIV-positive persons with symptoms consistent with acute hepatitis, 
unexplained flares of aminotransferases (even if suspected drug induced liver inju-
ry), unexplained elevated liver function tests, neuralgic amyotrophy, Guillain-Barrè, 
encephalitis or proteinuria.
19.  Screening should include anti-HEV IgG and IgM and NAT for HEV-RNA in blood 
and if possible in stool.
20.  Treatment with  RBV (600 mg daily) may be considered in cases of severe acute 
HEV, acute-on-chronic liver failure, extrahepatic HEV related disease or in persons-
with persisting HEV replication three months after first detection of HEV-RNA. RBV 
should be given for a duration of 12 weeks followed by HEV-RNA measurements 
in serum and stool. If HEV-RNA is undetectable in both, RBV can be stopped. In 
persons in whom HEV-RNA is still detectable in serum and/or stool, RBV may be 
continued for an additional three months.
Every person with HCV/HIV co-infection should receive IFN-free DAA therapy to eradicate HCV, regardless of liver fibrosis stage in the context of faster liver 
fibrosis progression in co-infected persons and the availability of DAAs with excellent tolerability and efficacy. DAAs achieve similar cure rates and tolerabil-
ity in HCV/HIV co-infected compared to HCV mono-infected persons. Therefore, treatment indication and regimens are the same as in HCV mono-infected 
persons. All persons with HBV/HIV co-infection should receive ART including TDF or TAF, unless history of tenofovir intolerance. Life-long therapy is recom-
mended if anti-HBV nucleos(t)ides are given as part of ART. In HBsAg-positive persons without HBV active ART (including 3TC), TDF/TAF should be added 
as prophylaxis regardless of baseline HBV-DNA levels in case of chemotherapy or other immunosuppression (e.g. rituximab treatment) [1].
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Treatment of HBV/HIV Co-infection
1.  All persons with HBV/HIV co-infection should receive ART that includes 
TDF or TAF unless history of tenofovir intolerance. 
2.  For HBV/HIV co-infected persons with bone mineral density changes or 
CKD, see recommendations for Dose Adjustment of ARVs for Impaired 
Renal Function and pages 49 and 52-54. 
3. If TDF or TAF is strictly contraindicated, entecavir may be prescribed in 
persons with no prior 3TC exposure and together with fully active ART. 
4. Persons with liver cirrhosis and low CD4 count require careful sur-
veillance in the first months after starting ART in order not to overlook 
immune reconstitution syndrome and subsequent liver decompensation 
due to flares of liver enzymes (for management of cirrhotic persons, see 
pages 57-61). Please note that diagnosis of cirrhosis may be difficult in 
persons already on HBV treatment.
5.  NRTI substitution should only be performed if feasible and appropriate 
from the perspective of maintaining HIV suppression.
 Caution is warranted to switch from a TDF/TAF-based regimen to drugs 
with a lower genetic barrier, e.g. FTC or 3TC, in particular in 3TC-pre-
treated cirrhotic persons as viral breakthrough due to archived YMDD 
mutations is likely to happen. This has also been described in individuals 
with previous 3TC HBV-resistance who have been switched from TDF to 
entecavir. 
6.  The optimal treatment duration for nucleos(t)ide analogues with anti-
 HBV activity has not yet been determined and experts recommend
 life-long therapy if anti-HBV nucleos(t)ides are given as part of ART. In 
those on ART where the nucleoside backbone needs changing, anti- 
HBV therapy may be stopped cautiously in HBeAg-positive persons 
who have achieved HBe-seroconversion for at least one year or after 
confirmed HBs-seroconversion in those who are HBeAg-negative. In 
persons with liver cirrhosis, stopping of effective anti-HBV treatment is 
not recommended in order to avoid liver decompensation due to flares of 
liver enzymes.
7. In case of chemotherapy or other immunosuppression (e.g. rituxi-
mab-treatment) TDF/TAF should be added as prophylaxis in HBsAg- 
positive persons without HBV active ART (including 3TC) regardless 
of baseline HBV-DNA levels, see Solid Organ Tranplantation (SOT) in 
HIV-positive Persons.
8.  Anti-HBc positive persons treated with severe immunosuppressive 
therapy (chemotherapy for lymphoma/leukaemia or stem-cell or solid-or-
gan transplantation) should receive TDF/TAF therapy to prevent HBV 
reactivation. For persons with other markers of possible HBV exposure 
including isolated anti-HBs positivity (without a history of vaccination) 
careful monitoring for HBV reactivation is required.
 9. In anti-HBc positive persons treated with other immunosuppressive 
therapy (e.g. TNF alpha inhibitor, rituximab) careful monitoring with HBV-
DNA and HBsAg is required for HBV re-activation. If this is not possible, 
addition of TDF/TAF is recommended.
10.  In case of non-response to HBV vaccinations, ART should contain TDF 
or TAF. 
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Diagnosis of HCV 
HCV-Ab (turn positive 1-6 months after infection as late seroconversions 
have been described, may rarely be lost due to immunosuppression) 
HCV-RNA levels(i) 
Evaluation of concurrent causes of liver disease and/or extra-hepatic 
HCV disease
Alcohol consumption, cardiac disease, renal impairment, autoimmunity, ge-
netic or metabolic liver diseases (e.g. genetic haemochromatosis, diabetes 
mellitus or obesity) and drug-induced hepatotoxicity
Status of liver damage 
Staging of fibrosis (e.g. FibroScan, liver biopsy, serum fibrosis markers(ii)) 
Complete blood count, ALT, AST, GGT, ALP, hepatic synthetic function (e.g. 
coagulation, albumin, cholinesterase) 
Ultrasound every 6 months if cirrhosis (gastroscopy upon diagnosis of 
cirrhosis and every 3-4 years thereafter according to presence of ongoing 
liver disease if negative for oesophageal varices), see page 57
Before IFN-free HCV treatment 
HCV genotype (GT)(iii), HCV-RNA, renal and liver function tests
Monitoring of IFN-free HCV treatment 
In persons with advanced fibrosis (≥ F3) differential blood count, creatinine, 
liver enzymes, bilirubin, albumin and INR after 2-4 weeks of therapy. In 
HBsAg negative persons with anti-HBc monitoring of ALT and HBV DNA in 
case of ALT elevation is recommended.
HCV-RNA during therapy only in order to assess compliance and/or break-
through in persons experienced to oral DAAs; HCV-RNA at end-of-treat-
ment and at week 12 or 24 after treatment cessation (to assess SVR). In 
persons receiving all oral DAA therapy no association between viral load at 
any given time-point during therapy and SVR has yet been found. If HCV-
RNA determination is not available SVR can be identified by a negative 
HCVAg 24 weeks after treatment end.
CD4 count and HIV-VL every 12 weeks
i There is no standard conversion formula for converting the amount of 
HCV-RNA reported in copies/mL to the amount reported in IU/mL. The 
conversion factor ranges from about one to five HCV-RNA copies per IU/
mL.
ii Serum fibrosis markers include APRI, FIB-4, Hyaluronic acid, Fibrome-
ter, Fibrotest, Forns, Hepascore and other indices; recently more com-
plex tests such as Fibrometer, Fibrotest and Hepascore have shown to 
more accurately predict liver fibrosis than simple biochemical tests such 
as APRI, FIB-4 or Forns. F4 diagnosis made by transient elastography 
measurement should be validated by a biomarker score, signs of cirrho-
sis in liver in sonography or at least repetition of transient elastography 
after 6 months. F3 diagnosis made by transient elastography measure-
ment should be confirmed by a second measurement after 6 months. 
Cut-offs for F4 (cirrhosis): 13.0 kPa, for F3: 10.0 kPa (http://www.easl.
eu/research/our-contributions/clinical-practice-guidelines/detail/easl-
recommendations-on-treatment-of-hepatitis-c-2018) and page 58.
  For HCC, see General Recommendation for Persons with Viral Hepa-
titis/HIV Co-infection, Cancer: Screening Methods and Liver Cirrhosis: 
Mangement.  
iii If the person is candidate for pangenotypic drugs, HCV GT determinati-
on is not mandatory before starting anti-HCV treatment. Re-test for GT 
and sub-type should be performed in persons with tests carried out befo-
re second-generation tests were available (second-generation line-probe 
assay or real-time PCR assay) or in persons at risk of ‘super-infection’ 
for whom the GT/sub-type should be performed on most recent available 
specimen.
 See online video lectures HCV/HIV Co-infection-Part 1, HCV/HIV Co-
infection-Part 2 and HCV/HIV Co-infection-Part 3 from the EACS online 
course Clinical Management of HIV.
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Treatment indication
1. Every person with HCV/HIV co-infection must be considered for DAA-
based (IFN- and preferably also RBV-free) anti-HCV treatment regard-
less of liver fibrosis stage.
2. Due to similar HCV cure rates and tolerability in HCV/HIV co-infected 
persons as in HCV mono-infected persons under DAA therapy, treatment 
indication and regimens are to be the same as in HCV mono-infection. 
3. Re-test for GT and sub-type should be performed in persons with tests 
carried out before second-generation tests were available (second-gene- 
ration line-probe assay or real-time PCR assay) or in persons at risk of 
‘super-infection’ for whom the GT/sub-type should be performed on the 
most recent available specimen.
Treatment selection
 
4. IFN- and preferably also RBV-free DAA combinations are now standard 
of care for chronic HCV see HCV Treatment Options in HCV/HIV Co-in-
fected Persons. IFN-containing HCV regimens are no longer recommen-
ded. For diagnostics and management of IFN-containing HCV regimens 
please refer to previous versions of these Guidelines, available online at 
http://www.eacsociety.org/files/guidelines_8.2-english.pdf.
5. Selection of DAA combinations is based upon HCV GT, stage of liver 
fibrosis, pre-treatment history and resistance-associated substitutions 
(RAS) if tested.
6.  Use of older, first generation HCV PIs (boceprevir and telaprevir; only 
indicated in GT1) are no longer recommended because of increased 
toxicities. The second generation PI simeprevir can cause hyperbilirubi- 
naemia and skin reactions/photosensibility.
7.  Due to drug-drug interactions in particular HIV and HCV PIs careful 
checking for interactions is urgently recommended prior to starting HCV 
therapy, see Drug-drug Interactions between DAAs and ARVs or http://
www.hep-druginteractions.org. 
8. The triple combination of SOF/VEL/VOX is the treatment of choice for 
re-treatment of persons who failed after a PI- and/or NS5A inhibitor-
containing regimen. If this combination is not available, re-treatment 
strategies should include at least 2 active drug classes according to 
resistance testing results with a preferential use of one drug with high 
genetic barrier to resistance and with extended treatment durations and 
potentially addition of RBV.
Treatment goal
9. The primary aim of HCV treatment is SVR12 defined as undetectable 
HCV-RNA 12 weeks after the end of therapy (evaluated using sensitive 
molecular tests) or HCV core antigen levels where HCV- RNA assays 
are not available or not affordable.
Treatment of acute HCV
10. IFN-containing HCV regimens are no longer recommended. For 
diagnostics and management of IFN-containing HCV regimens please 
see online EACS Guidelines v8.2 at http://www.eacsociety.org/files/
guidelines_8.2-english.pdf.
11. After diagnosis of acute HCV, HCV-RNA should be measured 4 weeks 
later. Treatment can be discussed in persons without a decrease of 
2*log of HCV-RNA at 4 weeks compared with initial HCV-RNA and in 
persons with persistent serum HCV-RNA 12 weeks after diagnosis of 
acute HCV, see Algorithm for Management of Acute HCV in Persons 
with HCV/HIV Co-infection. Immediate treatment of persons with high 
risk of transmission should be considered at diagnosis. IFN-free treat-
ment with DAAs is recommended as in non-cirrhotic chronic HCV/HIV 
co-infection, see pages 85-87. Shorter treatment duration is possible 
in persons with low baseline HCV-RNA (< 6*log IU/mL) [1]. Enrolment 
of persons with acute HCV co-infection in ongoing trials using IFN-free 
DAA combination therapy is strongly encouraged.
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IFN-free HCV treatment options (preferred regimens in bold, alternative regimens in light)
HCV GT Treatment regimen                                     Treatment duration & RBV usage
                      Non-cirrhotic Compensated 
cirrhotic
Decompensated 
cirrhotics CTP class 
B/C
1 & 4 EBR/GZR 12 weeks(i) Not recommended
GLE/PIB 8 weeks                                                               12 weeks Not recommended
SOF/LDV +/- RBV 8 weeks without RBV(ii)                               12 weeks with RBV(iii)
SOF/VEL 12 weeks 12 weeks with RBV
OBV/PTV/r + DSV 8(iv)-12 weeks in GT 1b 12 weeks in GT 1b Not recommended
OBV/PTV/r + DSV + RBV 12 weeks in GT 1a 24 weeks in GT 1a Not recommended
OBV/PTV/r + RBV 12 weeks in GT 4 Not recommended
SOF + DCV +/- RBV 12 weeks +/- RBV(v) 12 weeks with RBV(iii)
SOF + SMP +/- RBV GT 4 only: 12 weeks with RBV or 24 weeks without RBV(vi) Not recommended
SOF/VEL/VOX 8 weeks(vii)                         12 weeks Not recommended
2 GLE/PIB 8 weeks 12 weeks Not recommended
SOF/VEL           12 weeks                   12 weeks with RBV
SOF + DCV 12 weeks 12 weeks with RBV
SOF/VEL/VOX 8 weeks(vii)                           12 weeks Not recommended
3 GLE/PIB 8 weeks(viii) 12 weeks(viii)                              Not recommended
SOF/VEL +/- RBV 12 weeks +/- RBV(ix) or 24 weeks without 
RBV
12 weeks with RBV or 24 weeks without RBV
SOF + DCV +/- RBV 12 weeks +/- RBV(ix) or 24 weeks without 
RBV
24 weeks with RBV
SOF/VEL/VOX 8 weeks(vii) 12 weeks                Not recommended
5 & 6 GLE/PIB 8 weeks 12 weeks Not recommended
SOF/LDV +/- RBV 12 weeks +/- RBV(vi) 12 weeks with RBV(iii)
SOF/VEL 12 weeks 12 weeks with RBV
SOF + DCV +/- RBV 12 weeks +/- RBV or 24 weeks without 
RBV(vi)
12 weeks with RBV(iii)
SOF/VEL/VOX 8 weeks(vii)                            12 weeks Not recommended
DCV =  daclatasvir
DSV  =  dasabuvir
EBR =  elbasvir
GLE =      glecaprevir
GZR =  grazoprevir
LDV =    ledipasvir
OBV =   ombitasvir
PIB =        pibrentasvir
PTV/r =  paritaprevir/RTV
RBV =   ribavirin
SMP =   simeprevir
SOF =   sofosbuvir
VEL =  velpatasvir
VOX = voxilaprevir
RAS =  resistance associated substitutions
i Extension of treatment to 16 weeks and addition of RBV in persons with GT1a with baseline HCV-RNA > 800.000 IU/mL and/or NS5A RASs 
causing at least 5-fold reduction in activity of EBV to minimise the risk of treatment failure and in HCV GT4 experienced persons with HCV-RNA > 
800.000 IU/mL. 8 weeks in GT 1b treatment-naïve with F0-F2.
ii 8 weeks treatment without RBV only in treatment-naïve persons with F < 3 and baseline HCV-RNA < 6 million IU/mL.
iii In persons intolerant to RBV, treatment may be prolonged to 24 weeks. RBV can be omitted in treatment-naïve or -experienced persons with 
compensated cirrhosis without baseline NS5A RAS.
iv  8 weeks treatment without RBV only in persons without cirrhosis.
v Addition of RBV in GT1a treatment experienced persons, but not in persons without NS5A RASs, if RASs testing is available.
vi In treatment experienced (exposure to IFN/RBV/SOF) persons RBV treatment for 12 weeks or prolong treatment to 24 weeks without RBV. 
vii Extension of treatment to 12 weeks in DAA treatment experienced persons.
viii  Treatment duration in HCV GT3 who failed previous treatment with IFN and RBV +/- SOF or SOF and RBV should be 16 weeks.
ix  Addition of RBV only in treatment experienced persons with baseline NS5A RASs, if RAS testing available; if these persons are intolerant to RBV, 
treatment may be prolonged to 24 weeks without RBV.
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Drug-drug Interactions between DAAs and ARVs
HCV drugs ATV/c ATV/r DRV/c DRV/r LPV/r EFV ETV NVP RPV MVC BIC DTG EVG/c RAL ABC FTC 3TC TAF TDF
   
   
   
   
   
   
   
   
   
   
   
   
   
  D
A
A
s
daclatasvir ↑i ↑110%i ↑ ↑41% ↑15% ↓32%ii ↓ ↓ ↔ ↔ ↔ E33% ↑i ↔ ↔ ↔ ↔ ↔ ↑10%
E10%
elbasvir/
grazoprevir
↑ ↑ ↑ ↑ ↑ ↓54/83% ↓ ↓ ↔ ↔ ↔ ↔ ↑ E43% ↔ ↔ ↔ ↔ ↓7/14%
E34%
glecaprevir/
pibrentasvir
↑ ↑553/64% ↑ ↑397%/- ↑338/146% ↓ ↓ ↓ E84% E E ↔ ↑205/57%
E47%
E47% ↔ ↔ ↔ ↔ E29%
parita-
previr/r/
ombitasvir/
dasabuvir
↑ ↑94%iii ↑ Div ↑ vi ↓E ↓E Evii E E ↔ ↑ E134% ↔ ↔ ↔ E ↔
paritaprev-
ir/r/ombi-
tasvir
↑ ↑
iii
↑ ↑
v
↑ vi ↓E ↓E Evii E E ↔ ↑ E20% ↔ ↔ ↔ E ↔
simeprevir ↑ ↑ ↑ ↑ ↑ ↓71% ↓ ↓ ↑6%
E12%
↔ ↔ ↔ ↑ ↓11%
E8%
↔ ↔ ↔ ↔ ↓14%
E18%
sofosbuvir/
ledipasvir
↑viii ↑8/113%viii ↑viii ↑34/
39%viii
↔viii ↓-/34% ↔ ↔ ↔viii E ↔ ↔ ↑36/
78%viii
D≈20% ↔ ↔ ↔ E32% Eviii
sofosbuvir/
velpatasvir
↔viii ↑-/142%
viii
↔viii ↓28%/-viii ↓29%/-viii ↓-/53% ↓ ↓ ↔ E ↔ ↔ ↑viii ↔ ↔ ↔ ↔ ↔ Eviii
sofosbuvir/
velpatasvir/
voxilaprevir
↑ ↑40/93/331% ↑viii ↑-/-
/143%viii
↑ ↓ ↓ ↓ ↔ E ↔ ↔ ↑-/-/171% 
viii
↔ ↔ ↔ ↔ E Eviii
sofosbuvir ↔ ↔ ↑ ↑34% ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↓5%D27% ↔ ↔ ↔ ↔ ↔
Legend
↑  potential elevated exposure of DAA      
↓  potential decreased exposure of DAA
↔  no significant effect    
D  potential decreased exposure of ARV drug
E  potential elevated exposure of ARV drug
Numbers refer to decreased/increased AUC of DAAs and ARVs as observed 
in drug interactions studies. First/second numbers refer to AUC changes for 
EBR/GZR or GLE/PIB or SOF/LDV or SOF/VEL
First/second/third numbers refer to AUC changes for SOF/VEL/VOX   
  
ATV/c   ATV co-formulated with COBI (300/150 mg qd);  
DRV/c  DRV co-formulated with COBI (800/150 mg qd) 
i    DCV should be reduced to 30 mg qd with ATV/r or EVG/c. No dose 
reduction with unboosted ATV 
ii   DCV should be increased to 90 mg qd
iii   use only with unboosted ATV (ATV increased PTV exposure due to 
CYP3A4 and OATP1B1/3 inhibition, not recommended without DSV)  
iv   co-administration decreased DRV trough concentration by approximately 
50%. Although co-administration of DRV with OBV/PTV/r + DSV is not 
recommended in the US Prescribing Information, the European SPC 
advises that DRV (dosed at 800 mg qd and administered at the same 
time as OBV/PTV/r + DSV) can be used in the absence of extensive HIV 
PI resistance and should be taken without additional RTV 
v   not recommended due to increase in PTV exposure when co-adminis-
tered with DRV 800 mg given with OBV, PTV, RTV (Viekirax). Of note: 
exposures of PTV greater than this have been evaluated in phase 2 
studies and were not expected to have a clinically meaningful impact on 
safety
vi   severe tolerability issues
vii   not recommended unless benefit outweighs the risk due to potential for 
QT interval prolongation with higher concentrations of RPV, co-adminis-
tration should be only considered in persons without known QT prolonga-
tion and without other QT prolongation co-medicines
viii  monitoring of kidney function recommended due to increase of tenofovir 
concentration if the regimen contains TDF       
                
Note: no clinically significant interactions expected between ZDV and 
DAAs   
Colour legend
 no clinically significant interaction expected  
 these drugs should not be co-administered 
 potential interaction which may require a dosage adjustment or 
close monitoring  
 potential interaction likely to be of weak intensity. Additional action/
monitoring or dosage adjustment is unlikely to be required 
Note: the symbol (green, amber, red) used to rank the clinical significance 
of the drug interaction is based on http://www.hep-druginteractions.org.
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Algorithm for Management of Acute HCV in Persons with HCV/HIV Co-infection
Confirmed 
diagnosis 
of acute 
HCV*
Risk reduction 
programme
Repeat 
HCV RNA 
Week 4
Early treatment 
of concomitant 
STI, see page 
67 
HCV RNA-positive < 2*log10 
reduction in VL
HCV RNA-positive > 2*log10 
reduction in VL
Repeat 
HCV RNA 
Week 12
HCV RNA 
-positive
HCV RNA-
negative
a) Treat with short duration 
DAAs
b) Enrol in clinical trial for 
acute HCV treatment
Repeat HCV 
RNA at 24 
weeks and 48 
weeks to con-
firm spontane-
ous clearance
* Where available initiate DAA-based treatment immediately in persons with 
high risk of onward transmission.
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Part V Opportunistic Infections
Prevention and Treatment of Opportunistic Infections (OIs) in HIV-positive Persons
This section provides an overview of the most important aspects in management of the most frequent OIs occurring in HIV-positive persons in Europe. For 
more detailed discussion, we refer to national guidelines [1-7].
Recommendations for timing on ART initiation in HIV-positive persons with OIs, see Recommendations for Initiation of ART In HIV-positive Persons with 
Chronic Infection without prior ART Exposure.
See online video lectures HIV and Pulmonary Infections-Part 1, HIV and Pulmonary Infections-Part 2 and HIV and Pulmonary Infections-Part 3 and CNS and 
HIV-related opportunistic infections-Part 1 and CNS and HIV-related opportunistic infections-Part 2 from the EACS online course Clinical Management of HIV. 
Primary Prophylaxis of OIs according to stage of immunodeficiency
CD4 count threshold/indication
CD4 count < 200 cells/µL, CD4 percentage < 14%, recurrent oral thrush, or relevant concomitant immunosuppression*
Prophylaxis against Pneumocystis jirovecii Pneumonia (PcP) & Toxoplasma gondii
Stop: if CD4 count > 200 cells/µL over 3 months or CD4 count 100-200 cells/μL and HIV-VL undetectable over 3 months
* e.g. use of corticosteroids > 20 mg prednisone equivalent per day for > 2 weeks, cancer chemotherapy, biological agents such as rituximab and others. 
Decisions on installation and discontinuation in these situations have to be taken individually.
Drug Dose Comments
Positive or negative serology for  
toxoplasmosis
TMP-SMX 1 double-strength tablet (ds)
(800/160 mg) 3 x/week po or
1 single-strength tablet (ss)
(400/80 mg) 1 x/day po or
1 ds tablet 1 x/day po
Negative serology for toxoplasmosis pentamidine 300 mg in 6 mL sterile water
1 x inhalation/month
Does not prevent the rare extrapulmo-
nary manifestations of P. jirovecii
Negative serology for toxoplasmosis dapsone 1 x 100 mg/day po Check for G6PD-deficiency 
Negative serology for toxoplasmosis atovaquone suspension 1 x 1500 mg/day po (with food)
Positive serology for toxoplasmosis dapsone 200 mg 1 x/week po Check for G6PD-deficiency 
+ pyrimethamine 75 mg 1 x/week po
+ folinic acid 25-30 mg 1 x/week po
Positive serology for toxoplasmosis atovaquone suspension
+/- pyrimethamine
+ folinic acid
1 x 1500 mg/day po (with food)
75 mg 1 x/week po
25-30 mg 1 x/week po
CD4 count < 50 cells/µL
Prophylaxis against Non-Tuberculous Mycobacteria (NTM) (M. avium complex, M. genavense, M. kansasii)
Only consider prophylaxis if no clinical suspicion of disseminated NTM. Prophylaxis can be withheld if cART started within four weeks.
Stop: if CD4 count > 100 cells/µL over 3 months and person on effective ART (and HIV-VL undetectable in the opinion of some experts)
Regimens listed are alternatives azithromycin 1 x 1200-1250 mg/week po Check for interactions with ARVs, see 
Drug-drug Interactions between ARVs 
and Non-ARVs
or
clarithromycin 2 x 500 mg/day po
or
rifabutin 1 x 300 mg/day po Check for interactions with ARVs, see Drug-drug Interactions between ARVs 
and Non-ARVs
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Primary Prophylaxis, Treatment and Secondary Prophylaxis/Maintenance Treat-
ment of Individual OIs
Primary prophylaxis
Start: if CD4 count < 200 cells/µL, CD4 percentage < 14%, oral thrush or relevant concomitant immunosuppression (see above)
Stop: if CD4 count > 200 cells/µL over 3 months or CD4 count 100-200 cells/µL and HIV-VL undetectable over 3 months
Drug Dose Comments
Negative or positive serology for  
toxoplasmosis
TMP-SMX 1 double-strength tablet (ds)
(800/160 mg) 3 x/week po or
1 single-strength tablet (ss)
(400/80 mg) 1 x/day po or
1 ds tablet /1 x/day po
Negative serology for toxoplasmosis pentamidine 300 mg in 6 mL aqua
1 x inhalation/month
Does not prevent the rare extrapulmo-
nary manifestations of P. jirovecii
Negative serology for toxoplasmosis dapsone 1 x 100 mg/day po Check for G6PD-deficiency
Negative serology for toxoplasmosis atovaquone suspension 1 x 1500 mg/day po (with food)
Positive serology for toxoplasmosis dapsone 200 mg 1 x/week po Check for G6PD-deficiency 
+ pyrimethamine 75 mg 1 x/week po
+ folinic acid 25-30 mg 1 x/week po
Positive serology for toxoplasmosis atovaquone suspension
+/- pyrimethamine
+ folinic acid
1 x 1500 mg/day po (with food)
75 mg 1 x/week po
25-30 mg 1 x/week po
Treatment
Treat at least 21 days, then secondary prophylaxis until CD4 count > 200 cells/µL and HIV-VL undetectable over 3 months.
Diagnosis: 
-   Definitive diagnosis: Cough and dyspnoea on exertion AND diagnosis by cytology / histopathology of induced sputum (sensitivity up to 80%), broncho-
alveolar lavage (sensitivity > 95%) or bronchoscopic tissue biopsy (sensitivity > 95%)
-   Presumptive diagnosis: CD4 count < 200 cells/ µL AND dyspnoea / desaturation on exertion and cough AND radiology compatible with PcP AND no 
evidence for bacterial pneumonia AND response to PcP treatment
Drug Dose Comments
Preferred therapy TMP-SMX  3 x 5 mg/kg/day TMP iv/po + 
3 x 25 mg/kg/day SMX iv/po
+ prednisone 
if PaO2 < 10 kPa or < 70 mmHg, 
or alveolar/arterial O2 gradient 
> 35 mmHg. Start prednisone 
preferentially 15-30 min before 
TMP/SMX
2 x 40 mg/day po 5 days
1 x 40 mg/day po 5 days
1 x 20 mg/day po 10 days
Benefit of corticosteroids if started within 
72 hours after start of treatment
Alternative therapy for moderate to severe 
PcP
primaquine 1 x 30 mg (base)/day po Check for G6PD deficiency
+ clindamycin 3 x 600-900 mg/day iv/po
or
pentamidine 1 x 4 mg/kg/day iv (infused over
60 min.)
For each regimen:
+ prednisone, if PaO2 < 10 
kPa or < 70 mmHg, or alveolar/
arterial O2 gradient > 35 mmHg. 
Start prednisone preferentially 
15-30 min before TMP/SMX.
Some experts recommend 
adding caspofungin to stand-
ard treatment in persons with 
severe PcP (requiring intensive 
care unit admission)
2 x 40 mg/day po 5 days
1 x 40 mg/day po 5 days
1 x 20 mg/day po 10 days
1 x 70 mg iv day 1, then
1 x 50 mg/day iv
Benefit of corticosteroids if started within 
72 hours after start of treatment
Alternative therapy for mild to moderate PcP primaquine 1 x 30 mg (base)/day po Check for G6PD deficiency 
+ clindamycin  3 x 600-900 mg/day po
or
atovaquone suspension 2 x 750 mg/day po (with food)
or
dapsone 1 x 100 mg/day po Check for G6PD deficiency
In case of rash: reduce dose of TMP
(50%), antihistamines
+ trimethoprim 3 x 5 mg/kg/day po
Pneumocystis jirovecii Pneumonia (PcP)
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Secondary prophylaxis / Maintenance treatment
Stop: if CD4 count > 200 cells/µL and HIV-VL undetectable over 3 months 
Drug Dose Comments
Negative or positive serology for  
toxoplasmosis
TMP-SMX 1 ds tablet (800/160 mg) 
3 x/week po or 1 ss tablet 
(400/80) mg 1 x/ day po or 
1 ds tablet 1 x/day po
Negative serology for toxoplasmosis pentamidine 300 mg in 6 mL sterile water 
1 x inhalation/month
Not to use in the rare case of extrapul-
monary manifestations of P. jirovecii
Negative serology for toxoplasmosis dapsone 1 x 100 mg/day po Check for G6PD-deficiency
Negative serology for toxoplasmosis atovaquone suspension 1 x 1500 mg/day po (with food)
Positive serology for toxoplasmosis dapsone 200 mg 1 x/week po Check for G6PD-deficiency 
+ pyrimethamine 75 mg 1 x/week po
+ folinic acid 25-30 mg 1 x/week po
Positive serology for toxoplasmosis atovaquone suspension
+/- pyrimethamine
+ folinic acid
1 x 1500 mg/day po (with food) 
75 mg 1 x/week po
25-30 mg 1 x/week po
Toxoplasma gondii 
Encephalitis
Primary prophylaxis
Start: if CD4 count < 200 cells/µL, or CD4 percentage < 14%, oral thrush, or relevant concomitant immunosuppression (see above)
Stop: if CD4 count > 200 cells/µL over 3 months or CD4 count 100-200 cells/µL and HIV-VL undetectable over 3 months
Drug Dose Comments
Preferred prophylaxis TMP-SMX 1 double-strength tablet (ds)
(800/160 mg) 3 x/week po or
1 single-strength tablet (ss)
(400/80 mg) 1 x/day po or
1 ds tablet 1 x/day po
All regimens are also effective against 
PcP
Alternative prophylaxis atovaquone suspension 1 x 1500 mg/day po (with food)
dapsone 200 mg 1 x/week po Check for G6PD-deficiency 
+ pyrimethamine 75 mg 1 x/week po
+ folinic acid 25-30 mg 1 x/week po
atovaquone suspension
+ pyrimethamine
+ folinic acid
1 x 1500 mg/day po (with food) 
75 mg 1 x/week po
25-30 mg 1 x/week po
Treatment
Treat 6 weeks, then secondary prophylaxis until CD4 count > 200 cells/µL and HIV-VL undetectable over 6 months
Diagnosis: 
-   Definitive diagnosis: clinical symptoms, typical radiology of the cerebrum AND cytological / histological detection of organism 
-   Presumptive diagnosis: clinical symptoms, typical radiology AND response to empirical treatment. It is the standard in most clinical settings.
Drug Dose Comments
Preferred therapy pyrimethamine Day 1: 200 mg po, then 
• If ≥ 60 kg; 1 x 75 mg/day po
• If < 60 kg: 1 x 50 mg/day po
Monitor for myelotoxicity of pyrimeth-
amine, mostly neutropenia
+ sulfadiazine • If ≥ 60 kg: 2 x 3000 mg/day
po/iv
• If < 60 kg: 2 x 2000 mg/day
po/iv
Sulfadiazine is associated with crystal-
luria and may lead to renal failure and 
urolithiasis. Good hydration is essential. 
Check renal function and urine sediment 
for microhematuria and crystalluria
+ folinic acid 1 x 10-15 mg/day po
Alternative therapy pyrimethamine
+ clindamycin 
+ folinic acid
Day 1: 200 mg/day po, then
• If ≥ 60 kg: 1 x 75 mg/day po
• If < 60 kg: 1 x 50 mg/day po
4 x 600-900 mg/day po/iv
1 x 10-15 mg/day po
Monitor for myelotoxicity of pyrimeth-
amine, mostly neutropenia 
Additional PcP prophylaxis is necessary
or
TMP-SMX
2 x 5 mg TMP/kg/day iv/po
2 x 25 mg SMX/kg/day iv/po
Preferred intravenous regimen if oral 
route not possible
or
pyrimethamine
+ atovaquone
+ folinic acid
Day 1: 200 mg po, then
If ≥ 60 kg; 1 x 75 mg/day po
If < 60 kg: 1 x 50 mg/day po
2 x 1500 mg/day po (with food)
1 x 10-15 mg/day po
Monitor for myelotoxicity of pyrimeth-
amine, mostly neutropenia
or
sulfadiazine
+ atovaquone
• If ≥ 60 kg: 2 x 3000 mg/day
po/iv
• If < 60 kg: 2 x 2000 mg/day
po/iv
2 x 1500 mg/day po (with food)
Sulfadiazine is associated with crystal-
luria and may lead to renal failure and 
urolithiasis. Good hydration is essential. 
Check renal function and urine sediment 
for microhematuria and crystalluria
or
pyrimethamine
+ azithromycin
+ folinic acid
Day 1: 200 mg po, then
• If ≥ 60 kg; 1 x 75 mg/day po
• If < 60 kg: 1 x 50 mg/day po
1 x 900-1200 mg/day po
1 x 10-15 mg/day po
Monitor for myelotoxicity of pyrimeth-
amine, mostly neutropenia
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Secondary prophylaxis / Maintenance therapy
Stop: if CD4 count > 200 cells/µL and HIV-VL undetectable over 6 months 
Regimens listed are alternatives sulfadiazine
+ pyrimethamine
+ folinic acid
2-3 g/day po (in 2-4 doses)
1 x 25-50 mg/day po
1 x 10-15 mg/day po
or
clindamycin
+ pyrimethamine
+ folinic acid
3 x 600 mg/day po
1 x 25-50 mg/day po
1 x 10-15 mg/day po
Additional PCP prophylaxis is necessary
or
atovaquone suspension
+ pyrimethamine
+ folinic acid
2 x 750-1500 mg/day po
(with food)
1 x 25-50 mg/day po
1 x 10-15 mg/day po
or
atovaquone suspension
2 x 750-1500 mg/day po (with
food)
or
TMP-SMX
1 ds tablet (800/160 mg) 2 x/
day po
Cryptococcal meningitis
Treatment
14 days induction therapy, then 8 weeks consolidation therapy, then secondary prophylaxis for at least 12 months. Stop, if CD4 count > 100 
cells/µL and HIV-VL undetectable over 3 months
Diagnosis: positive microscopy, OR detection of antigen, OR culture from CSF
Other organ manifestations: Cryptococcal infection can also cause a pneumonitis which may be difficult to distinguish from Pneumocystis pneumonia. 
Infection may also involve other organs or may be disseminated.
Primary prophylaxis: One large RCT in Africa (the REALITY trial [9]) showed that an enhanced infection prophylaxis in severely immunosuppressed 
persons (< 50 CD4 cells/µL) including INH 12 weeks, fluconazole 100 mg/day for 12 weeks, azithromycin 500 mg/day for 5 days and albendazole 400 mg 
single dose may decrease overall opportunistic infections (including cryptococcal meningitis) and mortality. Whether these findings can be extrapolated to 
European countries with rapid diagnostics of subclinical cryptococcosis and latent TB, low TB and parasite prevalence and rapid start of cART is questiona-
ble.
Pre-emptive therapy: Early stages of disseminated cryptocccal infections may be oligosymptomatic. Newer data from mainly resource limited settings 
support determination of serum cryptococcal antigen in all newly diagnosed HIV-positive persons with CD4 counts < 100 cells/µL. If cryptococcal antigen 
is detected, CSF should be examined to rule out cryptococcal meningitis. If meningitis is ruled out, pre-emptive therapy with fluconazole 800 mg/day po for 
two weeks is recommended before starting cART to reduce the risk of unmasking IRIS.
Drug Dose Comments
Pre-emptive therapy fluconazole 1 x 800 mg/day po for 2 weeks
followed by 
1 x 400 mg/day po for 8 weeks
In case of: 
-  positive cryptococcal serum antigen
-  asymptomatic individual
-  cryptococcal meningitis ruled out by 
CSF examination
Induction therapy liposomal amphotericin B     
+ flucytosine
3 mg/kg/day iv                            
4 x 25 mg/kg/day po
14 days
- Then perform lumbar puncture (LP): 
if CSF culture is sterile, switch to oral 
regimen
- Opening pressure should always be 
measured, when LP is performed
- Repeated LPs or CSF shunting are 
essential to effectively manage in- 
creased intracranial pressure which is 
associated with better survival
- Corticosteroids have no effect in re-
ducing increased intracranial pressure, 
could be detrimental and are contrain-
dicated
- Flucytosine dosage must be adapted 
to renal function
- Defer start of cART for at least 4 weeks
- Amphotericin B deoxycholate may not 
be available in all European countries
- Flucytosine may not be available in all 
European countries. Consider replac-
ing it by fluconazole 2 x 400 mg/day 
during the induction phase
- In resource-limited settings, a large 
RCT suggested that one week of 
amphotericin B + flucytosine or two 
weeks of fluconazole 1200 mg/d plus 
flucytosine may be acceptable induc-
tion regimens [10].
or
amphotericin B deoxycholate 
+ flucytosine
0.7 mg/kg/day iv
4 x 25 mg/kg/day po
Consolidation therapy fluconazole 1 x 400 mg/day po
(loading dose 1 x 800 mg 1st 
day)
8 weeks. Repeated LP until opening 
pressure < 20 cm H20 
See Drug-drug Interactions between 
ARVs and Non-ARVs
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Candidiasis
Oropharyngeal Candidiasis
Diagnosis: typical clinical appearance, see Drug-drug Interactions Between ARVs and Non-ARVs, for all azole therapies
Drug Dose Comments
Preferred alternatives fluconazole 1 x 150-200 mg/day po Once or until improvement (5-7 days)
itraconazole 1-2 x 100-200 mg/day po
(oral solution fasting)
7-14 days. Be aware of interactions with
ARVs, see Drug-drug Interactions
Between ARVs and Non-ARVs
nystatin 3-6 lozenges at 400000 units 
(aprox. 4-6 mL)/day
7-14 days
or
amphotericin B
3-6 lozenges at 10 mg/day or
oral suspension 1-2 g/day
(in 2-4 doses)
Oesophagitis
Definitive diagnosis: macroscopic inspection at endoscopy, OR histology of biopsy, OR cytology of specimen from the mucosal surface 
Presumptive diagnosis: if 1. Recent onset of dysphagia AND 2. Oropharyngeal candidiasis
Drug Dose Comments
Preferred alternatives fluconazole 1 x 400 mg/day
or
400 mg loading dose, then 200 
mg/day po 
3 days
10-14 days
consider
itraconazole
or
posaconazole 
or
voriconazole 
or
caspofungin
1-2 x 100-200 mg/day po
(oral solution fasting)
2 x 400 mg/day po
2 x 200 mg/day po
1 x 70 mg iv/day, then 1 x 50 
mg/day iv
10-14 days. Be aware of interactions 
with ARVs, see Drug-drug Interactions
Between ARVs and Non-ARVs
In cases of refractory disease, treat 
according to resistance testing. 
Adapt posaconazole and voriconazole 
dose according to MIC's of candida and 
drug trough levels.
Histoplasmosis (Histoplasma capsulatum)
Treatment
Diagnosis: antigen detection in blood, urine or broncho-alveolar fluid, OR by positive microscopy, OR mycological culture of blood, urine, broncho-alveolar 
fluid, CSF or tissue biopsy.
Note: CSF, which shows typically a lymphatic pleocytosis, is usually microscopic and culture negative. Detection of Histoplasma antigen or antibody is 
more sensitive. Though, a clinical diagnosis is possible in case of negative Histoplasma antigen or antibody in CSF, if dissiminated histoplasmosis is pres-
ent and CNS infection is not explained by another cause.
 
Seek expert advice for the use of fluconazole, voriconazole or posaconazole, if itraconazole is not tolerated. Be aware of interactions of azoles with 
ARVs, see Drug-drug Interactions Between ARVs and Non-ARVs. Measurement of plasma concentration of itraconazole and voriconazole is advised to 
guide optimal treatment. 
Drug Dose Comments
Severe disseminated histoplasmosis Induction therapy:
liposomal amphotericin B   
Consolidation therapy:
itraconazole
3 mg/kg/day iv             
3 x 200 mg/day po for 3 days, 
then 2 x 200 mg/day po       
For 2 weeks or until clinical improvement
For at least 12 months
Moderate disseminated histoplamosis itraconazole 3 x 200 mg/day po for 3 days, 
then 2 x 200mg/day po 
For at least 12 months
Histoplasma meningitis Induction therapy:
liposomal amphotericin B
Consolidation therapy:
itraconazole
5 mg/kg/day iv    
2 x or 3 x 200 mg/day po                 
For 4-6 weeks
For at least 12 months and until resolu-
tion of abnormal CSF findings. Measure 
plasma concentration of itraconazole.
Secondary prophylaxis / Maintenance therapy
Stop: if CD4 count > 150 cells/µL and HIV-VL undetectable over 6 months, negative fungal blood cultures, Histoplasma antigen < 2 µg/L and > 1 year 
treatment
Consider long-term suppressive therapy in severe cases of meningitis and in cases of relapse despite adequate treatment
itraconazole 1 x 200 mg/day po 
or
fluconazole 1 x 400 mg/day po 
Secondary prophylaxis / Maintenance therapy
At least 12 months
Consider to stop: if CD4 count >100 cells/µL and HIV-VL undetectable over 3 months
Drug Dose Comments
fluconazole 1 x 200 mg/day po See Drug-drug Interactions between 
ARVs and Non-ARVs
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Herpes simplex virus (HSV) infections
Treatment
Diagnosis: antigen testing / PCR / culture of swab / CSF / biopsy. Clinical appearance of skin lesions not reliable
Drug Dose Comments
Initial genital / mucocutaneous HSV valaciclovir 2 x 1000 mg/day po 7-10 days or until lesions healed
or
famciclovir
2 x 500 mg/day po 7-10 days or until lesions healed
or
aciclovir
3 x 400-800 mg/day po 7-10 days or until lesions healed
Recurrent genital / mucocutaneous HSV
(> 6 episodes/year)
valaciclovir 2 x 500 mg/day po Chronic suppressive therapy. Alterna-
tively start early treatment as above if 
recurrences occur
Severe mucocutaneous lesions aciclovir 3 x 5 mg/kg/day iv After lesions begin to regress, switch to
oral treatment until lesions have healed
Encephalitis aciclovir 3 x 10 mg/kg/day iv 14-21 days
Aciclovir resistant mucocutaneous HSV 
infection
foscarnet 2 x 90 mg/kg/day iv Until clinical response
 Varicella zoster virus (VZV) infections
Treatment
Diagnosis: typical clinical appearance with/without antibody testing, OR antigen testing / PCR / culture of swab / CSF / biopsy
Drug Dose Comments
Primary Varicella infection (Chickenpox) valaciclovir 3 x 1000 mg/day po 5-7 days
Herpes Zoster (Shingles):
Not disseminated
valaciclovir 3 x 1000 mg/day po 7-10 days
or
famciclovir
3 x 500 mg/day po 7-10 days
Herpes Zoster: Disseminated aciclovir 3 x 10 mg/kg/day iv 10-14 days
Encephalitis (including vasculitis) aciclovir 3 x 10-15mg/kg/day 14-21 days
 Cytomegalovirus (CMV) infections
Treatment
Diagnosis of retinitis: clinical appearance of typical retinal lesions AND response to therapy. PCR of aqueous and vitreous humor optional
Diagnosis of esophagitis / colitis: endoscopic presence of ulcerations AND typical histopathological picture (cellular / nuclear inclusion bodies)
Diagnosis of encephalitis / myelitis: clinical appearance AND positive PCR in CSF
Antibody testing and PCR in blood not useful for diagnosis of end-organ disease
Drug Dose Comments
Retinitis, immediate sight-threatening le-
sions
ganciclovir 2 x 5 mg/kg/day iv 21 days, then secondary prophylaxis
or
foscarnet 2 x 90 mg/kg/day iv
Retinitis, small peripheral retinal lesions valganciclovir 2 x 900 mg/day po (with food) 14-21 days, then secondary prophylaxis
or
foscarnet
2 x 90 mg/kg/day iv
or
cidofovir
+ probenecid
+ NaCl 0.9% hydration
1 x 5 mg/kg/week iv 2 weeks then every 2 weeks. Cidofovir 
may not be available in all European 
countries
Oesophagitis/Colitis ganciclovir 2 x 5 mg/kg/day iv Treat 3-6 weeks, respectively until symp-
toms resolved
or
foscarnet
2 x 90 mg/kg/day iv
or
valganciclovir
2 x 900 mg/day po (with food) In milder disease if oral treatment 
tolerated
Encephalitis/Myelitis ganciclovir and / or  
foscarnet 
2 x 5 mg/kg/day iv
2 x 90 mg/kg/day iv
Treat until symptoms resolved and CMV 
replication in CSF has cleared (negative 
PCR in CSF)
Treatment is individualised according 
to clinical symptoms and response to 
treatment  
Secondary prophylaxis / Maintenance therapy: Cytomegalovirus (CMV) Retinitis
Stop: if CD4 count > 200 cells/µL and HIV-VL undetectable over 3 months
Regimens listed are alternatives valganciclovir 1 x 900 mg/day po (with food)
or
ganciclovir
1 x 5 mg/kg/day  (x 5 days/
week) iv
or
foscarnet
1 x 90-120 mg/kg/day (x 5 days/ 
week) iv
or
cidofovir
+ probenecid 
+ NaCL 0.9% hydration  
1 x 5 mg/kg every 2 weeks iv Cidofovir may not be available in all 
European countries
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 Progressive Multifocal Leukoencephalopathy (PML)
Treatment PML
Definitive diagnosis (laboratory): evidence of JCV-DNA in CSF AND presence of compatible clinical-radiological picture 
Definitive diagnosis (histology): typical histological findings with in situ evidence of JCV-DNA antigen or JCV-DNA AND presence of compatible clini-
cal-radiological picture
Presumptive diagnosis: compatible clinical-radiological picture if JCV-DNA in CSF negative or not performed. JCV-DNA in plasma may complement PML 
diagnosis, particularly if CSF not available. May also be a marker of disease progression [11].
Person off-ART Initiate cART immediately (following general guidelines for treatment, see Initial Combination Regimen for 
ART-naïve Adult HIV-positive Persons), INSTI may reasonably be preferred, given the importance of rapid 
immune reconstituion in PML. Attention should be made to development of IRIS (see below)
Person on-ART, HIV-VL failure Optimise cART (following general guidelines for treatment, see Virological Failure), INSTI may reasonably be 
preferred, given the importance of rapid immune reconstituion in PML. Attention should be made to develop-
ment of IRIS (see below)
Person on-ART, treated for weeks-
months or on effective cART
Continue current cART
Note: There is no specific treatment for JCV infection that proved to be effective in PML outside of anecdotal 
case reports, therefore there is no recommendation to use the following drugs which previously or occasion-
ally were used in PML: Alpha-IFN, cidofovir, corticosteroids (except for treatment of IRIS-PML, see below), 
cytarabine, iv immunoglobulins, mefloquine, mirtazapine and topotecan
Treatment Immune Reconstitution Syndrome (IRIS) – PML
Diagnosis:
- Paradoxical IRIS-PML: paradoxical worsening of PML symptoms in the context of cART-induced immune-reconstitution AND in association with inflam-
mation at MRI (oedema, mass effect and/or contrast enhancement) or in brain biopsy
- Unmasking IRIS-PML: onset of PML in the context of cART-induced immune-reconstitution AND in association with inflammation at MRI (oedema, mass 
effect, and/or contrast enhancement) or at brain biopsy
Treatment: 
-  Corticosteroids, e.g. high dose iv methylprednisolone (e.g.1 g/day for 3-5 days) or iv dexamethasone (e.g.0.3 mg/kg/day for 3-5 days), followed by oral 
tapering (e.g starting with 1 mg/kg/day and taper over 1-6 weeks)
Note: Use of corticosteroids is not justified in persons without signs of inflammation. There are no other treatments that proved to be effective in IRIS-PML 
outside of anecdotal case reports
 Bacillary Angiomatosis (Bartonella henselae, Bartonella quintana)
Treatment
Diagnosis: typical histology
Drug Dose Comments
doxycycline 2 x 100 mg/day po Until improvement (until 2 months)
Possible interactions with ARVs, see 
Drug-drug Interactions between ARVs 
and Non-ARVs
or
clarithromycin 2 x 500 mg/day po
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Primary prophylaxis
Only consider prophylaxis if no clinical suspicion of disseminated NTM. Prophylaxis can be withheld if cART started within four weeks
Stop: if CD4 count > 100 cells/µL over 3 months and person on effective ART (and HIV-VL undetectable in the opinion of some experts)
Regimens listed are alternatives azithromycin 1 x 1200-1250 mg/week po Check for interactions with ARVs, see 
Drug-drug Interactions between ARVs 
and Non-ARVsorclarithromycin
2 x 500 mg/day po
or 
rifabutin 1 x 300 mg/day po Check for interactions with ARVs, see 
Drug-drug Interactions between ARVs 
and Non-ARVs 
Treatment
Diagnosis: clinical appearance and cultures of blood, lymph nodes, bone marrow or other usually sterile specimen. For any treatment regimen, check 
interactions with ARVs, see Drug-drug Interactions between ARVs and Non-ARVs
Mycobacterium avium-intracellulare complex (MAC)
Preferred clarithromycin
+ ethambutol
+ rifabutin
rifabutin can be replaced by:
+ levofloxacin
or
+ amikacin
2 x 500 mg/day po
1 x 15 mg/kg/day po
1 x 300 mg/day po
1 x 500 mg/day po
1 x 10-15 mg/kg/day iv
12 months, then secondary prophylaxis
Rifabutin especially indicated if resist-
ance to macrolides or ethambutol is sus-
pected, severe immunodeficiency (CD4 
count < 50 cells/µL), high bacterial load 
(> 2*log of CFU/mL of blood), no cART
4th drug to consider for disseminated
disease
4th drug to consider for disseminated 
disease
azithromycin
+ ethambutol
1 x 500 mg/day po
1 x 15 mg/kg/day po
Consider additional drugs as above
Mycobacterium kansasii
rifampicin
+ isoniazid
+ ethambutol
1 x 600 mg/day po
(or rifabutin 1 x 300 mg/day po)
1 x 300 mg/day po
1 x 15 mg/kg/day po
12 months after negative culture 
or
rifampicin
+ clarithromycin
+ ethambutol
1 x 600 mg/day po 
(or rifabutin 1 x 300 mg/day po)
2 x 500 mg po
1 x 15 mg/day po
12 months after negative culture 
Secondary prophylaxis / Maintenance therapy for MAC infection
Stop: if CD4 count > 100 cells/µL and HIV-VL undetectable over 6 months and MAC treatment for at least 12 months
Mycobacterium avium (MAC) infection
Regimens listed are alternatives
clarithromycin
+ ethambutol
2 x 500 mg/day po
1 x 15 mg/kg/day po
or
azithromycin
+ ethambutol
1 x 500 mg/day po
1 x 15 mg/kg/day po
Infections with Non-Tuberculous Mycobacteria (NTM) (M. avium complex, M. genavense, M. kansasii)
 Cryptosporidiosis (C. parvum, C. hominis)
Treatment
Diagnosis of AIDS-defining cryptosporidiosis can be made only in cases of severe immunodeficiency (CD4 count < 100 cells/µL) AND chronic diarrhoea 
(over 4 weeks) by immunofluorescence or acid fast stain of stools or tissue.
Mainstay of therapy is the induction of ART to restore immune competence with CD4 count > 100 cells/µL. 
Additional measures are symptomatic treatment, rehydration and electrolyte management.
All antiprotozoal therapies can be used additively to cART in severe cases, but are not sufficient to achieve protozoal eradication without immune restora-
tion.
Drug Dose Comments
nitazoxanide 2 x 500-1000 mg/day po 14 days
or
paromomycin 4 x 500 mg/day po 14-21 days
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Cystoisosporiasis (Cystoisospora belli, formerly Isospora belli)
Treatment
Diagnosis of AIDS-defining cystoisosporiasis can be made only in cases of chronic diarrhoea (over 4 weeks) by UV fluorescence or microscopy of stools, 
duodenal aspirates or intestinal tissue biopsy.
Besides antiprotozoal treatment, additional measures are symptomatic treatment, rehydration and electrolyte management.
Drug Dose Comments
Preferred therapy TMP-SMX 2 x 2 double-strength tablet (ds) 
(800/160 mg)/day po
or
2 x 1 double-strength tablet (ds) 
(800/160 mg) /day po
Treat minimally 10 days, increase dura-
tion to 3-4 weeks if symptoms worsen 
or persist
Treat minimally 10 days, increase dose 
to 2 x 2 ds tablet/day, if symptoms wors-
en or persist
Alternative therapy, if TMP-SMX is not 
tolerated
pyrimethamin
+ folinic acid
or
ciprofloxacin
1 x 50-75 mg//day po
1 x 10-15 mg//day po
2 x 500 mg/day po 
10 days
Monitor for myelotoxicity, mostly neutro-
penia, for pyrimethamin
7 days
Secondary prophylaxis / Maintenance therapy
Stop: if CD4 count > 200 cells/µL and HIV-VL undetectable over 6 months and no signs of persistent cystoisosporiasis
Preferred therapy TMP-SMX 1 double-strength tablet (ds)
(800/160 mg) 3 x /week po or 
1 ds tablet/day po or 
2 ds tablet 3 x/week po
Alternative therapy, if TMP-SMX is not 
tolerated
pyrimethamin
+ folinic acid
1 x 25 mg/day po 
1 x 10-15 mg/day po 
Monitor for myelotoxicity, mostly neutro-
penia, for pyrimethamin
Leishmaniasis
Treatment
Diagnosis: microscopy or PCR in smears, body fluids or tissue
Drug Dose Comments
Preferred treatment liposomal amphotericin B 1 x 2-4 mg/kg/day iv for
10 consecutive days
Then secondary prophylaxis
or
liposomal amphotericin B 1 x 4 mg/kg/day iv on day 1-5,
10, 17, 24, 31 and 38
Alternative therapy lipidcomplex amphotericin B 1 x 3 mg/kg/day iv 10 days
or
amphotericin B deoxycholate 1 x 0.5-1 mg/kg/day iv
(total dose 1.5-2 g)
amphotericin B deoxycholate may not be
available in all European countries
or
pentavalent antimonium salt
(Glucantime®)
1 x 20 mg/kg/day iv or im 4 weeks
or
miltefosine 1 x 100 mg/kg/day po 4 weeks
Secondary prophylaxis / Maintenance therapy
Consider stopping: if CD4 count > 200-350 cells/µL and HIV-VL undetectable over 3 months, no relapse for at least 6 months and negative PCR in blood 
or negative urinary antigen
Preferred treatment liposomal amphotericin B 4 mg/kg every 2-4 weeks iv
or
lipidcomplex amphotericin B
3 mg/kg every 3 weeks iv
Alternative therapy pentavalent antimonium salts
(Glucantime®)
20 mg/kg every 4 weeks iv/im
or
miltefosine
1 x 100 mg/day po
or
pentamidine
300 mg every 3 to 4 weeks iv
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Diagnosis and Treatment of TB in HIV-positive Persons
Treatment of TB in HIV-positive persons
For standard treatment of TB in HIV-positive persons, including appropriate choice of 
ARVs, see table and ART in TB/HIV Co-infection
See online video lectures TB and HIV Co-infection-Part 1 and TB and HIV Co-infec-
tion-Part 2 from the EACS online course Clinical Management of HIV.
Disease Drug Dose Comments*
Susceptible Mycobacterium tuberculosis
Initial phase rifampicin     Weight based Initial phase for 2 months, then 
Continuation phase (rifampicin+isoniazid) 
according to TB type (see below)
Possibility to omit ethambutol, if M. tubercu-
losis is known to be fully drug sensitive
Preventive steroid therapy may be consid-
ered to avoid IRIS.
+ isoniazid 
+ pyrazinamide 
+ ethambutol 
Alternative rifabutin Weight based Initial phase for 2 months, then 
Continuation phase according to TB type 
(see below)
Possibility to omit ethambutol, if M. tubercu-
losis is known to be fully drug sensitive
+ isoniazid 
+ pyrazinamide 
+ ethambutol 
Continuation phase rifampicin/rifabutin
+ isoniazid
according to TB type
Total duration of therapy: 
1. Pulmonary, drug susceptible TB: 6 months
2. Pulmonary TB & positive culture at 8 
weeks of TB treatment: 9 months 
3. Extrapulmonary TB with CNS involvement 
or disseminated TB: 9-12 months
4. Extrapulmonary TB with bone/joint in-
volvement: 9 months
5. Extrapulmonary TB in other sites: 6-9 
months
* Intermittent regimens (2 or 3 times per week) are contraindicated in HIV-positive persons. Missed doses can lead to treatment failure, relapse or 
acquired drug resistance [12]. 
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Diagnosis of Multi-Drug Resistant TB (MDR-TB) /  
Extensively-Drug Resistant TB (XDR-TB)
MDR-TB/XDR-TB should be suspected in case of:
• Previous TB treatment
• Contact with MDR/XDR-TB index case 
• Birth, travel or work in an area endemic for MDR-TB 
• History of poor adherence
• No clinical improvement on standard therapy and/or sputum smear  
positive after 2 months of TB therapy or culture positive at 3 months
• Homelessness/hostel living and in some countries recent/current  
incarceration
• In areas with very high MDR-TB/XDR-TB prevalence
MDR-TB: Resistance to isoniazid and rifampicin
XDR-TB: Resistance to isoniazid and rifampicin and quinolones and at 
least one at the following injectable drugs: kanamycin, capreomycin or 
amikacin
Rapid detection
Gene Xpert or similar technology has the advantage of rapid detection  
of rifampicin resistance. Drug susceptibility testing is important for optimis-
ing treatment.
Some countries/regions have neither of the above and have to use an  
empirical approach.
Treatment of resistant TB [8]
INH-resistant TB
•  RIF or RFB + Z+ E for 2 months and RIF or RFB + E for 10 months
 
Some experts recommend to add a FQ in the intensive phase and replace 
E by the FQ in the maintenance phase.
Each dose of MDR/XDR-TB regimen should be given as DOT throughout 
the whole treatment. 
• In persons with rifampicin-resistant or MDR-TB, a regimen with at least 
five effective TB medicines during the intensive phase is recommended, 
including pyrazinamide and four core second-line TB medicines - one 
chosen from group A, one from group B, and at least two from group C.
• If the minimum of effective TB medicines cannot be composed as above, 
an agent from group D2 and other agents from D3 may be added to bring 
the total to five.
• In persons with rifampicin-resistant or MDR-TB, it is recommended that 
the regimen be further strengthened with high-dose isoniazid and/or 
ethambutol.
• Preliminary results of a recent RCT (Nix-TB trial) suggest that a 3-drug 
combination of pretomanid 200 mg/day, bedaquiline 200 mg tiw after a 
3-week load, and linezolid 1200 mg/day during 6 months (3 additional 
months if culture positive at 4th month) may be at least as effective as 
the 5-drug regimens suggested above. Majority of cases included were 
pulmonary TB.
Drug choices 
Each empiric regimen should be reassessed and modified if needed once 
drug sensitivity results become available.
Group A:                                          
Fluoroquinolones 
• levofloxacin (LFX)
• moxifloxacin (MFX)
• gatifloxacin (G)
Group B:
Injectable agents
• amikacin (Am)
• capreomycin (Cm)
• kanamycin  (Km)
• streptomycin (S): use only if susceptibi-
lity is proven and the above medica-
tions are unavailable
Group C:
Other core second-line agents 
• ethionamide (ETO) or prothionamide 
(PTO)
• cycloserine (CS) or terizidone (TRD)
• linezolid (LZD)
• clofazimine (CFZ)
Group D1:
Add on agents
• pyrazinamide (Z)
• ethambutol (E)
• high-dose isoniazid (high-dose INH)
Group D2: • bedaquiline (BED)
• delamanid (DLM)
Group D3: • p-aminosalicylic acid (PAS)
• imipenem-cilastatin (IPM/CLN)
• meropenem (MPM)
• amoxicillin clavulanate (Amx/CLV)
• thioacetazone (THZ)
Duration of MDR/XDR treatment
8 months of intensive phase using 5 or more drugs, followed by 12 months 
of 3 drugs depending on response.
E.g. 8 months of Z, MFX, Km, OFX, PTO and CS, followed by 12 months 
of MFX, PTO and CS.
In persons with rifampicin-resistant or MDR-TB who have not been 
previously treated with second-line drugs and in whom resistance to fluo-
roquinolones and second-line injectable agents has been excluded or is 
considered highly unlikely, a shorter MDR-TB regimen of 9-12 months may 
be used instead of a conventional regimen.
Drug interactions with ART and MDR/XDR regimens
Unless RFB is being used, use normal doses but with caution as few data 
are available on potential drug interactions, see ART in TB/HIV Co-infection
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Latent tuberculosis  
Indication: TST > 5 mm or positive IGRA or close contacts to persons with 
sputum smear positive tuberculosis 
Some national guidelines consider the ethnicity, CD4 count and ART usage 
to define indication for latent tuberculosis treatment.
Regimen* Comments
isoniazid 5 mg/kg/day (max 300 
mg) po 
+
pyridoxine (Vit B6) 25 mg/day po
6-9 months
Consider 9-month duration in 
high-prevalent TB countries.
rifampicin 600 mg/day po 
or rifabutin** po (dose according to 
current cART)
4 months, check interactions with 
ARVs, see Drug-drug Interactions 
between ARVs and Non-ARVs
rifampicin 600 mg/day po
or rifabutin** po (dose according to 
current cART) 
+
isoniazid 5 mg/kg/day (max 300 
mg) po
+
pyridoxine (Vit B6) 25 mg/day po
3 months, check interactions with 
ARVs, see Drug-drug Interactions 
between ARVs and Non-ARVs
rifampicin 600 mg 2 x/week po
+
isoniazid 900 mg 2 x/week po
+
pyridoxine (Vit B6) 300 mg 1 x/
week po 
3 months, check interactions with 
ARVs, see Drug-drug Interactions 
between ARVs and Non-ARVs
rifapentine 900 mg 1 x/week po
+
isoniazid 900 mg 1 x/week po
3 months, check interactions with 
ARVs, see Drug-drug interactions 
between ARVs and non-ARVs
Rifapentine is not yet available in 
Europe.
rifapentine 450 mg (< 45kg) or 600 
mg (> 45kg) /day po
+
isoniazid 300 mg/day po
+
pyridoxine (Vit B6) 25 mg/day po 
[13]
4 weeks, check interactions with 
ARVs, see Drug-drug interactions 
between ARVs and non-ARVs rifap-
entine is not yet available in Europe.
 
* Other preventive regimens may be considered if high risk of latent infec-
tion with MDR/XDR-TB.
** Rifabutin is not a WHO recommended regimen.
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